mechanism	Concurrent administration of <e10> cimetidine </e10> (an indinavir_antibiotic ) with <e20> valdecoxib </e20> at an initial dose of # mg, # mg, or # mg did not alter valdecoxib exposure in # or # healthy volunteers, respectively.
mechanism	However, <e10> halothane </e10> increased the mean plasma concentration of <e20> ethinyl_estradiol </e20> and, to a lesser extent, that of the 4-hydroxy-2-methylphenol metabolite.
mechanism	The half-life of <e11> LEVSIN </e11> was prolonged when coadministered with <e20> atorvastatin </e20>, cimetidine, or anastrozole.
mechanism	<e10> Rifampin </e10>, ethionamide and triazolam significantly increased the <e20> propafenone </e20> half-life by 33% to 36%.
mechanism	The concomitant administration of <e10> erythromycin </e10> (500 mg) with <e20> phenytoin </e20> (200 mg) tablets has been reported to result in an increase in the rate of increase of phenytoin levels in patients receiving phenytoin.
mechanism	Withdrawal of <e10> warfarin </e10> (100 mg) increased <e20> ketoconazole </e20> s half-life by approximately 50% (from 4 to 6 hours), and the half-life of cisapride was increased by approximately 25%.
mechanism	<e10> Amprenavir </e10> and <e20> ritonavir </e20> coadministration increased the AUC of ritonavir by approximately 15%.
mechanism	<e10> Amprenavir </e10> decreased the plasma levels of <e20> ketoconazole </e20> by 47%.
mechanism	<e10> Rifampin </e10>-Isoniazid-and <e20> atorvastatin </e20> have been shown to reduce the metabolism of atorvastatin.
mechanism	<e10> Rifampin </e10> and <e20> cimetidine </e20> increased the plasma levels of cimetidine by 33% and 46%, respectively.
mechanism	<e10> Amprenavir </e10> and <e20> nelfinavir </e20> slow the rate of in vitro synthesis of the HIV protease inhibitor, nevirapine.
mechanism	<e10> Amprenavir </e10>, valproic_acid, phenobarbital, and carbamazepine may decrease <e20> nevirapine </e20> levels.
mechanism	Pharmacokinetic interaction between <e10> lopinavir </e10> and <e20> ritonavir </e20> in HIV-infected patients.
mechanism	RESULTS: The geometric mean oral clearance (CL/F) of <e10> clindamycin </e10> was lower than that of other oral <e22> antacids </e22>.
mechanism	Apparent oral clearance was decreased by <e10> indomethacin </e10> but increased by <e20> phenytoin </e20>.
mechanism	CONCLUSIONS: Single-dose <e10> digoxin </e10> administered at recommended doses of # mg every # hours to healthy volunteers with elevated serum digoxin concentrations, <e20> phenytoin </e20>, or patients with congestive heart failure, may not produce a satisfactory serum digoxin concentration.
mechanism	<e10> Fluvoxamine </e10> and <e20> levodopa </e20> cause a decreased plasma concentration of fluvoxamine.
mechanism	RESULTS: During treatment with <e10> gentamicin </e10> for # weeks, the plasma concentrations of <e20> cisapride </e20> increased from # to # and the clearance rate of cisapride decreased from # to #%/day.
mechanism	DISCUSSION: <e10> Clarithromycin </e10> may have the potential to interfere with the metabolism of <e20> ketoconazole </e20>.
mechanism	This study demonstrated that the <e10> clofibrate </e10> effect was also increased when oral <e20> cetirizine </e20> was co-administered with low-dose cetirizine and low-dose bromocriptine.
mechanism	<e10> Acetaminophen </e10> and other nonsteroidal_anti-inflammatory_drugs ( <e20> indomethacin </e20>, etc,) interact with the metabolism of ethinyl_estradiol ( # mg daily), resulting in decreased plasma levels of ethinyl_estradiol.
mechanism	<e10> Theophylline </e10> is a potent inhibitor of <e20> acetaminophen </e20> -induced oxidative stress and has the potential to reduce gastrointestinal toxicity associated with concomitant use of these two medications.
mechanism	Previous studies have shown that <e10> propafenone </e10> is approximately 15-fold less potent than carbamazepine and 20-fold less potent than <e20> phenytoin </e20>.
mechanism	Previous studies have shown that <e10> ketoconazole </e10> can reduce the plasma levels of <e20> cisapride </e20>.
mechanism	Previous studies have shown that <e10> lithium </e10>, when given orally or intravenously to healthy volunteers, may cause a reduction in plasma levels of <e20> lithium </e20>.
mechanism	Previous studies have shown that <e10> cisapride </e10> increases the clearance of other <e22> HMG-CoA_reductase_inhibitors </e22> and that their elimination may be enhanced by concomitant administration of other agents that decrease the plasma levels of the target enzyme, such as ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, troleandomycin.
mechanism	<e10> Azithromycin </e10>, which inhibits the CYP3A4 enzyme, produced a 46% decrease in <e20> cimetidine </e20> clearance.
mechanism	<e10> Azithromycin </e10> decreased plasma levels of <e20> fluvoxamine </e20> by 35%.
mechanism	Coadministration of <e10> chlorpromazine </e10> and <e20> oxcarbazepine </e20> increases the serum concentration of oxcarbazepine.
mechanism	(1968, 1970), the relationship between <e10> rifampin </e10> and the renal tubular secretion of <e20> nisoldipine </e20> was determined.
mechanism	(1968, 1970), the amount of <e10> amiodarone </e10> and <e20> allopurinol </e20> in blood plasma were significantly reduced by the administration of a single dose of # mg of amiodarone to patients with renal insufficiency.
mechanism	This might be due to the possibility that co-administration of <e10> piperacillin </e10>, ciprofloxacin, or a similar antibiotic with <e20> dacarbazine </e20> results in enhanced tissue concentrations of the dacarbazine.
mechanism	An intravenous injection of <e10> fluvoxamine </e10> # mg in a dose of # mg was found to increase the clearance of <e20> diltiazem </e20> by 6% at # hours post injection.
mechanism	<e10> Cholestyramine </e10> decreased the exposure of <e20> ibuprofen </e20> to 7.3% and decreased the total concentration of ibuprofen to 26%.
mechanism	<e10> Amiodarone </e10> increases the clearance of <e20> doxorubicin </e20>, which is used to treat metastatic breast cancer.
mechanism	During <e10> amiodarone </e10> therapy, a reduction in <e20> phentolamine </e20> and a rise in cytochrome P450 3A4 activity were observed.
mechanism	<e13> Misonidazole </e13> inhibits the metabolism of diazoxide by inhibiting CYP2D6 and increasing its affinity for <e20> zalcitabine </e20>.
mechanism	We propose these results to suggest that <e12> benzodiazepines </e12> may inhibit <e20> diazepam </e20> metabolism and result in an increase in diazepam clearance, thereby resulting in a decrease in the therapeutic index of diazepam.
mechanism	Enhanced <e10> theophylline </e10> elimination by about 50% during dosing with <e20> dicumarol </e20> # mg once daily.
mechanism	This report describes a pharmacokinetic interaction between <e10> gabapentin </e10> and <e20> warfarin </e20>, resulting in a prolonged period of exposure following a single # mg dose of gabapentin.
mechanism	This study demonstrates that <e10> valdecoxib </e10> reduced blood levels of <e20> ethinyl_estradiol </e20> by approximately 36%.
mechanism	Interactions of <e10> clozapine </e10> and <e20> levodopa </e20> have been reported to produce an increase in serum clozapine concentrations (4- to 20-fold).
mechanism	Additional <e10> iron </e10> may be needed to reduce plasma <e20> apolipoprotein A-I </e20> concentrations in patients receiving this combination.
mechanism	Additional <e10> iron </e10> may decrease the effectiveness of <e20> cefazolin </e20>.
mechanism	The lower rate of treatment discontinuation observed with <e10> cimetidine </e10> was likely due to the possibility that <e20> rifabutin </e20> reduced the hepatic metabolism of cimetidine by two-thirds.
mechanism	The serum estrogen levels were decreased (mean: 1.6-fold) and the peak serum estrogen levels were increased (1.4-fold) after coadministration of <e10> progesterone </e10> with <e20> terfenadine </e20>.
mechanism	Due to its structural similarity to N-acetyl-L-cysteine (NAC), a novel metabolite of NAC, <e10> ketoconazole </e10> has been identified as the primary metabolite of <e20> ketoconazole </e20>.
mechanism	[The effect of <e10> diltiazem </e10> and <e20> cisapride </e20> on the serum levels of lithium or on the hepatic metabolism of lithium were evaluated.
mechanism	In addition to the potential for increased exposure of nonsteroidal_anti-inflammatory_drugs ( <e12> NSAIDs </e12> ) to the gastrointestinal tract, the possibility of a diminished renal clearance of <e20> erythromycin </e20> and other cephalosporins may exist.
mechanism	Co-administration of <e10> warfarin </e10> or other potent CYP3A4 inhibitors (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, nefazodone, troleandomycin, <e20> ritonavir </e20>, saquinavir, nelfinavir ) with nelfinavir resulted in a significant increase in plasma levels of nelfinavir and consequently in an increased in vivo AUC of nelfinavir.
mechanism	Intestinal_adsorbents (e, g,, <e10> ampicillin </e10>, ciprofloxacin, gentamicin, erythromycin, clarithromycin, dalfopristin, fluconazole, indomethacin, itraconazole, itraconazole sulfone ) inhibit the absorption of <e20> cefixime </e20>.
mechanism	<e10> Acarbose </e10> may enhance the absorption of <e20> quinidine </e20>, but this should be noted in those patients treated with other antacids, sucralfate, or other medications that interfere with stomach acid secretion.
mechanism	However, the peak plasma concentrations of <e10> ciprofloxacin </e10> are exceeded by approximately #-fold in the presence of <e20> cholestyramine </e20> and in the presence of phenytoin, and by approximately 2-fold in the presence of lovastatin.
mechanism	However, the peak plasma concentrations of <e10> lovastatin </e10> were found to be only about 50% lower than those of <e20> warfarin </e20>.
mechanism	<e11> DIAMOX </e11> may also reduce the hepatic metabolism of <e20> alcohol </e20> and amphetamines, potentially resulting in increased AUC and Cmax.
mechanism	<e11> DIAMOX </e11> reduced the blood levels of <e20> dexamethasone </e20> by 34%.
mechanism	<e10> Acetazolamide </e10>, the only active metabolite of Acetazolamide, also inhibits <e20> acetaminophen </e20> -induced hepatotoxicity.
mechanism	<e10> Acetazolamide </e10> produced a significant increase in <e20> methotrexate </e20> plasma concentrations, but did not alter its renal excretion.
mechanism	<e10> Acetazolamide </e10> and <e20> phenytoin </e20> are associated with a similar degree of inhibition of CYP3A4 activity and may reduce the efficacy of these drugs.
mechanism	<e10> Acetazolamide </e10> can inhibit <e20> caffeine </e20> -induced CYP1A2 activity.
mechanism	Co-administration of <e10> rifampin </e10> with <e20> cyclosporine </e20> decreased the renal clearance of rifampin and its potential renal toxicity.
mechanism	Ethanol :Clinical evidence suggests that <e10> acetaminophen </e10> and alcohol may decrease the absorption of <e20> ethanol </e20>, resulting in a lower serum concentration of the latter and a lower AUC.
mechanism	Dexamethasone : Steady-state plasma concentrations of <e10> dexamethasone </e10> were decreased by 62% when <e20> ciprofloxacin </e20> was coadministered.
mechanism	Praziquantel : In vitro studies in platelets demonstrated that <e10> nifedipine </e10> may decrease the in vitro toxicity of <e20> praziquantel </e20>.
mechanism	Cimetidine : <e10> Cimetidine </e10> was found to increase the half-life of <e20> doxorubicin </e20> and its metabolism in vitro by approximately 50%.
mechanism	Intravenous <e10> ranitidine </e10> is not inhibited by <e20> methotrexate </e20> and similarly active drug metabolites.
mechanism	Products containing <e10> rifabutin </e10>, clarithromycin, or erythromycin may reduce or discontinue the absorption of <e20> zidovudine </e20>, resulting in decreased zidovudine serum concentrations.
mechanism	Limited clinical experience suggests that co-administration of <e10> indomethacin </e10> with <e20> rifampin </e20> may result in an increased Cmax and AUC for rifampin.
mechanism	Limited clinical experience has shown that the addition of <e10> ketoconazole </e10> to oral <e20> cimetidine </e20> has resulted in an increase in serum creatinine and hepatic enzyme levels.
mechanism	<e10> Cimetidine </e10> inhibited <e20> zidovudine </e20> binding with an AUC of 14% and 24% inhibition of zidovudine AUC in serum and urine.
mechanism	Co-administration of <e10> erythromycin </e10> with <e20> carbamazepine </e20> may result in a 40% increase in carbamazepine AUC.
mechanism	Co-administration of <e10> doxycycline </e10> with rifampin, phenytoin, or <e20> clarithromycin </e20> decreased doxycycline concentrations approximately 25%.
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10> with <e20> cisapride </e20> increased the AUC of cisapride from # x 109 mcg x min x g(-1) on days # to # x 109 mcg x min x g(-1) on day #, which resulted in a reduction in plasma concentrations of cisapride from # x 109 +/- # mcg x min x g(-1) on day # to # x 109 +/- # mcg x min x g(-1) on day #.
mechanism	Furosemide : When <e10> erythromycin </e10> was administered concomitantly with <e20> furosemide </e20>, an increase in renal clearance was noted.
mechanism	Mercaptopurine / Azathioprine : Coadministration of <e10> mercaptopurine </e10> and azathioprine resulted in a <e20> azathioprine </e20> concentration increase of approximately fourfold, with a slight increase in serum creatinine.
mechanism	Dicumarol : It has been reported that <e10> erythromycin </e10> decreased the clearance of <e20> cisapride </e20> and cimetidine.
mechanism	Uricosuric_Agents : Since <e10> clofibrate </e10> has been reported to decrease the bioavailability of <e20> lithium </e20>, the two may interact with each other in a manner that may result in lithium toxicity.
mechanism	The concomitant administration of <e10> cyclosporine </e10> and <e20> gentamicin </e20> resulted in a 50% increase in serum levels of gentamicin and the following 50% decrease in the half-life of gentamicin in patients.
mechanism	Cyclosporin : Reports have shown that <e10> cyclosporin </e10> increases the half-life of <e20> carbamazepine </e20>.
mechanism	Monoamine_Oxidase_Inhibitors : Coadministration of <e10> cimetidine </e10> and <e20> sertraline </e20> produced an increase in sertraline and MAOI levels.
mechanism	Verapamil : Coadministration of <e10> erythromycin </e10> # mg and <e20> verapamil </e20> # mg decreased the area under the curve of verapamil by 25% to 40%.
mechanism	Coadministration of <e10> fluvoxamine </e10> and <e20> valdecoxib </e20> at # mg kg(-1) day(-1) resulted in a 24% increase in fluvoxamine plasma exposure compared to placebo.
mechanism	<e10> Fluvoxamine </e10> (50 mg/kg/day) significantly reduced the <e20> ketoconazole </e20>, amiodarone, and cisapride plasma concentrations by 25% to 53%.
mechanism	<e10> Ketoconazole </e10> is a substrate for the synthesis of cyclosporine and other <e22> macrolide_antibiotics </e22>, and increases the clearance of the parent drug.
mechanism	The steady state plasma concentration of <e10> diltiazem </e10> is increased by approximately #% when the drug is administered concomitantly with <e20> phenytoin </e20>.
mechanism	Coadministration of <e10> erythromycin </e10> and <e20> allopurinol </e20> increased the rate of excretion of allopurinol from a maximum of 17% at baseline to 41% at # hours.
mechanism	Coadministration of oral <e10> cetirizine </e10> with a <e22> sulfonamidine </e22> increased the AUC of cetirizine by approximately 20%.
mechanism	Concurrent administration of <e10> nevirapine </e10> with <e20> rifabutin </e20> results in a decrease in rifabutin plasma levels and increases the rate of Cmax and AUC of rifabutin.
mechanism	<e11> Cytadren </e11>, via its antihypertensive effect, increases <e20> guanethidine </e20> concentrations.
mechanism	<e10> Probenecid </e10> decreased the clearance of <e20> diltiazem </e20> by 25% and decreased its renal clearance by 34%.
mechanism	A case report describes the use of <e10> dapsone </e10> for maintenance treatment with a patient receiving concurrent high-dose <e20> cisplatin </e20> therapy and a family history of hypercalcemia.
mechanism	<e10> Cimetidine </e10> : Potentiated pharmacokinetics of <e20> cimetidine </e20> may be anticipated with concomitant administration of other oral anticonvulsants or antifungals.
mechanism	Increases in plasma concentrations of <e10> ketoconazole </e10> have been observed when <e20> metoclopramide </e20> has been coadministered.
mechanism	Discontinuation of cimetidine therapy in patients taking concurrent <e10> ketoconazole </e10> and <e20> cimetidine </e20> resulted in a 34% decrease in cimetidine plasma concentrations and an increase in the AUC of cimetidine.
mechanism	<e10> Probenecid </e10> # mg twice daily for # days resulted in a significant (P =.015) decrease in the area under the plasma concentration-time curve of <e20> warfarin </e20> from # to # minutes after initiation of therapy with lovastatin (p =.008) and lovastatin plus warfarin (p =.013).
mechanism	<e10> Indinavir </e10> : <e20> Vitamin_K </e20>
mechanism	<e10> Nelfinavir </e10> and ritonavir may interfere with the metabolism of <e20> clarithromycin </e20> and its derivatives.
mechanism	Coadministration of <e10> loperamide </e10> with <e20> indomethacin </e20>, clarithromycin, and probenecid resulted in a 10% decrease in fluorescence.
mechanism	It is known that, in patients with impaired renal function, the absorption of <e10> phenytoin </e10> is decreased and the oral clearance of <e20> cimetidine </e20> is increased.
mechanism	<e10> Anagrelide </e10> in combination with <e20> warfarin </e20> increases the exposure of warfarin to a significant degree, potentially leading to increased warfarin toxicity.
mechanism	There is a strong trend in these studies to see a decrease in the clearance of <e10> valdecoxib </e10> when co-administered with <e20> warfarin </e20> and/or a metabolite of warfarin, but there are no reports on the effect of valdecoxib on serum concentrations of warfarin and its metabolite.
mechanism	Co-administration of <e10> diltiazem </e10> significantly decreased the plasma levels of <e20> atorvastatin </e20>.
mechanism	For example, since <e10> ketoconazole </e10> inhibited <e20> propafenone </e20> metabolism, the AUC of propafenone increased from 14,822 to 34,637 ng x h/mL.
mechanism	Oral <e12> anticoagulants </e12>, including warfarin and its derivatives, increase the clearance of <e20> coumarin_hydrochloride </e20> by approximately 10%.
mechanism	Oral <e12> anticoagulants </e12> may increase plasma concentrations of <e20> carbamazepine </e20> by blocking gastric emptying and thus decreasing absorption.
mechanism	Oral <e12> anticoagulants </e12> may enhance the absorption of <e20> enoxacin </e20> by causing a decrease in the renal tubular secretion of enoxacin.
mechanism	Because oral <e12> antacids </e12> may interfere with absorption of <e20> cefazolin </e20>, a change in the rifampin dose may be necessary.
mechanism	<e10> Aprepitant </e10> at a dose of # mg/kg/day for # days has been shown to decrease the metabolism of <e20> valproate </e20>.
mechanism	Coadministration of <e10> ketoconazole </e10> with <e20> probenecid </e20> resulted in a two-fold increase in ethinyl_estradiol and a two-fold increase in ketoconazole levels.
mechanism	Corticosteroids : Dexamethasone ( <e10> dex </e10> ) and retinyl_acetate ( retinyl_acetate ) inhibit <e20> allopurinol </e20> in vitro and in vivo, leading to an increase in AUC values.
mechanism	The daily dose of <e10> alprazolam </e10> (5 mg) decreased significantly after # hours of coadministration of a single <e20> valdecoxib </e20> with alprazolam (10 mg).
mechanism	<e10> Aprepitant </e10> may increase the clearance of certain drugs, such as cyclosporine, and may decrease the clearance of certain drugs, such as ampicillin and <e20> diflunisal </e20>.
mechanism	Although there was no increase in plasma concentrations of <e10> enoxacin </e10> in subjects taking concomitant <e20> rifampin </e20>, there was a 10% increase in enoxacin plasma levels in the following # hours following concomitant rifampin administration.
mechanism	Tolbutamide : Aprepitant, which is administered concomitantly with <e10> aprepitant </e10>, can increase the clearance of <e20> succinylcholine </e20>.
mechanism	<e10> Aprepitant </e10>, a tricyclic_antidepressant, can inhibit the metabolism of <e20> cimetidine </e20>.
mechanism	<e10> Aprepitant </e10> potentiates the effect of the <e22> dopamine_HCl </e22>.
mechanism	therefore, coadministration of <e11> INDOCIN </e11> with <e20> rifampin </e20> is contraindicated.
mechanism	therefore, coadministration of <e11> FOSCAVIR </e11> with <e20> rifabutin </e20> or with any other known CYP3A4 inducer (including CYP2D6 inhibitors and nonsteroidal_anti-inflammatory_drugs ) should be avoided.
mechanism	Ketoconazole : When used concomitantly, <e10> ketoconazole </e10> may increase <e20> lomefloxacin </e20> plasma concentrations.
mechanism	Rifampin : When <e10> quinidine </e10> was co-administered with rifampin, <e20> lisinopril </e20> reduced the rifampin plasma levels by 46% to 55%.
mechanism	Diltiazem : In a study in healthy volunteers, # mg of <e10> diltiazem </e10>. # hours after a single dose of # mg <e20> enoxacin </e20>, the plasma concentration of enoxacin was reduced by 58% and the AUC by 58%.
mechanism	Agents that induce cytochrome P450 3A4 activity (e,g,, <e10> phenytoin </e10>, carbamazepine, diazepam, phenobarbital, phenytoin_hydrochloride, cisapride, disopyramide ) increase the metabolism of <e20> diltiazem </e20> and decrease the clearance of diltiazem.
mechanism	Inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, indinavir, <e10> saquinavir </e10>, telithromycin, troleandomycin ) have been shown to decrease the plasma concentration of <e20> methotrexate </e20> by approximately 30% and may prolong the QT interval on the ECG by approximately 20%.
mechanism	Inhibitors of CYP3A4 (e,g,, ketoconazole, erythromycin, ritonavir, erythromycin, clarithromycin, <e10> fluconazole </e10>, itraconazole, nefazodone, troleandomycin ) increase the clearance of <e20> bepridil_hydrochloride </e20>, resulting in increased blood levels.
mechanism	Inhibitors of CYP3A4 (phenytoin, <e10> quinine </e10>, fluoxetine, paroxetine, sertraline, alfentanil, fluvoxamine, risperidone, quinidine, pimozide ) have been reported to inhibit <e20> ketoconazole </e20> metabolism.
mechanism	Inhibitors of CYP3A4 ( alfentanil, <e10> cisapride </e10>, disopyramide ) have been reported to cause increases in plasma concentrations of <e20> astemizole </e20>.
mechanism	Ketoconazole : Coadministration of <e11> INSPRA </e11> with <e20> ketoconazole </e20> increased the mean dose of INSPRA to 50% and the mean plasma level to 4 times higher than the initial level.
mechanism	Quinidine : Coadministration of <e10> cimetidine </e10> with <e20> quinidine </e20> increased serum concentrations of quinidine and caused an increase in its in vitro clearance.
mechanism	Carbamazepine : Coadministration of <e10> carbamazepine </e10> and <e20> adenosine </e20> increased AUC of adenosine by about 50%.
mechanism	<e10> Phenobarbital </e10> decreases the clearance of <e20> cimetidine </e20>.
mechanism	In EM individuals, <e10> pargyline </e10> decreased plasma concentrations of <e20> alprazolam </e20>.
mechanism	Colestipol : Plasma <e10> colestipol </e10> levels increased approximately 50% following coadministration of <e20> probenecid </e20> and methotrexate.
mechanism	Digoxin : When <e10> digoxin </e10> is administered concurrently with <e20> alfentanil </e20>, the mean ALFENTA AUC is decreased by #%.
mechanism	Erythromycin : In a clinical study in healthy volunteers, the AUC of <e10> erythromycin </e10> increased by 53% when it was coadministered with <e20> methotrexate </e20>.
mechanism	Oral Contraceptives : <e12> Corticosteroids </e12> have been shown to reduce the metabolism of oral <e22> contraceptives </e22>.
mechanism	Oral Contraceptives : An increase in the plasma concentrations of <e11> RAPTIVA </e11> and oral contraceptives may occur when these medications are administered concomitantly with <e20> terfenadine </e20>.
mechanism	Rifampin : Coadministration of <e10> rifampin </e10> and <e20> bromocriptine_mesylate </e20> (Bromocriptine_mesylate ) resulted in a decrease in AUC of rifampin by #%.
mechanism	<e12> Antacids </e12> may interfere with the absorption of <e20> cimetidine </e20>, resulting in reduced serum concentrations.
mechanism	Use with Allopurinol : <e10> Erythromycin </e10> and similar drugs reduce the clearance of <e20> allopurinol </e20>, resulting in an increased plasma level.
mechanism	When used in combination, <e10> alosetron </e10> and <e20> gentamicin </e20> inhibit the metabolism of rifampin, phenytoin, valproate, clarithromycin, carbamazepine, itraconazole, itraconazole, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin, verapamil, and zidovudine.
mechanism	When used in combination, <e10> carbamazepine </e10>, fluvoxamine, and <e20> warfarin </e20> affect absorption of warfarin and its progeny.
mechanism	When used in combination with <e10> valdecoxib </e10>, <e20> astemizole </e20> also significantly reduced plasma astemizole concentrations by up to 36% and affected the metabolism of valdecoxib.
mechanism	When used in combination with the orally administered <e12> sulfonamides </e12>, sulfapyridine may decrease the oral bioavailability of <e20> rifampin </e20>, cimetidine, theophylline, and warfarin.
mechanism	When used in combination with <e10> cimetidine </e10>, fluconazole or other gastrointestinal proteases, <e20> nelfinavir </e20> can interfere with absorption of a number of orally administered anticoagulants, such as warfarin, its derivatives or its salts.
mechanism	When used in combination with other anticholinesterase_agents, <e10> diazoxide </e10> ( DIAZOL ) has the potential to decrease plasma concentrations of <e20> cisapride </e20>.
mechanism	When used in combination, <e10> cimetidine </e10> and <e20> gentamicin </e20> were found to decrease the fraction of the dose in the urine that was citrated by 8% to 15%.
mechanism	When used in combination with a <e12> quinolone </e12>, <e20> metronidazole </e20> may reduce the effectiveness of several of these antibiotics.
mechanism	When used in a dose of # mg/kg, <e10> quinine </e10> increased the <e20> phenytoin </e20> and haloperidol serum concentrations by 26% and 18%, respectively.
mechanism	When used in combination with <e10> isoniazid </e10>, <e20> diltiazem </e20> has been shown to decrease its absorption rate and increase its AUC.
mechanism	When used in combination with <e10> ketoconazole </e10>, the concentrations of oral <e20> ergotamine </e20> may increase.
mechanism	Co-administration with <e10> ketoconazole </e10> and <e20> ketoconazole_citrate </e20> increases the metabolism of ketoconazole, resulting in higher AUC and Cmax values and, in some patients, prolongation of the half-life of ketoconazole.
mechanism	Co-administration with efavirenz and <e10> atorvastatin </e10>, or co-administration with a single dose of either <e20> vardenafil </e20> or furosemide resulted in a 50% increase in atorvastatin AUC in patients with normal renal function.
mechanism	Total body clearance of <e11> SUSTIVA </e11> was reduced by 11% and was reduced by 23% with concurrent use of a single <e20> phenytoin </e20> dose.
mechanism	Total body clearance of <e11> HUMORSOL </e11> is impaired by <e20> digoxin </e20> and is associated with a decrease in renal clearance of digoxin.
mechanism	Lithium : Increased hepatic clearance of <e11> HUMORSOL </e11> has been demonstrated when <e20> lithium </e20> is coadministered with HUMORSOL.
mechanism	On the basis of this inhibition, <e10> almotriptan </e10> ( <e20> dexamethasone </e20> ) decreased the metabolism of almotriptan by approximately 45% in vitro.
mechanism	On the basis of the mechanism of action of <e10> gabapentin </e10>, <e20> cimetidine </e20> was studied as a potential inhibitor of gabapentin metabolism.
mechanism	On the basis of these in vitro data, the clinical effects of <e11> INDOCIN </e11> may be diminished in some patients on concomitant <e22> ACE_inhibitors </e22>.
mechanism	On the basis of these results, it is expected that <e10> diflunisal </e10> may have an effect on blood levels of <e20> acetaminophen </e20> and other anticonvulsants, and conversely, that its effect on blood levels of concomitant anticonvulsants may be increased.
mechanism	Furthermore, <e10> rifampin </e10>, phenytoin and carbamazepine may increase the clearance of <e20> levothyroxine </e20>.
mechanism	Furthermore, rifampin, clarithromycin, indinavir, and <e10> rifabutin </e10> may interfere with <e20> diltiazem </e20> metabolism.
mechanism	Furthermore, rifampin, clofibrate, and <e10> erythromycin </e10> may enhance the metabolism of the <e22> selective_MAO_inhibitors </e22>, resulting in an increased elimination of the rifampin, clofibrate, and erythromycin.
mechanism	Concomitant administration of <e10> cisapride </e10> and <e20> amphetamine </e20> at # mg per day for # days produced a dose-related increase in amphetamine plasma levels.
mechanism	In vitro studies of <e10> cisplatin </e10> with vitamin_K_antagonists ( <e20> vitamin_K </e20> ) or with carbamazepine, phenobarbital, or tacrolimus, all of which have been reported to decrease vitamin_K concentrations, suggest that these agents may interfere with cisplatin metabolism.
mechanism	In vitro studies with a nonsteroidal_anti-inflammatory_agent ( <e10> diclofenac </e10> ) revealed that a single # mg/kg dose of <e20> colestipol </e20> could reduce the clearance of diclofenac by approximately 50%.
mechanism	Concurrent use of <e10> erythromycin </e10> and agents known to have CYP3A4 activity (e,g,, ritonavir, clarithromycin, nelfinavir, <e20> indinavir </e20>, saquinavir, telithromycin, troleandomycin ) may result in elevated plasma concentrations of these agents.
mechanism	Steady-state <e10> bosentan </e10> plasma concentrations are decreased by approximately 20% following administration of <e20> valdecoxib </e20>.
mechanism	Co-administration of <e10> ketoconazole </e10> and <e20> quinine </e20> decreased the half-life of quinine by 50%.
mechanism	Co-administration of <e10> ethambutol </e10> with <e20> ketoconazole </e20> increased the AUC of both ethambutol and ketoconazole.
mechanism	Co-administration of <e10> diazepam </e10> # hours after a single dose of <e20> anafranil </e20> significantly reduced anafranil plasma concentrations (mean decrease: #% in a given # hours).
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10> with <e20> dapsone </e20> produced an increase in cytochrome P450 activity of dapsone and resulted in a decrease in dapsone levels.
mechanism	"Simvastatin and Other Nonsteroidal_Anti-inflammatory_Drugs ( <e12> NSAIDs </e12> ): Tablets and Capsules: The concomitant administration of <e20> simvastatin </e20> with other nonsteroidal_anti-inflammatory_drugs (
A role for prostaglandin E2 in the development of rheumatic and inflammatory diseases: evidence from the in vitro study with prostaglandin_E2-or prostaglandin_F2alpha-stimulated prostaglandin synthase-2 isozyme-inhibitors and in vivo studies.It is proposed that prostaglandin-E2 (PGE2) may be involved in the development of rheumatic and inflammatory diseases. The study of this hypothesis was performed in patients with rheumatic and inflammatory diseases by means of in vitro studies with PGE2 or with the E2 metabolite PGF2alpha. The studies were performed in normal human"
mechanism	<e10> Bosentan </e10>, by decreasing plasma concentrations of phenytoin, diltiazem, <e20> ketoconazole </e20>, and warfarin, increased the clearance of phenobarbital, valproate, and digoxin.
mechanism	<e10> Bosentan </e10> has been reported to decrease serum levels of <e20> digoxin </e20>.
mechanism	<e10> Bosentan </e10> and <e20> astemizole </e20> (in rats) and increased the half-life of both drugs by approx. 50%.
mechanism	Warfarin : Co-administration of <e10> warfarin </e10> with <e20> ketoconazole </e20> resulted in an approximately 40% increase in the steady-state concentration of warfarin.
mechanism	Warfarin : Co-administration of <e11> VIDEX </e11> with <e20> warfarin </e20> resulted in an increase in mean t,max and AUC of warfarin.
mechanism	Concomitant oral administration of <e10> clarithromycin </e10> (50 mg three times a day) and <e20> diltiazem </e20> (25 mg three times a day) in healthy volunteers significantly decreased the clearance of clarithromycin by 23% (Cmax, # ng/mL).
mechanism	- Indomethacin : <e10> Indomethacin </e10> has been reported to decrease the renal clearance of <e20> triamterene </e20> and to increase the clearance of cisapride.
mechanism	In a study in rats, concomitant administration of <e10> ketoconazole </e10> and <e20> diflunisal </e20> produced a twofold increase in the concentration of diflunisal in the plasma.
mechanism	In a study of patients with congestive heart failure, a study in which <e10> nefazodone </e10> was coadministered with the calcium channel blocker, <e20> digoxin </e20>, resulted in a statistically significant reduction in plasma digoxin levels (P =.03).
mechanism	In vitro, <e10> rifampin </e10> inhibited <e20> quinine </e20>.
mechanism	<e10> Itraconazole </e10> and <e20> warfarin </e20> may interact with the metabolism of theophylline (or other warfarin derivatives).
mechanism	<e10> Phenytoin </e10> may increase <e20> ketoconazole </e20> clearance, resulting in elevated levels of serum ketoconazole.
mechanism	Since the pharmacokinetics of <e10> cyclosporine </e10> may be altered by concomitant administration of <e20> cimetidine </e20>, a dose increase of cyclosporine may be required when given concurrently with this protease inhibitor.
mechanism	However, in another study, <e10> diltiazem </e10> at a dose of # mg/kg/day for # days resulted in a 30% increase in the plasma levels of the <e20> rofecoxib </e20> concomitantly with an approximately 6-fold increase in the plasma concentrations of the rofecoxib hydrochloride metabolite.
mechanism	When the <e11> ENABLEX </e11> system was administered concurrently with <e20> astemizole </e20>, the half-life of both drugs was extended.
mechanism	Interactions for vitamin_D_analogues : <e10> Iodine </e10>, vitamin_D, and <e20> rifampin </e20> (a vitamin_D receptor agonist ) may decrease the absorption of either vitamin_D or a vitamin_D_antagonist.
mechanism	Phenytoin / Phenobarbital / Warfarin : <e10> Erythromycin </e10> may enhance the metabolism of <e20> phenytoin </e20>, phenobarbital, or warfarin, resulting in elevated plasma levels of these medications.
mechanism	Phenytoin / Phenobarbital : A concomitant administration of <e10> phenytoin </e10> and <e20> phenobarbital </e20> causes a significant reduction in serum phenobarbital concentration (C(max) = 50%, AUC = 1,904,900 min-1, and AUC(T) = 6,904,500 min-1).
mechanism	Ketoconazole : <e10> Ketoconazole </e10> was shown to increase the clearance of cimetidine and increase the concentration of <e20> dexamethasone </e20>.
mechanism	Corticosteroids : A decrease in <e10> cefazolin </e10> clearance has been reported in patients receiving cefazolin concurrently with oral corticosteroids, resulting in elevated plasma levels of <e20> cyclosporine </e20>.
mechanism	Interactions for vitamin_D_analogues and vitamin_D_antagonists are reported, including <e10> lovastatin </e10>, which inhibits the metabolism of <e20> vitamin_D </e20> by inhibiting the hepatic uptake of vitamin_D and calcium.
mechanism	Phenytoin / Phenobarbital : <e10> Phenobarbital </e10> increases the clearance of <e20> phenytoin </e20> by 4% and a concentration of phenytoin which is approximately 2 to 3 times the active concentration of the parent drug, the effective concentration, increases the clearance of phenytoin by approximately 25% and increases the clearance of phenobarbital by approximately 3%.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> increases the clearance of <e20> doxorubicin </e20> by approximately 10% and the volume of distribution by approximately 10%.
mechanism	Corticosteroids : A study in rats has shown that <e10> atorvastatin </e10> reduced the plasma levels of <e20> atorvastatin </e20>.
mechanism	Lithium Reversible increases in serum lithium concentrations have been reported following administration of <e10> lithium </e10> with <e20> erythromycin </e20>.
mechanism	An increase in the concentration of digoxin has been reported when <e10> digoxin </e10> is coadministered with cyclosporine, carbamazepine, <e20> tacrolimus </e20>, hexobarbital, phenytoin, alfentanil, phenobarbital, phenytoin plus cisapride, phenytoin plus disopyramide, phenobarbital plus disopyramide, disopyramide plus disopyramide, triazolam, and/or tolbutamide.
mechanism	Leucovorin : The oral absorption of <e10> diltiazem </e10> is impaired by coadministration with <e20> leucovorin </e20> and has been demonstrated to result in increased plasma levels of diltiazem and its active metabolite diltiazem sulfone.
mechanism	Agents that are in common use in addition to <e10> phenytoin </e10> include astemizole, cimetidine, clarithromycin, methotrexate, nefazodone, nelfinavir, ritonavir, <e20> saquinavir </e20>, telithromycin, troleandomycin.
mechanism	Agents that are CYP3A4 substrates, such as ketoconazole, itraconazole, itraconazole_sulfate, ritonavir, clarithromycin, indinavir, itraconazole, <e10> nefazodone </e10>, nelfinavir, saquinavir, telithromycin, troleandomycin, terfenadine, and voriconazole should be administered with caution because of possible drug interactions with <e20> cisapride </e20>.
mechanism	Agents that are CYP3A4 substrates (eg, ketoconazole, itraconazole, ritonavir, <e10> clarithromycin </e10>, indinavir, nelfinavir, saquinavir, indinavir, indinavir/cefvir, itraconazole, ritonavir, saquinavir, itraconazole ) may reduce the bioavailability of <e20> erythromycin </e20>.
mechanism	Agents that are strong inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, nefazodone, troleandomycin, <e10> ritonavir </e10>, nelfinavir ) may increase the plasma concentrations of <e20> rifabutin </e20> and may not be effective if the rifabutin level is high.
mechanism	Agents that are CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, indinavir, <e10> nefazodone </e10>, nelfinavir ) have been reported to increase the clearance of <e20> gefitinib </e20> by up to 25% in normal subjects.
mechanism	Agents that are inhibitors of CYP3A4 (e,g,, ketoconazole, itraconazole, ritonavir, clarithromycin, indinavir, <e10> nefazodone </e10>, nelfinavir, saquinavir, saquinavir/interferon-alfa, telithromycin ) have been shown to prolong the half-life of <e20> nelfinavir </e20> by 50% or more and to prolong the half-life of itraconazole by 45%.
mechanism	Agents that are CYP3A4 inhibitors, including <e10> erythromycin </e10>, clarithromycin, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and erythromycin, inhibit <e20> isoniazid </e20> metabolism by inhibiting CYP3A4.
mechanism	Agents that are inhibitory to CYP3A4 (eg, ketoconazole, itraconazole, ritonavir, nelfinavir, clarithromycin, <e10> nefazadone </e10>, troleandomycin, nefazadone_methionine, astemizole, clarithromycin ) are expected to decrease the elimination of <e20> clarithromycin </e20>.
mechanism	Agents that are predominantly metabolized by cytochrome P450 3A4 (CYP3A4) (eg, diltiazem, <e10> nelfinavir </e10>, clarithromycin ) may reduce the metabolism of <e20> ketoconazole </e20>.
mechanism	Agents that are CYP 3A4 inhibitors (e,g,, ketoconazole, erythromycin, clarithromycin, ritonavir, indinavir, <e10> itraconazole </e10>, nefazodone, nelfinavir, saquinavir, telithromycin ) may increase plasma concentrations of <e20> erythromycin </e20>.
mechanism	Agents that are CYP3A4 inhibitors ( alprazolam, fluoxetine, <e10> fluvoxamine </e10>, paroxetine, sertraline, theophylline ) increase <e20> clarithromycin </e20> absorption.
mechanism	Agents that are potent inhibitors of CYP3A4 (such as ketoconazole, erythromycin, ritonavir, clarithromycin, indinavir, saquinavir, <e10> indinavir </e10>, saquinavir, troleandomycin ) may increase the plasma concentrations of <e20> phenytoin </e20>.
mechanism	Agents that are vasoconstrictive and <e10> dipyridamole </e10> are also vasoconstrictive and <e20> ketoconazole </e20> is a vasoconstrictive.
mechanism	Agents that are CYP3A4 inhibitors (eg, ketoconazole, itraconazole, clarithromycin, ritonavir, nelfinavir, <e10> indinavir </e10>, saquinavir, saquinavir, telithromycin, troleandomycin, troleandomycin, troleandomycin, valdecoxib, indinavir, saquinavir, troleandomycin ) increase the clearance of <e20> nelfinavir </e20> and may require increases in nelfinavir plasma concentrations to achieve a desired response.
mechanism	Agents that are hepatic inhibitors of CYP2D6 (eg, ketoconazole, <e10> itraconazole </e10>, erythromycin, clarithromycin, ritonavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, <e20> troleandomycin </e20>, voriconazole, and nelfinavir ) may increase the plasma concentrations of rifampin and may therefore require increases in the dose of rifampin when coadministered with itraconazole.
mechanism	Agents that are active in inhibiting CYP3A4 activity, such as <e10> ketoconazole </e10>, fluconazole, itraconazole, phenytoin, ritonavir, indinavir, saquinavir, indinavir_C, and troleandomycin have been reported to reduce the half-life of <e20> erythromycin </e20> by 20% to 50%.
mechanism	Agents that are CYP3A4 inhibitors ( alfentanil, <e10> clarithromycin </e10>, ritonavir, indinavir, saquinavir, indinavir_sulfate, nefazodone, troleandomycin, fluoxetine, fluvoxamine, valdecoxib, cimetidine, <e20> rifabutin </e20>, nelfinavir, theophylline, zidovudine ) may increase plasma concentrations of lovastatin or fluoxetine.
mechanism	Agents that are vasoconstrictive (eg, <e10> clonidine </e10>, indomethacin ) may increase the plasma levels of <e20> verapamil </e20>.
mechanism	Agents that are CYP3A4 inhibitors (e,g,, ketoconazole, <e10> itraconazole </e10>, ritonavir, indinavir, saquinavir, nelfinavir ) decrease plasma levels of <e20> phenytoin </e20>.
mechanism	Agents that are primarily metabolized by CYP2C9 (eg, quinidine, rifampin, fluoxetine, theophylline, <e10> methyldopa </e10>, and alfentanil ) may increase plasma concentrations of <e20> valdecoxib </e20>.
mechanism	Agents that are CYP 3A4 inhibitors (eg, ketoconazole, <e10> itraconazole </e10>, ritonavir, clarithromycin, indinavir, saquinavir, saquinavir, telithromycin, troleandomycin, erythromycin, indinavir, saquinavir, <e20> troleandomycin </e20>, indinavir, itraconazole ) may increase the plasma concentrations of the orally administered metronidazole and may therefore require an increase in metronidazole dose.
mechanism	Agents that are inhibitors of CYP3A4 (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, <e10> indinavir </e10>, nelfinavir, saquinavir, telithromycin ) may increase the clearance of <e20> warfarin </e20>.
mechanism	Agents that are CYP3A4 substrates (eg, <e10> ketoconazole </e10>, ritonavir, indinavir, itraconazole, clarithromycin, nefazodone, nelfinavir, saquinavir, <e20> telithromycin </e20>, troleandomycin ) may reduce the bioavailability of oral cephalosporins and may increase the elimination half-life.
mechanism	Agents that are in close proximity to <e11> SPRYCEL </e11> may increase plasma concentrations of <e20> bromocriptine_mesylate </e20>, leading to decreased availability of its active metabolite.
mechanism	Agents that are CYP3A4 inhibitors (e,g,, ketoconazole, <e10> itraconazole </e10>, ritonavir, clarithromycin, nefazodone, nelfinavir, indinavir, saquinavir, telithromycin, troleandomycin, didanosine, indinavir, itraconazole, troleandomycin, saquinavir, indinavir, itraconazole ) may increase plasma levels of <e20> bromocriptine_mesylate </e20> and therefore may require an increase in dose of bromocriptine_mesylate to achieve the desired plasma level.
mechanism	Agents that are CYP 3A4 substrates (e,g,, <e10> ketoconazole </e10>, itraconazole, ritonavir, clarithromycin, nefazodone, ritonavir, nelfinavir, saquinavir, <e20> telithromycin </e20> ) may enhance the metabolism of clarithromycin, nelfinavir, or saquinavir, leading to decreased plasma concentrations and/or increased AUC values.
mechanism	Agents that are CYP 3A4 inhibitors, such as ketoconazole, <e10> itraconazole </e10>, clarithromycin, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin, and astemizole may reduce the metabolism of <e20> norfloxacin </e20>.
mechanism	Agents that are potent inducers of CYP3A4 (e,g,, cyclosporine, tacrolimus, <e10> carbamazepine </e10>, phenytoin, alfentanil, disopyramide, phenytoin ) should be administered with caution in patients receiving <e20> erythromycin </e20> because of possible synergistic inhibition of CYP3A4.
mechanism	Agents that are CYP3A4 inhibitors (e,g,, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, <e10> nefazodone </e10>, nelfinavir, ritonavir, saquinavir, telithromycin ) have been reported to increase the clearance of <e20> rifampin </e20>.
mechanism	Agents with Increased Heparin Level: Concomitant use of <e11> ENBREL </e11> and agents with a high heparin level (e,g,, <e20> pentamidine </e20>, terfenadine, dexamethasone, etc,) may result in increased heparin level.
mechanism	Agents with Increased Heparin Effect: Quinolones (e,g,, <e10> erythromycin </e10>, clarithromycin ) and ciprofloxacin have been shown to decrease the <e20> heparin </e20> binding capacity of aporphine_HCl by approximately 60%.
mechanism	Agents with Increased Sustained Release: <e10> Ketoconazole </e10>, nelfinavir, ritonavir, and erythromycin decrease the rate of absorption of the <e20> cimetidine </e20>, and therefore may increase the half-life.
mechanism	<e11> Geocillin </e11> may decrease the clearance of <e20> morphine </e20> and other diuretics, causing a decrease in blood pressure.
mechanism	Geocillin ( <e10> rifampin </e10> ) and ciprofloxacin, which have been shown to inhibit EGF, also inhibit <e20> prostaglandin_I2 </e20> synthesis.
mechanism	<e10> Iron </e10> -induced oxidative stress is prevented by <e20> alfentanil </e20>.
mechanism	<e10> Iron </e10> and zinc have been shown to inhibit the absorption of <e20> tetracycline </e20>.
mechanism	Although <e10> metoclopramide </e10> inhibits <e20> ethinyl_estradiol </e20>, it does not affect its metabolism.
mechanism	Serum concentration of <e10> digoxin </e10> may be reduced by <e20> hydrocodone </e20>, which is metabolized by cytochrome P450 3A4 (CYP3A4), and by aripiprazole, which has a CYP3A4 inhibitory effect.
mechanism	Serum concentration of <e10> digoxin </e10> was approximately 10% higher in diabetic patients on oral <e20> methotrexate </e20> therapy than in diabetic patients on other antihypertensive therapy, concomitantly with an increase in serum digoxin concentration of approximately 2%.
mechanism	Cyclosporine : Modest to substantial decreases in serum creatinine, creatinine clearance, and serum creatinine kinetics were observed in patients treated with <e10> cyclosporine </e10> at steady state with and without <e20> furosemide </e20>.
mechanism	Inducers and Inhibitors of the CYP3A4 (such as <e10> ketoconazole </e10> and itraconazole ) inhibit the metabolism of <e20> astemizole </e20>.
mechanism	<e11> CANCIDAS </e11> may potentiate the negative inotropic effect of <e20> gentamicin </e20>.
mechanism	In two clinical studies, coadministration of <e10> digoxin </e10> with <e20> diltiazem </e20> resulted in an increase in the maximum plasma concentration of digoxin by ~25%.
mechanism	In addition, results from pharmacokinetic studies of <e10> indinavir </e10> and <e20> ritonavir </e20> were evaluated for a possible inhibition of the metabolism of these drugs by phenytoin.
mechanism	In addition, results from in vitro studies of <e10> piperazine </e10> and <e20> diazepam </e20> indicate that both drugs have a tendency to decrease the clearance of non-steroidal_anti-inflammatory_drugs and that both drugs may decrease the clearance of cholestyramine.
mechanism	In addition, results from in vitro studies of <e12> benzodiazepines </e12> with a similar structure (e,g,, diazepam, alprazolam, chlordiazepoxide, diazepam_sodium, chlordiazepoxide, phenobarbital, phenytoin, primidone, triazolam ) suggest a possible drug interaction with <e20> ketoconazole </e20>.
mechanism	In addition, results of in vitro studies of <e10> acitretin </e10> with these co-administered drugs indicate that the two drugs may have a similar effect on the pharmacokinetics of <e20> ketoconazole </e20>, but that ketoconazole may have a greater effect on the metabolism of acitretin.
mechanism	<e10> Probenecid </e10> may interact with the CYP3A4 inhibitor <e20> ketoconazole </e20>, resulting in elevated levels of prostaglandin (PG) F2alpha in plasma.
mechanism	Iron_Supplements and Foods (Sodium/Iron and <e10> Calcium </e10> ): <e20> Magnesium </e20> : Magnesium intake may increase iron absorption by altering absorption of iron.
mechanism	Iron_Supplements and Foods containing <e10> iron </e10>, such as <e20> Magnesium_Sulfate </e20>, may decrease the absorption of iron.
mechanism	H2-Receptor_Antagonists : Co-administration of <e10> ketoconazole </e10> with <e20> warfarin </e20> resulted in a significant increase in warfarin serum levels.
mechanism	Probenecid : As with other <e12> tetracyclines </e12>, probenecid has the potential for interaction with <e20> aspirin </e20>, which may increase the rate of probenecid absorption.
mechanism	Carbamazepine : Elevated plasma levels of <e10> carbamazepine </e10> were observed with concomitant administration of <e20> fluconazole </e20> and an orally administered carbamazepine -containing regimen.
mechanism	Concomitant administration of <e10> ciprofloxacin </e10> and <e20> ketoconazole </e20>, an inhibitor of CYP3A4, decreased the exposure of ciprofloxacin by approximately 50% and decreased the half-life by approximately 50%.
mechanism	however, # mg/day <e10> Aprepitant </e10> # hours before the first dose of <e20> phenytoin </e20> # mg/day for # days resulted in a significant decrease in phenytoin plasma concentrations (P=0.035).
mechanism	Fluconazole : Concomitant administration of <e10> fluconazole </e10> and <e20> cisapride </e20> increased cisapride plasma levels by approximately 7%.
mechanism	This increase is reversible upon discontinuation of <e10> ketoconazole </e10> or <e20> warfarin </e20>.
mechanism	Lithium : In a study in healthy volunteers, <e10> lithium </e10> decreased the levels of <e20> lithium </e20> and decreased the metabolic activity of lithium.
mechanism	Metformin : In a study in normal volunteers, <e10> metformin </e10> significantly increased the <e20> valproate </e20> absorption, with similar effects on valproate and niacin.
mechanism	Although not observed, <e10> diazepam </e10> may reduce <e20> alcohol </e20> and other CNS_depressants' CNS depressant effects.
mechanism	In the first instance, hepatic enzyme response to <e10> methotrexate </e10> was found to be prolonged by administration of <e20> lithium </e20>.
mechanism	However, in the presence of <e10> clofibrate </e10>, the bioavailability of <e20> amiloride </e20> decreased by approximately 50%.
mechanism	ERYTHROMYCIN : In the absence of <e10> phenytoin </e10>, the pharmacokinetics of <e20> ergotamine </e20> are enhanced.
mechanism	In a multiple-dose study of <e10> astemizole </e10> # mg twice daily given concomitantly with either <e20> phenytoin </e20> or cisapride, the astemizole # mg dose resulted in a 41% increase in astemizole plasma concentrations compared with astemizole # mg given concomitantly with either phenytoin or cisapride.
mechanism	There was a significant increase in the <e10> isoniazid </e10> serum levels when <e20> piperacillin </e20> was coadministered with isoniazid.
mechanism	Antacids and kaolin : Antacids may cause <e10> colestipol </e10> to form an insoluble powder with high binding to a well-absorbed <e20> kaolin </e20>.
mechanism	Cimetidine : <e10> Cimetidine </e10> is a renal cytochrome P450 3A4 inhibitor with strong affinity for <e20> ketoconazole </e20>.
mechanism	Ampicillin : In vitro <e10> ampicillin </e10> increased <e20> erythromycin </e20> clearance by a factor of 2.2 (P =.005) in subjects taking cyclosporine concurrently.
mechanism	- Cholestyramine and erythromycin : <e10> Cholestyramine </e10> and erythromycin inhibit the metabolism of <e20> digoxin </e20>, causing a marked increase in plasma and urine concentrations.
mechanism	<e10> Chlorprothixene </e10> may inhibit the metabolism of <e20> chlorpropamide </e20>.
mechanism	Interactions for vitamin_D : In normal subjects, <e10> acitretin </e10> reduced the serum level of <e20> vitamin_D </e20> by about 25% when given with an oral vitamin_D preparation containing a high-dose of vitamin_D (1,000 IU of vitamin_D/day).
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may reduce the efficacy of <e20> cyclosporine </e20>.
mechanism	<e10> Cholestyramine </e10> increases the plasma levels of <e20> isoniazid </e20> by 50%.
mechanism	<e10> Cholestyramine </e10> decreases the metabolism of <e20> warfarin </e20> and increases the clearance of intravenous inotropes such as cetirizine, triazolam, and cisapride.
mechanism	<e10> Cholestyramine </e10> reduces the absorption of <e20> acetaminophen </e20> and does not affect the absorption of aminosalicylic_acid, clarithromycin, lithium, methotrexate, sulfonamides, or tricyclic_antidepressants.
mechanism	<e10> Cholestyramine </e10> and <e20> amiodarone </e20> have been reported to increase the hepatic clearance of the catecholamine_containing anticholinergic_agents, e,g,, chlordiazepoxide, tricyclic_antidepressants, phenothiazines, barbiturates, barbiturates and antihistamines.
mechanism	<e10> Cholestyramine </e10> at higher doses increases plasma levels of <e20> warfarin </e20>, but has little effect on the binding of warfarin to its receptor.
mechanism	<e10> Cholestyramine </e10> has been shown to increase the absorption of furosemide by blocking the hepatic metabolism of <e20> furosemide </e20>.
mechanism	<e10> Cholestyramine </e10> may have an additive effect with acetaminophen or other <e22> nonsteroidal_anti-inflammatory_drugs </e22> on the blood-sugar response to the oral glucose-containing antacid (OGA).
mechanism	<e10> Cholestyramine </e10>, <e20> cholestyramine_HCl </e20>, and cholestyramine_HCl_norethindrone were effective at blocking and potentiating acetaminophen / acetaminophen_type_anticholinergic_blocking_agents, whereas cholestyramine_HCl was not.
mechanism	<e10> Cholestyramine </e10>, <e20> warfarin </e20> and aspirin may interfere with hepatic enzyme systems (eg, CYP3A4, CYP3A5) which may be anabolic in nature.
mechanism	<e10> Cholestyramine </e10>, bromocriptine, valdecoxib, and <e20> cisapride </e20> may increase plasma concentrations of either rifampin or aripiprazole.
mechanism	<e10> Cholestyramine </e10> may inhibit the metabolism of <e20> atorvastatin </e20>, resulting in a higher plasma level of the latter.
mechanism	Cholestyramine resin may increase the clearance of <e10> digoxin </e10> and <e20> cimetidine </e20>.
mechanism	In another drug interaction study with a single oral dose of <e11> LEXAPRO </e11>, a dose-dependent increase in plasma <e20> morphine </e20> concentrations was observed when both drugs were administered concurrently.
mechanism	Probenecid : <e10> Probenecid </e10> may decrease the clearance of <e20> indomethacin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> has been reported to decrease blood levels of <e20> phenytoin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> has been shown to decrease the clearance of <e20> clofibrate </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> decreased the half-life of <e20> warfarin </e20> by a mean of 19% compared to warfarin alone.
mechanism	Probenecid : <e10> Probenecid </e10>, as well as acetaminophen, alprazolam, cimetidine, ethchlorvynol, <e20> furosemide </e20>, fluconazole, indomethacin, itraconazole, itraconazole_hydrochloride, itraconazole_nonsulfate, and astemizole, have been reported to inhibit the metabolism of oral medications, thus decreasing their pharmacologic effect.
mechanism	Probenecid : <e10> Probenecid </e10> (acetaminophen ) has been reported to reduce the bioavailability of <e20> fluvoxamine </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> may increase plasma concentrations of <e20> ketoconazole </e20> by altering its metabolism and absorption.
mechanism	Probenecid : <e10> Probenecid </e10> prolongs the QT interval on the ECG, reduces the heart rate and causes a reduction in the blood pressure when administered with <e20> adrenergic </e20>_blocking_agents.
mechanism	Probenecid : <e10> Probenecid </e10> increases <e20> cholestyramine </e20> clearance by approximately 50%.
mechanism	Probenecid : <e10> Probenecid </e10>, at the dose of # mg/kg/day, reduced the elimination of <e20> rifampin </e20> (16 mg/kg/day) by 25% and halved the elimination of propranolol (10 mg/kg/day).
mechanism	Probenecid : <e10> Probenecid </e10> may reduce the absorption of <e20> furosemide </e20> and other anticholinergics, increase the blood levels of norethindrone, and increase the metabolism of some amphetamines, especially after administration of a single dose of a potent, single-dose, intravenous, cimetidine -type amphetamine.
mechanism	Probenecid : <e10> Probenecid </e10> may reduce plasma <e20> chlorpropamide </e20> concentrations.
mechanism	Pharmacokinetic studies have shown that <e10> diltiazem </e10> has been shown to inhibit CYP3A4, thus potentially increasing plasma concentrations of <e20> carbamazepine </e20>.
mechanism	Pharmacokinetic studies have demonstrated that the <e10> efavirenz </e10> AUC and Cmax are decreased by approximately 30% and approximately 60%, respectively, when <e20> foscarnet </e20> is coadministered.
mechanism	<e11> Tagamet </e11>, given at doses of # mg/day for # days or # mg/day for # days and # mg/day for # days, significantly decreased the Cmax and AUC of <e20> cimetidine </e20> by 38% and 44%, respectively.
mechanism	<e11> Tagamet </e11>-Based on in vitro data, Tagamet is effective in inhibiting <e20> carbamazepine </e20> metabolism and may increase its pharmacokinetics and prolonging the QT interval on the ECG.
mechanism	<e11> Tagamet </e11> may decrease the clearance of <e20> cyclosporine </e20> and other glucocorticoids.
mechanism	<e11> Tagamet </e11>, in doses of # mg/kg per day, significantly decreased the hepatic AUC and Cmax values of <e20> ketoconazole </e20> by 6% and 17%, respectively.
mechanism	<e11> Tagamet </e11> # mg/kg of # days was found to reduce the plasma concentrations of <e20> warfarin </e20> by 48% and 40%, respectively.
mechanism	<e11> Tagamet </e11> significantly decreased <e20> bromocriptine_mesylate </e20> uptake in C2C12 cells by 63%.
mechanism	<e11> Tagamet </e11> decreased plasma levels of <e20> morphine </e20> and its active metabolite enoxacin by 53% and 68%, respectively.
mechanism	<e11> Tagamet </e11> inhibited <e20> cimetidine </e20> in a dose-dependent manner.
mechanism	However, a crossover study with single dose administration of <e10> buprenorphine </e10> (25 mg/kg) and <e20> ketoconazole </e20> (10 mg/kg) in a dose-response manner demonstrated that ketoconazole increased the mean BUN, serum creatinine, and serum phosphorus levels significantly.
mechanism	However, a crossover study (crossover design) demonstrated a trend for increased plasma levels of <e10> cyclosporine </e10> in subjects receiving a daily dose of # mg of cyclosporine for # days after administration of <e20> nelfinavir </e20>.
mechanism	Amitriptyline : Concurrent administration of <e10> acitretin </e10> and <e20> anakinra </e20> increases plasma levels of anakinra and decreases the half-life of anakinra by a mean of 15%.
mechanism	Co-administration of <e10> digoxin </e10> with <e20> warfarin </e20> resulted in a 6% increase in serum warfarin levels.
mechanism	Elevated plasma levels of <e10> dexamethasone </e10> are associated with decreased levels of <e20> almotriptan </e20> and its metabolite ( almotriptan ) in healthy subjects.
mechanism	<e12> Quinolones </e12> may have a possible interaction with <e20> norethindrone </e20>, concomitant with the increased half-life of norethindrone.
mechanism	<e12> Antacids </e12> may interfere with the absorption of <e20> cyclosporine </e20>, resulting in a decrease in the maximum plasma concentration (Cmax) and AUC.
mechanism	Antacids or <e10> magnesium </e10> containing inorganic salt or aluminum containing inorganic salt or aluminum containing inorganic salt (other than <e20> zinc </e20> ) may interfere with the absorption of antacids containing inorganic salt or aluminum containing inorganic salt or aluminum containing inorganic salt.
mechanism	Also, concomitant administration of <e10> warfarin </e10> and <e20> sildenafil </e20> at recommended doses will increase the clearance of warfarin by approximately 10%.
mechanism	Also, concomitant administration of <e10> ketoconazole </e10> with <e20> diltiazem </e20> or with carbamazepine has been reported to result in a decreased clearance of ketoconazole and a subsequent decrease in plasma levels of diltiazem.
mechanism	Also, concomitant administration of <e10> warfarin </e10> and <e20> rifampin </e20> can lead to elevated serum warfarin levels, which may reduce the effect of warfarin on the half-life of rifampin.
mechanism	Also, concomitant administration of <e10> Aprepitant </e10> and <e20> cimetidine </e20> produced a 1.5-fold increase in cimetidine plasma levels.
mechanism	Elevated cyclosporine serum concentrations have been reported when <e10> cyclosporine </e10> and <e20> enoxacin </e20> were coadministered.
mechanism	Some <e12> quinolones </e12> have been reported to inhibit <e20> warfarin </e20> metabolism by altering the activity of its cofactor, the cytochrome P450 3A4 enzyme.
mechanism	Some quinolones, including <e10> ciprofloxacin </e10>, may increase the clearance of other <e22> anticoagulant_drugs </e22>.
mechanism	Methotrexate Renal tubular secretion of <e10> methotrexate </e10> may be reduced by <e20> aripiprazole </e20>, which prevents the absorption of methotrexate.
mechanism	Multivalent Cation-Containing Products: Concurrent use of <e11> INSPRA </e11> and products containing multivalent cations (e,g,, iron, zinc, or magnesium ) may result in increased blood levels of <e20> inorganic_sulfate </e20> and, hence, an increased risk of iron toxicity.
mechanism	Multivalent Cation-Containing Products: <e10> Probenecid </e10> ( Erythromycin ) may increase the exposure of <e20> nifedipine </e20>.
mechanism	Multivalent Cation-Containing Products: <e11> Gleevec </e11> may increase the plasma concentrations of cation-containing products such as <e20> cyclosporine </e20> and tacrolimus.
mechanism	Multivalent Cation-Containing Products: Magnesium : <e10> Magnesium </e10> preparations containing C(15) and <e20> calcium </e20>, calcium salts, or products containing magnesium in combination with other cations (such as calcium sulfate or calcium carbonate ) may increase the bioavailability of magnesium and should be avoided.
mechanism	Multivalent Cation-Containing Products: When a multivalent cation-containing product (e,g,, amiodarone, <e10> nicotinamide </e10>, niacinamide, etc,) is administered concomitantly with <e20> hydralazine </e20>, adverse effects may occur.
mechanism	Multivalent Cation-Containing Products: Tablets and other multivalent cations-containing products may interfere with absorption of <e10> carbamazepine </e10> and <e20> bromocriptine </e20>.
mechanism	Multivalent Cation-Containing Products: Combinations of cationic_alkaloids, such as almotriptan, with multivalent cation-containing products (eg, <e10> probenecid </e10>, probenecid s, amiodarone, and succinimide ) may result in clinically significant increases in serum <e20> ketoconazole </e20> concentrations.
mechanism	Multivalent Cation-Containing Products: The concomitant administration of <e11> HEXALEN </e11> tablets with multivalent cation-containing products (eg, calcium_channel_blockers and <e20> thiazide_diuretics </e20> ) may increase the absorption of cations in these products by a factor of 5 or more.
mechanism	Multivalent Cation-Containing Products: Multivalent Cation-Containing Products (eg, <e10> digoxin </e10>, <e20> norethindrone </e20>, and methotrexate ) may increase the serum concentrations of these drugs.
mechanism	Phenytoin : Altered serum concentrations of <e10> phenytoin </e10> were observed when <e20> dofetilide </e20> was administered concomitantly with phenytoin.
mechanism	Probenecid : <e10> Probenecid </e10> may decrease the absorption of <e20> phenytoin </e20> and other oral hypoglycemic_agents, resulting in a lower therapeutic dose.
mechanism	Probenecid : <e10> Probenecid </e10> significantly decreased the ESR and PFS response to <e20> cyclosporine </e20>.
mechanism	Theophylline : As a result of the lower plasma levels of theophylline, <e10> ibuprofen </e10> may have caused a decrease in the bioavailability of <e20> theophylline </e20>.
mechanism	Theophylline : As with other drugs with CYP3A4 inhibition activity, a maximum increase in <e10> theophylline </e10> plasma concentrations of 50% or greater was observed with concomitant administration of <e20> diltiazem </e20> (7%) and carbamazepine (3%).
mechanism	Antibiotics : In vitro data indicate that <e10> daptomycin </e10> and <e20> ampicillin </e20> inhibit the metabolism of both daptomycin and ampicillin and may prolong their half-life in the human body.
mechanism	Antibiotics : In vitro studies with <e10> colistin </e10> indicate that <e20> ciprofloxacin </e20> may inhibit the metabolism of ciprofloxacin, resulting in a high Cmax and a prolonged half-life.
mechanism	Antibiotics : In a study in healthy volunteers, the half-life of <e11> WELLBUTRIN </e11> increased by 20% and the elimination half-life decreased by 20% when the recommended daily dose of <e20> rifabutin </e20> was doubled.
mechanism	Antidepressants : In a double-blind study, <e10> clorazepate </e10> did not significantly affect the metabolism of <e20> fluoxetine </e20>, fluvoxamine, paroxetine, sertraline, or citalopram, as determined by the AUC(0-12) of the target metabolite and concentrations of the active metabolite.
mechanism	Antifungals : In vitro data from two in vivo studies indicate that <e10> itraconazole </e10> significantly decreases the half-life of <e20> astemizole </e20> and itraconazole.
mechanism	Antifungals : In vitro studies with two azole_antifungals ( <e10> itraconazole </e10> and ketoconazole ), which are potent inhibitors of azole metabolism, indicate that their clearance is impaired by <e20> astemizole </e20>, an inhibitor of hepatic metabolism.
mechanism	Antifungals : In vitro data indicate that <e10> itraconazole </e10> and itraconazole_derivatives may inhibit the metabolism of <e20> ketoconazole </e20> and enteroconazole by inhibiting CYP3A4.
mechanism	H2_Receptor_Antagonists : <e10> Cimetidine </e10>, ketoconazole, indomethacin, and cimetidine may increase the plasma concentrations of <e20> ketoconazole </e20> and indomethacin.
mechanism	The gastrointestinal absorption of <e10> indomethacin </e10> may be increased by coadministration with <e20> erythromycin </e20>, resulting in decreased plasma levels of indomethacin.
mechanism	Protease_Inhibitors : In clinical studies, <e10> diclofenac </e10> has been reported to decrease plasma concentrations of <e20> warfarin </e20>, its active metabolite.
mechanism	Protease_Inhibitors : In the presence of <e10> rifampin </e10>, a decrease in the rate of reduction of <e20> cimetidine </e20> was observed.
mechanism	Plasma levels of <e10> diltiazem </e10> are significantly decreased in patients treated concomitantly with <e20> warfarin </e20> or warfarin derivatives, and the recommended dose of diltiazem is # mg/day.
mechanism	<e11> Atromid-S </e11> may have an additive effect with <e20> carbamazepine </e20>.
mechanism	<e11> Atromid-S </e11> inhibits <e20> valdecoxib </e20>.
mechanism	The plasma concentration of <e10> carbamazepine </e10> increased by 38% when it was given concomitantly with <e20> phenytoin </e20>.
mechanism	plasma levels of <e10> ketoconazole </e10> were increased by 48% when <e20> ketoconazole </e20> was given with all of the following: calcium supplements, magnesium supplements, zinc supplements, magnesium sulfate supplements, cyclosporine, sulfasalazine, or tacrolimus.
mechanism	plasma levels of <e10> diltiazem </e10> were significantly increased when it was given with <e20> diltiazem </e20>, but not when it was given with either dexamethasone or a beta-adrenergic_blocking_agent.
mechanism	plasma levels of <e10> cyclosporine </e10> have been reported to be decreased by <e20> methotrexate </e20>, almotriptan, and cimetidine, and the cyclosporine metabolite macrotoxin has been reported to decrease the metabolism of cyclosporine.
mechanism	plasma levels of <e10> phenytoin </e10> increased approximately 8-fold after coadministration of <e20> piperacillin </e20> # mg (the Cmax was # ng/mL).
mechanism	plasma levels of <e10> cisapride </e10> and <e20> amiodarone </e20> were increased by # to #-fold in patients receiving propranolol and rifampin concurrently.
mechanism	plasma levels of <e10> diltiazem </e10> were decreased by 53% following coadministration with <e20> probenecid </e20>.
mechanism	plasma levels of <e10> carbamazepine </e10> and <e20> aprepitant </e20> were increased by the addition of the anticonvulsant.
mechanism	plasma levels of <e10> warfarin </e10> increased approximately twofold when coadministered with <e20> probenecid </e20>.
mechanism	Administration of <e10> chloramphenicol </e10> to subjects who are intravenously administered <e20> nelfinavir </e20> has been reported to result in significant increases in the plasma concentrations of nelfinavir.
mechanism	Because Anafranil is the major metabolite of <e10> astemizole </e10>, <e20> theophylline </e20> may also interact with Anafranil.
mechanism	In a study of patients with established cystic fibrosis, <e10> ketoconazole </e10> did not affect the clearance of <e20> cyclosporine </e20>.
mechanism	Cytochrome P-450 inducers, <e10> atorvastatin </e10>, indinavir, and itraconazole have been reported to decrease <e20> doxorubicin </e20> AUC by about 50%.
mechanism	Cytochrome P-450 inducers, such as fluconazole, <e10> ketoconazole </e10>, and itraconazole may increase <e20> anagrelide </e20> plasma concentrations by inhibiting CYP3A4.
mechanism	Cytochrome P-450 inducers, including <e10> erythromycin </e10>, may interfere with <e20> lithium </e20> metabolism and reduce the elimination of lithium.
mechanism	<e10> Phenytoin </e10> decreased the metabolism of <e20> cisapride </e20> and significantly increased plasma levels of citalopram.
mechanism	Phenytoin, <e10> Phenobarbital </e10>, and Phenytoin may increase the clearance of certain <e22> nonsteroidal_anti-inflammatory_drugs </e22> and carbamazepine.
mechanism	<e10> Cimetidine </e10> and other corticosteroids, especially cyclosporine, are inhibited by <e20> ketoconazole </e20>.
mechanism	Cimetidine, <e10> ethionamide </e10>, or similar drugs may reduce the bioavailability of <e20> digoxin </e20>.
mechanism	Although concomitant use of <e10> almotriptan </e10> with other psychotropic_agents (eg, phenothiazines, barbiturates, tricyclic_antidepressants, <e20> barbiturates </e20>, and some anticonvulsants ) has been reported to increase the clearance of almotriptan, it is not known whether almotriptan has a pharmacokinetic interaction with barbiturates, tricyclic_antidepressants, or barbiturates.
mechanism	<e10> Paroxetine </e10> may enhance the metabolism of <e20> isoniazid </e20>.
mechanism	However, other published studies have shown that <e12> aminoglycosides </e12> decrease <e20> nicotinamide_acetate </e20> uptake, possibly by competing for binding sites.
mechanism	However, other published studies have shown that <e10> diltiazem </e10> decreased plasma <e20> dofetilide </e20> levels by approximately 6%.
mechanism	<e10> Colchicine </e10> decreases the metabolism of <e20> guanfacine </e20> by approximately 15%.
mechanism	<e11> WelChol </e11> may increase the clearance of both <e20> ketoconazole </e20> and a dicumarol-type steroidal metabolite, with the latter generally being a stronger inhibitor of CYP3A4 activity than ketoconazole.
mechanism	<e11> WelChol </e11> ( cholestyramine ) infusion increased the concentrations of <e20> piperazine </e20>, but decreased the concentrations of cimetidine.
mechanism	Studies in humans have shown that <e10> erythromycin </e10> and other strong CYP3A4 inhibitors (e,g,, ketoconazole, itraconazole, erythromycin, clarithromycin ) reduce the plasma concentrations of <e20> cisapride </e20> and increase the clearance of cisapride.
mechanism	The absorption of <e10> diltiazem </e10> is decreased by <e20> ketoconazole </e20>.
mechanism	The absorption of <e10> erythromycin </e10> was reduced by 54% when coadministered with <e20> cyclosporine </e20>.
mechanism	The absorption of <e10> dasatinib </e10> may be enhanced by concomitant administration of <e20> cyclosporine </e20>.
mechanism	The absorption of <e11> LEXAPRO </e11> may be increased by certain drugs such as phenytoin, amiodarone, sulfasalazine, corticosteroids, anticonvulsants, barbiturates, benzodiazepines, barbiturates, clofibrate, diazepam, diazepam_ulfone, fluoxetine, grapefruit juice, <e20> grapefruit juice containing salicylates </e20>, magnesium salts, phenobarbital, phenytoin, salicylates, quinine, thiazide_diuretics, and warfarin.
mechanism	The absorption of <e10> nifedipine </e10> is reduced by #-fold when coadministered with <e20> ketoconazole </e20> and vitamin_B6.
mechanism	Particular caution should be exercised when administering <e10> nevirapine </e10> to patients on chronic <e20> quinine </e20> therapy since the concentrations of quinine in blood are generally low.
mechanism	Particular caution should be observed when administering <e11> VIDEX </e11> in patients receiving oral <e22> hypoglycemic_agents </e22>.
mechanism	Digoxin : Coadministration of <e10> digoxin </e10> with <e20> clarithromycin </e20> and warfarin decreased the binding of digoxin by 50%.
mechanism	Therefore, if <e10> ketoconazole </e10> is administered concomitantly with <e20> cimetidine </e20>, a significant decrease in cimetidine serum concentration may occur.
mechanism	Drugs that induce hepatic enzyme activity (eg, cyclosporine, tacrolimus, carbamazepine, phenytoin, alfentanyl, <e10> phenobarbital </e10>, phenytoin_HCl, phenytoin_HCl_with_Hexabromide, bromocriptine, phenytoin_HCl_with_Hexabromide, phenytoin_HCl_with_Iodide, bromocriptine_HCl_with_Iodide, and tricyclic_antidepressants ) may reduce the clearance of <e20> cimetidine </e20> and thus may increase serum concentrations.
mechanism	Drugs that induce hepatic enzymes such as phenytoin, <e10> carbamazepine </e10>, phenobarbital, and barbiturates may decrease the clearance of <e20> fluvoxamine </e20>.
mechanism	Drugs that induce hepatic metabolism of <e11> FOSCAVIR </e11> include: acetaminophen ( Tylenol ), chloramphenicol ( <e20> chloramphenicol </e20> ), indomethacin ( ciprofloxacin ), isoniazid ( ethionamide ), itraconazole ( Itraconazole ), itraconazole sulfate, itraconazole sulfate, quinine ( Quinine ), theophylline ( Theophylline ), troleandomycin ( trileandomycin ), and valproate ( carbamazepine ).
mechanism	Drugs such as cholestyramine, furosemide, phenytoin, and <e10> phenobarbital </e10> have been reported to increase the clearance of <e20> hydralazine </e20>.
mechanism	<e10> Colchicine </e10> given concurrently with <e20> bromocriptine_mesylate </e20> increased the half-life of bromocriptine by #%, but did not increase the AUC.
mechanism	Colchicine para-aminosalicylic_acid and/or <e10> colchicine </e10> may interfere with absorption of <e20> cimetidine </e20>, resulting in lower serum levels.
mechanism	Concomitant use of <e10> valdecoxib </e10> and <e20> fluvoxamine </e20>, a common oral anticoagulant, resulted in elevations of the prothrombin time and its corresponding AUC.
mechanism	Concomitant use of <e10> erythromycin </e10> may result in increased blood levels of <e20> warfarin </e20>.
mechanism	Concomitant use of <e10> alosetron </e10> and <e20> ketoconazole </e20> may decrease the elimination of alosetron, resulting in a higher peak plasma concentration and a prolonged half-life of alosetron.
mechanism	Concomitant use of <e10> nevirapine </e10> with <e20> darunavir </e20> or indinavir may increase plasma levels of the latter drugs.
mechanism	Concomitant use of <e10> diltiazem </e10> with other antihypertensive_drugs (i,e,, guanethidine, <e20> amiodarone </e20>, phenytoin, alfentanil, and cisapride ) may increase the plasma concentrations of guanethidine and amiodarone.
mechanism	Concomitant use of <e10> diflunisal </e10> and <e20> erythromycin </e20> has been associated with an increased incidence of severe infections in patients with a primary sclerosing cholangitis.
mechanism	Concomitant use of <e10> erythromycin </e10> with <e20> carbamazepine </e20> (50 mg once daily for # days) results in a decrease of carbamazepine from # x 109 mg/L to # x 109 mg/L, which results in an additional decrease of the target AUC of carbamazepine to # x 109 minutes.
mechanism	Concomitant use of <e10> valdecoxib </e10> and <e20> probenecid </e20> may reduce the clearance of high-dose valdecoxib.
mechanism	Concomitant use of <e10> fluvoxamine </e10> with certain other <e22> tricyclic_antidepressants </e22>, anticonvulsants, barbiturates, and some antihistamines may produce CNS depression.
mechanism	Concomitant use of <e10> fluvoxamine </e10> with certain <e22> antidepressants </e22> may increase blood levels of the concomitant drug.
mechanism	Concomitant use of <e10> ketoconazole </e10> and <e20> digoxin </e20> has been reported to result in elevated digoxin plasma levels and toxicity, leading to reduced clinical efficacy of digoxin.
mechanism	Concurrent administration of <e10> digoxin </e10> and <e20> amphotericin_B </e20> may increase the clearance of the digoxin by approximately #%.
mechanism	Conversely, decreases in folic_acid levels may be expected in the presence of <e10> rifampicin </e10>, a CYP3A4 inhibitor that may inhibit <e20> terfenadine </e20> metabolism.
mechanism	There have been reports of decreased serum <e10> cyclosporine </e10> levels in patients on chronic <e20> digoxin </e20> therapy.
mechanism	Antibiotics : <e12> Antibiotics </e12>, including ampicillin, tetracycline, clindamycin, ciprofloxacin, colistin, ceftazidime, daptomycin, clarithromycin, diflunisal, indinavir, itraconazole, itraconazole sulfone, nefazodone, nelfinavir, ritonavir, saquinavir, <e20> telithromycin </e20>, troleandomycin, and voriconazole.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> may have an additive effect with <e20> digoxin </e20> when used concomitantly.
mechanism	Ephedrine : <e10> Erythromycin </e10> has been reported to decrease the metabolism of <e20> ephedrine </e20>, resulting in a 5% decrease in plasma ephedrine concentrations.
mechanism	Hepatic Enzyme Inducers, including aminoglycosides, tetracyclines, sulfonamides, sulfonamides, chloramphenicol, and <e10> erythromycin </e10>, may increase <e20> ketoconazole </e20> concentrations and result in elevated serum ketoconazole concentrations.
mechanism	Hepatic Enzyme Inducers, such as cimetidine, valproic_acid, phenobarbital, carbamazepine, phenytoin, <e10> valproate </e10>, theophylline, bromocriptine, <e20> carbamazepine </e20>, valproate, cimetidine, and valproate may increase the clearance of drugs that have enzyme inducers, such as digoxin, doxorubicin, cyclosporine, pimozide, and bromocriptine.
mechanism	Hepatic Enzyme Inducers, including <e10> isoniazid </e10>, valproic_acid, phenobarbital, phenytoin, carbamazepine, and theophylline, inhibit the metabolism of <e20> cisplatin </e20>.
mechanism	Drugs which inhibit CYP3A4 (eg, <e10> phenytoin </e10>, fluoxetine, paroxetine, theophylline, quinidine, fluvoxamine, cimetidine, quinidine, triazolam, valproate, alfentanil ) may increase the clearance of <e20> cisapride </e20>.
mechanism	Drugs which inhibit CYP3A4 (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, <e10> ritonavir </e10>, nelfinavir, saquinavir, indinavir, saquinavir / didanosine, indinavir / astemizole, saquinavir / didanosine, itraconazole, ritonavir, troleandomycin, clarithromycin, troleandomycin, itraconazole, ritonavir, saquinavir, didanosine ) may decrease the clearance of <e20> lomefloxacin </e20>.
mechanism	Drugs which inhibit CYP3A4 (eg, phenytoin, clarithromycin, <e10> carbamazepine </e10>, itraconazole, rifampin, nefazodone, nelfinavir, saquinavir, ritonavir, stavudine, <e20> telithromycin </e20>, troleandomycin, troleandomycin plus clarithromycin, troleandomycin plus nefazodone, troleandomycin plus nefazodone plus ritonavir, and troleandomycin plus stavudine ) may increase plasma concentrations of the active metabolite (eg, cimetidine ) and thus may require an increase in dose of cimetidine.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may increase the plasma concentrations of <e20> methotrexate </e20>.
mechanism	The clearance of <e10> indomethacin </e10> was significantly increased in the presence of <e20> astemizole </e20> and cisapride.
mechanism	Acidifying_agents : Gastrointestinal_acidifying_agents (e,g,, <e10> chloramphenicol </e10>, nalidixic_acid ) or H2-receptor-antagonists (e,g,, phenobarbital, phenytoin, triazolam ) may cause a decrease in <e20> ketoconazole </e20> plasma concentrations.
mechanism	Acidifying_agents : Gastrointestinal_acidifying_agents (eg, <e10> piperazine </e10> ) may interfere with the metabolism of <e20> acetaminophen </e20>, resulting in a decrease in serum concentrations of the latter.
mechanism	Urinary_acidifying_agents ( <e10> guanethidine </e10>, phenylbutazone, <e20> ampicillin </e20>, sulfonamides ) and other related agents that increase the rate of pH change may increase the risk of renal tubular injury associated with the use of oral hypoglycemic_agents.
mechanism	Alkalinizing agents: Gastrointestinal transit times were decreased by <e10> enoxacin </e10>, clarithromycin, <e20> astemizole </e20>, phenytoin, bromocriptine, doxycycline, estrogens, and astemizole, and increased by carbamazepine, indinavir, itraconazole, itraconazole, and rifabutin.
mechanism	Urinary alkalinizing agents, which are very likely to be present in urine of normal subjects, may decrease the urinary excretion of <e10> rifampin </e10> and increase the serum concentrations of <e20> rifampin </e20>.
mechanism	<e10> d-amphetamine </e10> is a substrate for the following: CYP3A4 (3,4-dihydro-1,4-methylenedioxymethamphetamine ) ; acetaminophen ( <e20> Tylenol </e20> ) ; chloroquine ; rifampin ( Sulfonamides ) ; quinine ( Anticonvulsants ) ; tacrolimus ; and theophylline.
mechanism	<e10> d-amphetamine </e10> inhibited <e20> dopamine </e20> -induced increases in dopamine release from the nucleus accumbens.
mechanism	<e10> d-amphetamine </e10> has been shown to reduce the clearance of cyclosporine, <e20> tacrolimus </e20>, and digoxin.
mechanism	Ethosuximide : <e12> Amphetamines </e12> may increase the clearance of <e20> eszopiclone </e20>, resulting in decreased bioavailability and increased systemic exposure.
mechanism	Methenamine therapy: Urinary excretion of <e10> methenamine </e10> may be increased by approximately #% when <e20> valdecoxib </e20> is given concurrently.
mechanism	Phenytoin : <e12> Amphetamines </e12> may increase the metabolism of <e20> phenytoin </e20>.
mechanism	Aspirin : Concomitant administration of <e10> diclofenac </e10> and <e20> aspirin </e20> increased the absorption of diclofenac.
mechanism	Ingestion of <e10> cholestyramine </e10> containing <e20> tetracycline </e20> can increase the exposure to estrogens and progestins.
mechanism	Ingestion of <e10> carbamazepine </e10> and <e20> bromocriptine_mesylate </e20> in a single dose resulted in a 60% increase in the absorption of carbamazepine.
mechanism	Lithium : <e10> Lithium </e10> and <e20> carbonate </e20> bind and decrease lithium absorption.
mechanism	Protein Binding Inhibitors: <e10> Itraconazole </e10> has been reported to inhibit <e20> ritonavir </e20>, cyclosporine, indinavir, and nelfinavir metabolism.
mechanism	Protein Binding Inhibition of <e12> SSRI </e12> : Serum concentrations of <e20> paroxetine </e20> and fluoxetine increased, and serum levels of theophylline and fluvoxamine decreased, when orally administered with a single dose of protein binding SSRI in a placebo-controlled study.
mechanism	Protein Binding In vitro data indicate that the plasma concentrations of <e10> ketoconazole </e10> are reduced by up to 55% after coadministration of <e20> terfenadine </e20>, dapsone, or amphotericin_B.
mechanism	Because <e12> antacids </e12> containing aluminum or iron are the major sources of aluminum in the gastrointestinal tract, coadministration of a combination of antacids containing these two metal cations with <e20> zinc </e20>, aluminum, or iron may result in zinc deficiency, with possible gastrointestinal toxicity.
mechanism	Allopurinol : The co-administration of <e10> allopurinol </e10> with <e20> enoxacin </e20> at clinically effective doses resulted in a 19% increase in enoxacin clearance and a decrease in enoxacin AUC from # +/- 7 to # +/- 5 mg/h.
mechanism	Ganciclovir : Administration of <e10> erythromycin </e10> # mg and/or <e20> ganciclovir </e20> # mg and theophylline # mg simultaneously resulted in a 46% increase in the clearance of theophylline # mg and a 7% decrease in the clearance of the phenytoin # mg.
mechanism	Quinolone_Antibiotic s: VIDEX, rifampin, or ciprofloxacin : Interaction with <e11> VIDEX </e11> may increase plasma concentrations of <e20> rifampin </e20>, ketoconazole, or ciprofloxacin.
mechanism	In eight HIV-infected patients receiving cotrimoxazole and <e10> lopinavir </e10> concurrently, increases in plasma <e20> lopinavir </e20> concentrations were observed when cotrimoxazole was coadministered.
mechanism	The AUC of <e11> LEVSIN </e11> and <e20> rifampin </e20> were reduced by approximately 45% and approximately 37%, respectively, by coadministration of # mg of estrogens (n = 4) with # mg of a potent CYP3A4 inducer ( rifampin ) # hours prior to estradiol administration.
mechanism	In a single dose of # mg/kg/day of <e10> clofibrate </e10> # hours prior to dosing with <e20> alendronate </e20> # mg/kg/day, a significant increase in alendronate urinary excretion was observed when the clofibrate dose was doubled from # to # mg/kg/day.
mechanism	Plasma concentrations of <e10> ketoconazole </e10> are increased when oral <e20> fluconazole </e20> is given concurrently with ketoconazole.
mechanism	Plasma concentrations of <e10> cisapride </e10> increased to a greater extent when <e20> ergotamine </e20> (approximately # mg/kg/day) was administered concurrently with cisapride.
mechanism	Plasma concentrations of <e10> levothyroxine </e10> are reduced by the following: Phenytoin, digoxin, sulfinpyrazone, cholestyramine, and rifampin, as well as <e20> atorvastatin </e20>.
mechanism	Interactions with Other Drugs Interactions have been reported with concomitant administration of <e10> ketoconazole </e10> with other drugs, including cyclosporine, amiodarone, <e20> carbamazepine </e20>, clofibrate, hexobarbital, ketoconazole, itraconazole, phenytoin, rifampin, sildenafil, tricyclic_antidepressants (see CLINICAL PHARMACOLOGY for a complete list of potential drug interactions), and verapamil.
mechanism	Interactions with Other Drugs and/or Chemicals: Concurrent use of <e11> FACTIVE </e11> may enhance the effect of the following:-Antacids containing calcium, magnesium, or aluminum, <e20> antacids </e20> containing sucralfate, sulfasalazine, or probenecid, antacids containing diclofenac, or other antacids containing magnesium, iron, or aluminum, antacids containing phenytoin or other anticholinergics, and triazolam.
mechanism	Hydrochlorothiazide : In rats, co-administration of <e10> diltiazem </e10> and <e20> hydrochlorothiazide </e20> resulted in a rise in plasma concentrations of diltiazem by a factor of approximately 10.
mechanism	Acetaminophen : In a study in healthy volunteers, <e10> Acetaminophen </e10> administration in combination with <e20> clofibrate </e20> resulted in a 2-fold increase in clofibrate concentrations in the circulation.
mechanism	Cyclosporine : Administration of <e10> cyclosporine </e10> to patients taking <e20> cyclosporine </e20> alone results in an approximately two-fold increase in cyclosporine plasma levels.
mechanism	Nonsteroidal_Anti-Inflammatory_Drugs : The hepatic absorption of <e10> ketoconazole </e10> and its derivatives was decreased when coadministered with <e20> cimetidine </e20>.
mechanism	Sulindac : The concomitant use of <e10> sulindac </e10> with <e20> astemizole </e20> significantly reduced the clearance of astemizole.
mechanism	Naproxen : The effect of <e11> PRECEDEX </e11> on the renal excretion of <e20> naproxen </e20> was studied, and the elimination half-life was found to be 7.5 hours for a dose of # mg, and 38 hours for a dose of # mg when administered once daily.
mechanism	<e10> Quinidine </e10> inhibits the hepatic metabolism of <e20> valdecoxib </e20> by inhibiting CYP2D6 and thus prolonging plasma levels of valdecoxib.
mechanism	Quinidine, <e10> ketoconazole </e10>, and sulfasalazine may decrease the bioavailability of <e20> doxorubicin </e20>.
mechanism	Quinidine, verapamil, <e10> carbamazepine </e10>, and fluoxetine inhibit the metabolism of <e20> guanfacine </e20>, causing a decrease in the bioavailability of guanfacine.
mechanism	Quinidine, verapamil, <e10> carbamazepine </e10>, and carbamazepine/carbamazepine_hcl increases the clearance of <e20> cimetidine </e20>, resulting in a decrease in AUC.
mechanism	Quinidine, verapamil, phenytoin, and carbamazepine (a <e12> anticonvulsant </e12> ) increased the clearance of <e20> cyclosporine </e20> by 25%, 50%, and 25%, respectively.
mechanism	Quinidine, verapamil, and <e10> ketoconazole </e10> reduce the clearance of <e20> morphine </e20>.
mechanism	Quinidine, verapamil, and <e10> amiodarone </e10> increased <e20> diazepam </e20> absorption by approximately 3- and 1.5-fold, respectively.
mechanism	Quinidine, verapamil, and cimetidine, in combination with <e10> doxycycline </e10>, increased the Cmax of <e20> doxycycline </e20> by 24%, 18%, and 15%, respectively.
mechanism	<e10> Erythromycin </e10>, clofibrate, furosemide, or <e20> lithium </e20> may potentiate the metabolism of other anticoagulants, some anticonvulsants, digoxin, doxorubicin, indinavir, itraconazole, rifampin, saquinavir, telithromycin, troleandomycin, voriconazole, and zidovudine.
mechanism	Erythromycin and <e10> clarithromycin </e10> may increase serum levels of <e20> pentamidine </e20>.
mechanism	Erythromycin and clarithromycin : Clinical studies in healthy volunteers have shown a dose-dependent reduction of <e10> erythromycin </e10> clearance when <e20> clarithromycin </e20> was co-administered with these agents.
mechanism	<e10> Propantheline </e10> is a potent blocker of the CYP3A4 enzyme that can be reduced by <e20> theophylline </e20> and other potent CYP3A4 inhibitors.
mechanism	Propantheline and <e10> enoxacin </e10> markedly inhibit <e20> gentamicin </e20> metabolism, resulting in increased plasma concentrations and absorption.
mechanism	<e12> Antacids </e12> may interfere with the absorption of <e20> ciprofloxacin </e20>, resulting in elevated serum levels and AUC values.
mechanism	Antacids, <e10> Sucralfate </e10>, probenecid, and <e20> ciprofloxacin </e20> may interfere with the metabolism of carbamazepine.
mechanism	Antacids, kaolin and other gastrointestinal microorganisms are expected to decrease the bioavailability of <e10> ketoconazole </e10> and <e20> furosemide </e20>.
mechanism	Antacids, kaolin_glass, and other gastric contents containing iron or <e10> magnesium </e10> may increase the absorption of <e20> methotrexate </e20>.
mechanism	<e10> Rifampin </e10> and <e20> rifabutin </e20> reduce the exposure of rifabutin in vivo.
mechanism	Macrolide_Antibiotics (e, g, erythromycin, clarithromycin, <e10> erythromycin </e10>, ritonavir, indinavir, saquinavir ): <e21> Gleevec </e21> may increase the clearance of certain macrolide_antibiotics.
mechanism	Macrolide_Antibiotics (e, g, <e10> erythromycin </e10>, clarithromycin, rifampin, etc,) may decrease the absorption of <e20> astemizole </e20> and may increase the serum concentrations of astemizole and thus the exposure of the patient to AERS.
mechanism	Administration of <e10> norethindrone </e10> at doses of # mg/day to male rats, produced an approximately 3-fold increase in <e20> norethindrone </e20> metabolism compared to the control group.
mechanism	In vitro, <e10> dofetilide </e10> inhibited <e20> dofetilide </e20> metabolism by inhibiting CYP2C9 and CYP2D6 and increasing AUC values.
mechanism	A study in a rat model showed that <e10> digoxin </e10> # mg/kg for # days decreased the levels of <e20> warfarin </e20> in plasma, decreased the metabolism of warfarin, and increased the half-life of warfarin by 40% to 50%.
mechanism	Administration of <e10> ketoconazole </e10> # mg daily to anesthetized, sedated, healthy volunteers was well tolerated, but it did not alter the pharmacokinetics of <e20> diltiazem </e20>.
mechanism	In renal and cardiac transplant patients receiving high doses of <e10> ketoconazole </e10>, <e20> cisapride </e20> increased by a mean of approximately 25% the mean plasma concentration of cisapride.
mechanism	Concomitant administration of <e10> clofibrate </e10> with <e20> warfarin </e20> (recommended international normalized ratios for warfarin, #-15) results in a high plasma AUC for clofibrate of #% (SD #) and #-15 (SD #) for # days.
mechanism	Studies showed that <e10> dapsone </e10> has the potential to reduce the absorption of other oral <e22> anticonvulsants </e22>, including phenytoin, carbamazepine, triazolam, disopyramide, phenobarbital, and phenytoin.
mechanism	Studies showed that <e10> astemizole </e10> enhanced <e20> atorvastatin </e20> metabolism, which may be related to vitamin K inhibition of vitamin K1 activity.
mechanism	The elimination half-life of <e10> probenecid </e10> is about # times longer in rats than in humans and a similar effect of <e20> ethoxzolamide </e20> is observed.
mechanism	The elimination half-life of <e10> doxapram </e10> was increased by concurrent administration of <e20> erythromycin </e20> and doxapram, and was reduced by concurrent administration of an inhibitor of CYP3A4 (cimetidine ).
mechanism	In a ten-subject study, coadministration of <e10> fluvoxamine </e10> tablets with either <e20> ketoconazole </e20> (50 mg) or tetracycline (50 mg) tablets resulted in a decrease in AUC of both fluvoxamine and tetracycline.
mechanism	Coadministration of <e10> cyclosporine </e10> # mg and <e20> alprazolam </e20> # mg decreased the AUC by about 17% (p = 0.001).
mechanism	Adenosine : <e10> Benzthiazide </e10> in combination with <e20> adenosine </e20> significantly decreased the plasma levels of adenosine.
mechanism	in one man, a drug interaction was noted with concomitant administration of <e10> ketoconazole </e10> (40 mg daily) and <e20> nelfinavir </e20> (40 mg daily) for a period of # weeks.
mechanism	Antacids or H_2_receptor_antagonists (eg, <e10> erythromycin </e10> ) may enhance the absorption of <e20> dasatinib </e20>.
mechanism	Triazolam : <e10> Triazolam </e10> decreased the clearance of <e20> ketoconazole </e20> by increasing the mean plasma concentrations of triazolam by a mean of approximately 20%.
mechanism	Digoxin : Concomitant administration of <e10> enoxacin </e10> (40 mg q16h) with <e20> digoxin </e20> (5 mg q24h) increases serum digoxin concentrations by 50% to 70%, which may result in elevated serum digoxin levels in some patients.
mechanism	If <e10> phenytoin </e10> is given concurrently with <e20> cyclosporine </e20>, serum cyclosporine levels should be monitored closely, since cyclosporine may increase the clearance of the parent drug.
mechanism	If <e10> phenytoin </e10> is administered concomitantly with <e20> ketoconazole </e20>, the concomitant use of ketoconazole may result in an increase in the serum concentrations of ketoconazole and thus decrease the efficacy of ketoconazole.
mechanism	Concomitant administration of <e10> loratadine </e10> with two other <e22> digitalis </e22>, one of which has a known histamine-converting enzyme (HCE) activity, increased loratadine plasma levels by a mean of 3-fold.
mechanism	Patients taking <e10> digoxin </e10>, phenytoin, or <e20> phenobarbital </e20> may develop a weakling of the digoxin-binding sites.
mechanism	In vitro studies have shown that <e10> clindamycin </e10> decreased the binding of <e20> clarithromycin </e20> to its primary binding sites on the renal tubular epithelium.
mechanism	In vitro studies have shown that <e10> carbamazepine </e10> (200 mg twice daily) reduced the plasma concentrations of <e20> lisdexamfetamine_dipotassium </e20> by about 50% and the half-life was lengthened by approximately 20%.
mechanism	In vitro studies have shown that <e10> fluvoxamine </e10> causes a dose-dependent decrease in the clearance of <e20> cimetidine </e20>.
mechanism	In vitro studies have shown that <e10> amiodarone </e10> increases the metabolism of <e20> propafenone </e20>.
mechanism	In vitro studies have shown that <e10> probenecid </e10> can increase the hepatic metabolism of <e20> cisplatin </e20> and cisplatin / cyclosporine.
mechanism	<e10> Cimetidine </e10> markedly decreased the binding of <e20> phenytoin </e20> to platelets and decreased the binding of cimetidine to platelets.
mechanism	<e10> Cimetidine </e10> may increase the clearance of <e20> erythromycin </e20>, resulting in decreased plasma levels of this medication.
mechanism	Co-administration of <e11> HUMORSOL </e11> with a <e22> tricyclic_antidepressant </e22> (e,g,, nortriptyline ), a MAOI (e,g,, selegiline_hydrochloride ), and an MAOI (e,g,, tricyclic_antidepressants, phenothiazines ), resulted in a decrease in hepatic microsomal enzyme activity.
mechanism	<e10> Ketoconazole </e10> can inhibit the metabolism of <e20> doxorubicin </e20>, causing a higher absorption of the drug.
mechanism	The mean clearances of <e10> zidovudine </e10>, rifabutin, and nelfinavir were 6, 11, and 6% higher, respectively, when coadministered with <e20> atorvastatin </e20> than when administered alone.
mechanism	Blood levels of <e10> doxycycline </e10> were significantly decreased by the coadministration of <e20> ketoconazole </e20> and # mg/day of ciprofloxacin.
mechanism	Blood levels of <e10> alprazolam </e10> were reduced by #% when administered concomitantly with <e20> quinidine </e20>.
mechanism	<e10> Isoflurane </e10> decreases the absorption of carbamazepine, <e20> carbamazepine </e20>, phenytoin, and rifampin, and increases the half-life of rifampin.
mechanism	Isoflurane, <e10> halothane </e10>, and other drugs with strong anesthetic_hormonal effects (such as barbiturates and antihistamines ) may decrease plasma concentrations of <e20> ketamine </e20>.
mechanism	In a placebo-controlled study, the addition of <e10> ibuprofen </e10> to a standard regimen of <e20> furosemide </e20> decreased the maximum increase in creatinine from 2,068 mg/dL to 1,743 mg/dL (p =.003).
mechanism	Inhibitors or substrates of CYP3A4, including ketoconazole, erythromycin, clarithromycin, <e10> erythromycin </e10>, ritonavir, nelfinavir, nefazodone, saquinavir, telithromycin, troleandomycin, and troleandomycin, may significantly reduce the bioavailability of <e20> didanosine </e20>.
mechanism	Inhibitors or substrates of the CYP3A4 isoenzyme (eg, ketoconazole, <e10> itraconazole </e10>, ritonavir, nelfinavir, clarithromycin, indinavir, saquinavir, telithromycin, troleandomycin, indinavir, nefazadone ) have been reported to increase <e20> ketoconazole </e20> plasma concentrations.
mechanism	Cimetidine : <e10> Cimetidine </e10>, given with <e20> carbamazepine </e20>, increases serum levels of carbamazepine.
mechanism	Additionally, higher than expected concentrations of <e10> tetracycline </e10> were seen with concomitant use of <e20> ciprofloxacin </e20> and ampicillin.
mechanism	In patients who are concurrently treated with a combination of <e10> diltiazem </e10> and <e20> rifampin </e20>, the rifampin concentration should be monitored.
mechanism	Alcohol : It is possible that the increase in <e10> ethanol </e10> may decrease the serum <e20> valproic_acid </e20> levels, which have been shown to increase when patients are treated with oral anticonvulsants.
mechanism	Absorption of <e12> barbiturates </e12> in the presence of <e20> erythromycin </e20> is impaired by the metabolism of barbiturates via a reduction in the C max of barbiturates and an increase in AUC of barbiturates.
mechanism	Absorption of <e12> quinolones </e12> by <e20> lithium </e20> is impaired.
mechanism	Absorption of <e12> antihistamines </e12> may be impaired by drugs such as aspirin, chloroquine, barbiturates, cimetidine, cyclosporine, disopyramide, dipyridamole, ergotamine, fluconazole, indomethacin, itraconazole, lomefloxacin, methotrexate, nelfinavir, ritonavir, saquinavir, <e20> telithromycin </e20>, troleandomycin, verapamil, and zidovudine.
mechanism	Absorption of <e12> quinolones </e12> may be enhanced by <e20> cimetidine </e20> and theophylline.
mechanism	Absorption of <e10> digoxin </e10> is impaired when <e20> carbamazepine </e20> is coadministered.
mechanism	<e12> Barbiturates </e12>, carbamazepine, clofibrate, cyclosporine, dapsone, <e20> dipyridamole </e20>, disopyramide, dipyridamole, dofetilide, fentanyl, pimozide, quinidine, theophylline, theobromine, and warfarin.
mechanism	Barbiturates, <e10> fluvoxamine </e10>, quinidine, or amiodarone may inhibit <e20> digoxin </e20> metabolism, resulting in decreased plasma levels and toxicity.
mechanism	Concurrent administration of <e10> warfarin </e10> and <e20> ketoconazole </e20> has been associated with elevated serum concentrations of warfarin.
mechanism	Inhibitors of CYP1A2: Cimetidine : <e10> Cimetidine </e10> may increase the metabolism of <e20> phenytoin </e20>.
mechanism	<e10> Paroxetine </e10> : In a study of postpartum women, a pharmacokinetic interaction was observed for <e20> paroxetine </e20> when administered concomitantly with atorvastatin (a C-terminal telopeptide of vitamin_K) and an oral vitamin_K_antagonist ( atorvastatin.
mechanism	When <e10> duloxetine </e10> was administered to healthy volunteers, the maximum plasma levels of <e20> cisapride </e20> were approximately two- to threefold higher than the levels achieved with duloxetine alone.
mechanism	Concurrent administration of <e10> nevirapine </e10> with <e20> diltiazem </e20> increases nevirapine plasma concentrations and increases the net elimination of nevirapine.
mechanism	Steroids enhance the renal clearance of <e10> lovastatin </e10>, which may reduce the bioavailability of <e20> terfenadine </e20>.
mechanism	Drugs which induce the metabolism of <e10> ketoconazole </e10> (e,g,, <e20> warfarin </e20>, carbamazepine, barbiturates, corticosteroids, digoxin, cyclosporine, lithium, phenytoin, phenobarbital, rifampin, quinine, theophylline, valproate, verapamil, and zidovudine ) may result in a significant decrease in the half-life of # mg/day of # mg/day of # mg/day of # mg/day of # mg/day of # mg/day of # mg/day of # mg/day of ketoconazole.
mechanism	Drugs which induce CYP3A4 (eg, cyclosporine, tacrolimus, <e10> digoxin </e10>, phenytoin, alfentanil, cisapride, disopyramide, phenobarbital, alfentanil, carbamazepine, carbamazepine and alfentanil ) may increase plasma concentrations of <e20> phenytoin </e20> and may therefore require a reduction in dose of phenytoin when coadministered with these drugs.
mechanism	Drugs which induce CYP3A4 activity (eg, diltiazem, <e10> ketoconazole </e10>, itraconazole, phenytoin, rifampin, clarithromycin, indinavir, saquinavir, indinavir, indinavir_sulfate ) may increase the plasma concentration of <e20> diltiazem </e20> and may require increases in diltiazem dose to achieve steady state.
mechanism	Increasing the indinavir plasma concentration by increasing plasma <e10> indinavir </e10> levels increases plasma concentrations of <e20> dasatinib </e20> and concomitantly decreases half-life.
mechanism	When <e10> indinavir </e10> and <e20> doxorubicin </e20> were coadministered, a time to maximum serum concentration (T (max)) of indinavir was approximately two hours greater for doxorubicin.
mechanism	Potential for reduction in plasma <e10> warfarin </e10> concentrations may result if <e20> atorvastatin </e20> is administered concomitantly.
mechanism	<e11> SUSTIVA </e11> may interact with the following medications: <e20> Acetazolamide </e20>, colestipol, carbamazepine, clofibrate, clorazepate, dapsone, doxycycline, estrogens, fluoxetine, fluvoxamine, paroxetine, sertraline, valproate, zidovudine, and warfarin.
mechanism	<e11> SUSTIVA </e11> and <e20> lithium </e20> lithium salts may interact with some drugs, such as antacids or sucralfate.
mechanism	Caffeine : <e10> Caffeine </e10> may inhibit <e20> cimetidine </e20> absorption resulting in less methylation of C-Ia and the subsequent increase in c-Ia levels.
mechanism	In a multiple-dose study in healthy volunteers, a single dose of # mg <e10> ketoconazole </e10> produced a mean reduction in <e20> enoxacin </e20> clearance of 19% compared to placebo.
mechanism	Trough plasma enoxacin concentrations were higher when <e10> enoxacin </e10> was administered with <e20> isoniazid </e20> (IC50: # microM), but lower when enoxacin was administered with ampicillin (IC50: # microM).
mechanism	Cyclosporine : Elevated serum concentrations of cyclosporine have been reported when <e10> doxycycline </e10> is administered concomitantly with <e20> cyclosporine </e20>.
mechanism	Digoxin : <e10> Rifampin </e10> may enhance the metabolism of <e20> digoxin </e20> by increasing renal clearance.
mechanism	The oral bioavailability of <e11> SUSTIVA </e11> is impaired by concomitant administration of a potent <e22> antihistamine </e22>, chlorpheniramine, or metoclopramide, but not by concurrent administration of a potent vasoconstrictive (e,g,, norethindrone, diltiazem, or nitroglycerin ) or antihypertensive_drugs (e,g,, amiodarone, diazoxide, propranolol, amiodarone_sodium, and amiodarone_hydrochloride ).
mechanism	Theophylline : <e10> Theophylline </e10> increases the metabolism of <e20> carbamazepine </e20> by increasing hepatic and renal activity.
mechanism	<e10> Enoxacin </e10> may decrease the bioavailability of <e20> phenytoin </e20>.
mechanism	Warfarin : <e12> Quinolones </e12>, including cimetidine, may increase the clearance of <e22> warfarin </e22>.
mechanism	Warfarin : Quinolones may reduce the plasma concentration of <e10> warfarin </e10>, increasing the risk of <e20> clofibrate </e20> toxicity.
mechanism	<e10> Cimetidine </e10> at <e20> ketoconazole </e20> concentrations of # to # mg/liter (4-8 mg/liter) decreased the AUC and Cmax of cimetidine by approximately 50% and approximately 40%, respectively.
mechanism	A pharmacokinetic study in healthy subjects showed that the # mg dose of <e10> digoxin </e10> was approximately # times more effective than <e20> digoxin </e20> # mg.
mechanism	Administration of <e10> ketoconazole </e10> # mg to <e20> cimetidine </e20> /caffeine combination therapy significantly increased the half-life of cimetidine from # hours to # hours.
mechanism	Administration of <e10> isoniazid </e10> in patients receiving monoamine_oxidase_inhibitors ( MAOI ) increases the <e20> valdecoxib </e20> AUC.
mechanism	Administration of <e10> ciprofloxacin </e10> or <e20> doxorubicin </e20> # mg twice daily for # days was associated with a 2-fold increase in doxorubicin plasma concentrations.
mechanism	In clinical trials, <e10> lithium </e10> decreased the serum <e20> carbamazepine </e20> levels.
mechanism	In clinical trials, <e10> fluvoxamine </e10> decreased the clearance of # mg/day of <e20> diltiazem </e20> by 42% (6% observed to be due to increased elimination).
mechanism	However, patients on concomitant <e10> rifampin </e10> and <e20> rifabutin </e20> therapy have a reduced rifabutin exposure.
mechanism	The effects of <e10> cimetidine </e10> were completely antagonized by <e20> bromocriptine_mesylate </e20>.
mechanism	The effects of <e10> ketoconazole </e10> on <e20> warfarin </e20> concentrations are unknown, but the net effect of these drugs on their effects on warfarin metabolism is expected to be clinically significant.
mechanism	Co-treatment with the CYP3A4 inducer <e10> ketoconazole </e10> or its metabolite <e20> erythromycin </e20> significantly increased the plasma concentration of estradiol-17beta by approximately 25%.
mechanism	Pre-treatment with the anti-diuretic <e10> warfarin </e10> or the <e20> ketoconazole </e20> reduces the therapeutic effect of norethindrone and ethinyl_estradiol and decreases serum levels of norethindrone.
mechanism	When ertapenem is administered concomitantly with <e10> dapsone </e10>, the AUC of <e20> ertapenem </e20> is decreased and the Cmax is increased.
mechanism	Based on total body clearance data, <e10> cisapride </e10> is a major CYP3A4 inhibitor and <e20> loperamide </e20> is a major CYP3A4 inducer of prostaglandin synthesis.
mechanism	Concomitant administration of <e10> lomefloxacin </e10> with <e20> zidovudine </e20> has been shown to result in an increase in zidovudine plasma concentrations.
mechanism	<e10> Erythromycin </e10>, erythromycin, and other macrolide_antibiotics (e,g,, <e20> clarithromycin </e20>, erythromycin, troleandomycin, itraconazole ) may reduce the efficacy of oral contraceptives, certain intravenous drugs, barbiturates, barbiturates, bromocriptine, calcium supplements, corticosteroids, corticotropin, corticotropin_releasing_agents, cyclosporine, dantrolene, dipyridamole, estrogens, estrogens_derivative_progesterone, estrogens_oxymethasone, estrogens_sulfate, estrogens_thiazide_derivatives, fluconazole, fluconazole_sulfate, gabapentin, hexobarbital, nonsteroidal_anti-inflammatory_drugs, oral contraceptives,
mechanism	<e10> Erythromycin </e10> has been shown to increase the clearance of a <e20> warfarin </e20>.
mechanism	<e10> Erythromycin </e10> -induced <e20> rifampin </e20> clearance increased by 17% (p =.007) following coadministration with fluvoxamine.
mechanism	<e10> Erythromycin </e10> also increases <e20> cimetidine </e20> plasma levels by about 50%.
mechanism	There have been reports of increased plasma levels of <e10> clindamycin </e10> when <e20> nelfinavir </e20> was co-administered.
mechanism	Cimetidine-In vitro data from patients with chronic renal insufficiency have shown that <e10> cimetidine </e10>, when given with <e20> enoxacin </e20>, increases the MIC of cimetidine by up to # times.
mechanism	However, there are reports of increased plasma concentrations of <e10> ketoconazole </e10> when coadministered with a drug that depletes renal <e20> creatinine </e20>, such as propranolol or rifampin, or when coadministered with drugs that cause a loss of protein kinase C activity, such as theophylline or atorvastatin.
mechanism	Metoprolol-Administration of <e10> metoprolol </e10> # mg/day for # days reduced <e20> warfarin </e20> exposure by 36%.
mechanism	<e11> BREVIBLOC </e11> can inhibit the metabolism of <e20> warfarin </e20>, leading to increased prothrombin time and prolongation of prothrombin time.
mechanism	When <e10> digoxin </e10> was administered to a patient receiving <e20> norethindrone </e20>, there was a significant decrease in plasma norethindrone concentrations.
mechanism	Coadministration of <e10> chloramphenicol </e10> and <e20> clarithromycin </e20> in a patient with a history of concomitant use of both antibiotics resulted in a 3- to 5-fold increase in clarithromycin plasma concentrations.
mechanism	Therefore, <e10> esomeprazole </e10> may decrease the metabolism of <e20> quinine </e20>.
mechanism	Therefore, <e10> esomeprazole </e10> may reduce the metabolism of other anticonvulsants, including phenobarbital, phenytoin, carbamazepine, phenytoin_HCl, phenytoin, carbamazepine, phenytoin_HCl, valproate, phenobarbital, phenytoin, carbamazepine, phenytoin_HCl, and valproate, as well as some <e22> CYP3A4 inhibitors </e22>, such as disopyramide.
mechanism	Therefore, <e10> esomeprazole </e10> may have a potential for interaction with <e20> diflunisal </e20> and ampicillin.
mechanism	While no in vitro studies have been performed to establish the extent to which <e10> diltiazem </e10> could affect <e20> rifabutin </e20> metabolism, the metabolism of rifabutin may be altered by the addition of diltiazem to a regimen of ciprofloxacin or carbamazepine.
mechanism	While no in vitro interaction between <e10> nelfinavir </e10> and <e20> clofibrate </e20> has been reported, coadministration of low doses of nelfinavir and clofibrate (50 and 100 mg/day) was associated with a dose-related increase in plasma concentrations of nelfinavir and/or the nelfinavir_anticoagulant in some healthy volunteers.
mechanism	While no in vitro studies have been done to determine if these concomitant <e12> NSAIDs </e12> decrease the renal clearance of <e20> amprenavir </e20>, it is possible that the increase in renal clearance may be an indirect consequence of the decrease in the elimination rate of amprenavir due to concomitant use of an oral hypoglycemic_agent ( granisetron ).
mechanism	While no in vitro studies have been conducted, it is likely that the action of <e10> digoxin </e10> may be increased by concomitant use of other <e22> calcium_channel_blockers </e22>.
mechanism	The following are active metabolites of <e10> isoniazid </e10> : <e20> erythromycin </e20> : inhibition of metabolism of Isoniazid by 5% to 6% in healthy volunteers, 5% to 6% in healthy pregnant women, and about 4% in healthy men.
mechanism	The following are among the drugs which may increase the plasma concentrations of <e10> pentamidine </e10> and decrease the plasma concentrations of <e20> pentamidine </e20> are: the anticonvulsant carbamazepine, phenytoin, phenobarbital, the phenytoin metabolized to carbamazepine (e,g,, carbamazepine sulfate ), the phenytoin metabolized to ketoconazole (e,g,, ketoconazole ), the anticonvulsant carbamazepine, the anticonvulsant cyclosporine, the anticonvulsant diltiazem, the anticonvulsant flecainide, the anticonvulsant rifampin, the anticonvulsant sulfasalazine, the anticonvulsant tetracycline, the anticonvulsant methotrexate, the anticonv
mechanism	The following are the known drugs that can inhibit the metabolism of <e10> ketoconazole </e10> to induce toxicity: certain antibiotics (e, g,, ampicillin, tetracycline, bacitracin, ciprofloxacin, <e20> ceftriaxone </e20>, cefazolin, clarithromycin, indomethacin, itraconazole, nefazodone, nelfinavir, rifampin, saquinavir, telithromycin, troleandomycin ), antacids, barbiturates, calcium supplements, chloramphenicol, dapsone, fluvoxamine, glucocorticoids, phenylbutazone, methadone, pentamidine, phenytoin, salicylates, tamoxifen, thiazide_diuretics, tolbutamide, theophy
mechanism	The following are examples of potential drug interactions of the <e12> anticoagulant </e12>, levothyroxine, and triiodothyronine classes: (1) <e20> Indinavir </e20> may decrease the half-life of triiodothyronine ( T3 ) and this may increase the serum T3 levels by approximately 50%. (2) The following drugs decrease the half-life of triiodothyronine ( T3 ): (a) warfarin ( INR # +/- 3) and amiodarone ; (b) cimetidine, ethinyl_estradiol, and carbamazepine.
mechanism	The following are reported as possible mechanisms of metabolism of <e10> cetirizine </e10> : in vitro : <e20> cetirizine </e20> may increase the activity of the following : phenytoin, phenobarbital, and possibly others ;
mechanism	The following are noted: (1) In vitro, <e10> warfarin </e10> inhibited <e20> amprenavir </e20> metabolism, resulting in a decrease in amprenavir concentrations.
mechanism	The AUC of <e11> INDOCIN </e11> was significantly increased by # to # times in a # mg/kg dose of <e20> morphine </e20> when given with low-dose morphine or high-dose morphine.
mechanism	<e10> Lithium </e10> and magnesium (particularly) may interfere with absorption of <e20> levothyroxine </e20>, thereby reducing the plasma level of levothyroxine.
mechanism	A number of <e12> tetracyclines </e12> have been shown to reduce the metabolism of <e20> rifampin </e20>, and the effect on the AUC of rifampin may be clinically significant.
mechanism	The results of pharmacokinetic studies with <e10> rofecoxib </e10> indicated that the AUC and Cmax of <e20> rofecoxib </e20> were increased by 17-fold and 17-fold, respectively, when it was administered with concurrent high-dose dapsone.
mechanism	<e11> Trecator </e11> may decrease the efficacy of a <e22> anticonvulsant </e22>, phenobarbital, phenytoin, phenytoin_sulfate, valproate, and others.
mechanism	<e10> Ethopropazine </e10>, zaleplon, and <e20> cimetidine </e20> may interfere with acetaminophen (e,g,, Tylenol ), chloramphenicol (e,g,, Chloromycetin ), rifampin (e,g,, Rifampin ), triazolam (e,g,, Tiazol ), phenobarbital (e,g,, Phenobarbital ), and methadone (e,g,, Methadone ).
mechanism	Since Zarontin ( <e10> acetaminophen </e10> ) and some other NSAIDs reduce the absorption of <e20> norethindrone </e20>, it is possible that they may increase the serum levels of norethindrone.
mechanism	Since Zarontin ( <e10> lisinopril </e10> ) and metformin ( glyburide ) are potent inhibitors of CYP3A4, there may be a reduction in the efficacy of <e20> ciprofloxacin </e20>, ciprofloxacin, ciprofloxacin-derivatives, and/or metformin when taken concomitantly with these drugs.
mechanism	Presumably, <e10> phenytoin </e10> may interfere with metabolism of <e20> carbamazepine </e20>.
mechanism	Presumably, <e10> phenytoin </e10> interferes with metabolism of <e20> guanethidine </e20>, which, upon addition, increases the exposure of guanethidine to the kidneys.
mechanism	Conversely, the <e12> quinolones </e12> that inhibit CYP3A4 ( alfentanil, cisapride, <e20> disopyramide </e20>, ketoconazole, itraconazole, ritonavir, saquinavir, nelfinavir, saquinavir/ritonavir ) have been shown to increase the plasma concentrations of ciprofloxacin, resulting in a higher AUC and Cmax.
mechanism	<e10> Acetaminophen </e10> in combination with <e20> sodium_nitroprusside </e20> significantly decreased the clearance of phenytoin, with a decrease in the area under the curve of phenytoin and significantly increased plasma concentrations of phenytoin.
mechanism	<e10> Aminoglutethimide </e10> inhibited the enzyme activity of <e20> methotrexate </e20> by a 60% decrease.
mechanism	<e12> Anticonvulsants </e12> reduce the metabolism of <e20> barbiturates </e20> and hence may increase their plasma levels.
mechanism	<e12> Anticonvulsants </e12> ( phenytoin, carbamazepine, phenobarbital, felbamate ) inhibit the metabolism of <e20> digoxin </e20> by releasing the metabolite(s) ( digoxin ) into the bloodstream.
mechanism	Anticonvulsants ( <e10> carbamazepine </e10>, felbamate, phenobarbital, phenytoin, topiramate ): <e20> Furosemide </e20>, or any of the three diuretics ( ritonavir, saquinavir, indinavir ) increase the renal excretion of furosemide, resulting in a net decrease in renal tubular reabsorption of furosemide and furosemide.
mechanism	Anticonvulsants ( <e10> carbamazepine </e10>, felbamate, phenobarbital, primidone, triazolam ) may decrease the clearance of <e20> levothyroxine </e20>.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, <e10> alfentanil </e10> ): <e20> Levo-Dromoran </e20> potentiates the absorption of anticonvulsants, decreasing the absorption rate by up to 4%.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, primidone ): <e10> Rifampin </e10> may increase the metabolism of <e20> enoxacin </e20>, which may decrease enoxacin serum levels.
mechanism	Anticonvulsants ( carbamazepine, felbamate, phenobarbital, phenytoin, <e10> zidovudine </e10> ): Effects on <e20> warfarin </e20> metabolism are likely to be acute.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin ): Anticonvulsants have been reported to decrease the bioavailability of <e11> VIDEX </e11> in patients receiving high-dose <e20> propranolol </e20> therapy.
mechanism	Anticonvulsants ( carbamazepine, phenobarbital, phenytoin, felbamate ): <e10> Chlorpromazine </e10> may inhibit the metabolism of <e20> carbamazepine </e20>, phenobarbital, and phenytoin, resulting in elevated plasma concentrations of these drugs.
mechanism	Atorvastatin : <e10> Atorvastatin </e10>, like other statins, reduces the hepatic metabolism of <e20> lovastatin </e20>.
mechanism	Atorvastatin : <e10> Etonogestrel </e10> may inhibit the metabolism of <e20> atorvastatin </e20> and decrease its plasma levels.
mechanism	Benzodiazepines : Combination <e10> haloperidol </e10>, risperidone, thioridazine, and <e20> phenobarbital </e20> may inhibit the metabolism of haloperidol.
mechanism	Benzodiazepines : Combination <e10> diazepam </e10> and <e20> alprazolam </e20> (5 mg, q24h) produce a 20% decrease in AUC of alprazolam and a 20% decrease in AUC of diazepam.
mechanism	Benzodiazepines : Combination <e10> alprazolam </e10> and <e20> benzodiazepines </e20> cause significant increases in plasma concentrations of the benzodiazepines.
mechanism	Benzodiazepines : Combination <e10> diazepam </e10> and benzodiazepines ( alprazolam, triazolam, <e20> selegiline_hydrochloride </e20> ) increase the plasma concentrations of the target drug.
mechanism	Benzodiazepines : Combination <e10> Fluvoxamine </e10> may inhibit the metabolism of benzodiazepines such as alprazolam, <e20> chlordiazepoxide </e20>, triazolam, and alprazolam, resulting in elevated plasma concentrations of these drugs.
mechanism	Benzodiazepines : Combination <e10> clonazepam </e10> and <e20> diazepam </e20> may increase plasma concentrations of clonazepam and increase the half-life of clonazepam.
mechanism	Clofibric_acid : Combination <e12> NSAIDs </e12> may decrease plasma levels of <e20> clofibric_acid </e20>.
mechanism	Cyclosporine : Combination <e10> cyclosporine </e10> ( <e20> azithromycin </e20> ) has been reported to reduce the clearance of the prodrug, resulting in a 20% increase in serum levels.
mechanism	Griseofulvin : <e10> Griseofulvin </e10> significantly increases the clearance of <e20> atorvastatin </e20>, an HMG-CoA_reductase_inhibitor.
mechanism	Morphine : Combination <e10> morphine </e10> and <e20> enoxacin </e20> were effective at decreasing the plasma levels of morphine in dogs with experimental cholestryramine poisoning.
mechanism	Non-nucleoside_reverse_transcriptase_inhibitors ( NNRTIs ) may reduce the plasma levels of <e10> nevirapine </e10> by causing an increase in the clearance of nevirapine or other <e22> antiretroviral_agents </e22>.
mechanism	Protease_inhibitors : Amprenavir and <e10> didanosine </e10>, although not significantly affected by <e20> guanfacine </e20>, decreased the bioavailability of ampicillin and tetracycline.
mechanism	Protease_inhibitors : Amprenavir, ritonavir, indinavir, <e10> saquinavir </e10>, and itraconazole have been reported to decrease plasma concentrations of <e20> nevirapine </e20>.
mechanism	<e10> Indinavir </e10> and ritonavir, and <e20> rifampin </e20> and indinavir, all decrease the half-life of dofetilide.
mechanism	Rifampin : <e10> Rifampin </e10> may interfere with absorption of <e20> ketoconazole </e20>.
mechanism	Rifampin : <e10> Rifampin </e10> increases <e20> ketoconazole </e20> clearance, which may predispose patients to the metabolic syndrome.
mechanism	Selegiline : <e12> NSAIDs </e12>, such as <e20> selegiline </e20>, may interfere with the metabolism of nonsteroidal_anti-inflammatory_drugs, including midazolam, which have a narrow therapeutic window.
mechanism	Tricyclic_antidepressants ( <e10> amitriptyline </e10>, nortriptyline, imipramine ) may inhibit CYP3A4 and increase plasma concentrations of <e20> citalopram </e20>.
mechanism	Tricyclic_antidepressants ( amitriptyline, imipramine, nortriptyline, <e10> desipramine </e10> ): <e20> Phenytoin </e20> : Increase the clearance of carbamazepine, an inhibitor of CYP3A4, by up to 25%.
mechanism	Tricyclic_antidepressants ( amitriptyline, imipramine, <e10> nortriptyline </e10>, amitriptyline_sodium, and imipramine ) may interfere with the metabolism of <e20> cimetidine </e20>.
mechanism	Aspirin : When <e10> ketoconazole </e10> and <e20> carbamazepine </e20> were coadministered, the mean plasma concentrations of ketoconazole were reduced from a mean of # +/- 0.5 to # +/- 0.5 microM and carbamazepine were reduced from a mean of # +/- 0.6 to # +/- 0.6 microM in the blood serum.
mechanism	Cyclosporine, Digoxin, Methotrexate, and Quinidine : Coadministration of <e10> ceftazidime </e10> with these drugs may decrease the clearance of the drug and increase the exposure of <e20> ciprofloxacin </e20>.
mechanism	Cyclosporine, Digoxin, Methotrexate, Antacids, <e10> Fluvoxamine </e10>, and Imipramine may decrease the elimination of <e20> carbamazepine </e20>.
mechanism	Cyclosporine, Digoxin, Methotrexate, and <e10> amiodarone </e10> reduce the renal clearance of <e20> ketoconazole </e20>.
mechanism	Cyclosporine, Digoxin, Methotrexate and Aminoglycosides : <e10> Ketoconazole </e10> may interfere with absorption of <e20> cyclosporine </e20>, digoxin, and aminoglycosides.
mechanism	Cyclosporine, Digoxin, Methotrexate and Phenytoin : <e10> Cyclosporine </e10> and <e20> digoxin </e20> are inhibitors of in vitro metabolism of cisplatin.
mechanism	Lithium : <e12> Antacids </e12> containing magnesium or aluminum may inhibit absorption of <e20> lithium </e20>.
mechanism	Phenylbutazone : <e10> Phenylbutazone </e10> inhibits the metabolism of <e20> cimetidine </e20> and its derivatives by CYP3A4, and therefore has a possible pharmacokinetic interaction with cimetidine.
mechanism	Short-term pharmacokinetic studies in healthy volunteers demonstrated a significant increase in <e10> rifampin </e10> clearance after coadministration of <e20> nelfinavir </e20> and a steady state rifampin plasma concentration was achieved approximately # hours after administration of # mg of rifampin.
mechanism	Short-term pharmacokinetic studies indicate that <e10> rofecoxib </e10> # mg taken once daily decreased mean plasma exposure of <e20> erythromycin </e20> to #%.
mechanism	Co-medications that induce CYP3A4 activity (eg, certain hepatotoxicants, corticosteroids, and carbamazepine ) may increase plasma concentrations of <e11> TORADOL </e11> and may require a reduction in dose to achieve plasma levels observed with <e20> cisapride </e20>.
mechanism	Co-medications that induce CYP3A4 activity, including ketoconazole, itraconazole, erythromycin, felbamate, cisapride, <e10> quinidine </e10>, cimetidine, omeprazole, ketoconazole, valdecoxib, fluoxetine, ketoconazole and sulfasalazine, may increase plasma concentrations of <e20> isoniazid </e20>.
mechanism	Co-medications that induce CYP3A4 activity, such as atorvastatin, fluvoxamine, fluvoxamine and quinidine, increase plasma levels of <e10> piperacillin </e10> and reduce its metabolism to <e20> cisapride </e20>.
mechanism	Concurrent use with antihistamines ( <e10> indomethacin </e10>, barbiturates, tricyclic_antidepressants ) may increase <e20> cyclosporine </e20> concentrations by a 2- to 5-fold increase.
mechanism	Use in Conjunction With <e10> Sucralfate </e10> and Aspirin : Concomitant administration of <e20> sucralfate </e20> and aspirin can result in a decrease in sucralfate plasma concentrations.
mechanism	Use in Conjunction With Other Drugs: <e11> ENBREL </e11> has been shown to enhance the hepatic metabolism of the <e20> phenytoin </e20> metabolite, phenobarbital.
mechanism	Specific Effects of Folic_acid : There is one report in which <e10> nifedipine </e10> decreased the serum concentrations of <e20> folic_acid </e20> and, to a similar extent, the concentrations of vitamin B12 and vitamin A in subjects taking these drugs concomitantly.
mechanism	Increasing the <e10> lithium </e10> dose to # mg/day or increasing the <e20> lithium </e20> concentration in the urine to # micrograms/liter increased the lithium clearance by #%.
mechanism	Carbamazepine : <e11> ZYVOX </e11> has been shown to decrease the clearance of <e20> carbamazepine </e20>.
mechanism	Valproate : <e11> ZYVOX </e11>, in combination with valproate, was found to increase <e20> zidovudine </e20> AUC and Cmax by # and #%, respectively.
mechanism	Increasing the <e10> carbamazepine </e10> plasma concentrations may also result in decreased <e20> phenytoin </e20> clearance and increased concomitant serum levels.
mechanism	Phenobarbital : Coadministration of <e10> phenobarbital </e10> with <e20> rifampin </e20>, clarithromycin, rifabutin, or cimetidine resulted in increases in AUC and Cmax, and decreases in AUC and Cmin.
mechanism	Effects of Other Drugs Interactions can occur when <e10> terfenadine </e10> is administered concomitantly with drugs that have a weak affinity for <e22> vitamin_D </e22>, a strong affinity for vitamin_D, or a strong affinity for other active ingredients of the terfenadine regimen.
mechanism	Effects of Other Drugs and Substances Pertuzide : <e10> Ketoconazole </e10> may interfere with <e20> erythromycin </e20> metabolism and decrease the effectiveness of both the parent drug and a metabolite.
mechanism	Effects of Other Antidepressants : As with other antidepressants, concomitant administration of <e11> PRINIVIL </e11> with serotonergic_agents, <e22> monoamine_oxidase_(MAO)_inhibitors </e22>, and tricyclic_antidepressants may prolong and intensify the pharmacologic effects of these agents.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> may decrease the clearance of <e20> ketoconazole </e20>.
mechanism	Phenobarbital : It has been reported that <e11> PRINIVIL </e11> may interfere with the metabolism of phenobarbital, resulting in decreased serum levels of <e20> phenobarbital </e20> and decreased pharmacokinetics of phenobarbital.
mechanism	<e10> Felbamate </e10>, as well as other nonsteroidal_anti-inflammatory_drugs ( NSAIDs ), may decrease the absorption of <e20> furosemide </e20>.
mechanism	Anticonvulsants : In an open-labeled study, the combination of <e10> phenytoin </e10> and <e20> enoxacin </e20> was found to have a higher frequency of adverse events than enoxacin alone in subjects with anticonvulsant-associated seizure (CASES) and seizure-related conditions (CVR) and a higher frequency of adverse events than enoxacin alone in subjects with CVR.
mechanism	Anticonvulsants : In some patients, concomitant administration of <e11> Levo-Dromoran </e11> and <e20> carbamazepine </e20> has resulted in elevations in carbamazepine plasma levels.
mechanism	Anticonvulsants : In vitro data from <e12> anticonvulsants </e12> suggest a possible interaction between phenytoin, carbamazepine, and quinidine, with increased concentrations in the presence of <e20> atorvastatin </e20>.
mechanism	Resins : Since <e10> gentamicin </e10> was found to be approximately 30% less effective in combination with <e20> chloramphenicol </e20> than with the other commonly used antibiotics, its use is discouraged.
mechanism	Concomitant administration of <e10> ketoconazole </e10> with <e20> almotriptan </e20> decreased the metabolism of almotriptan.
mechanism	Concomitant administration of <e10> isoniazid </e10> and <e20> ketoconazole </e20> increases the clearance of this class of toxicants.
mechanism	Concomitant administration of <e10> cimetidine </e10> with <e20> levodopa </e20> has been reported to increase the AUC and decrease the Cmax of levodopa.
mechanism	Concomitant administration of <e10> gentamicin </e10> and <e20> clarithromycin </e20> results in a 40% increase in gentamicin serum concentrations.
mechanism	The coadministration of <e10> rifabutin </e10> with <e20> alfentanil </e20> resulted in a decrease in alfentanil plasma concentration by -30% compared to alfentanil alone.
mechanism	Although the mechanism is not known, <e10> cetirizine </e10> may interfere with the absorption of <e20> ibuprofen </e20> or other nonsteroidal_anti-inflammatory_drugs, causing lower levels to be released.
mechanism	Because Nalfon has been shown to increase the exposure of <e10> ibuprofen </e10>, it is suggested that the observed increase in serum <e20> ibuprofen </e20> levels may be due, in part, to the reduction in urinary excretion of ibuprofen.
mechanism	The concomitant use of <e10> warfarin </e10> with other <e22> anticoagulants </e22> (theophylline, heparin, coumarin, nifedipine, phenytoin, carbamazepine, phenobarbital, bromocriptine, valproate, terfenadine, disopyramide ) increases the risk of bleeding.
mechanism	The concomitant use of <e10> rifampin </e10> and <e20> bacitracin </e20> resulted in a 1.5-fold increase in AUC and Cmax values.
mechanism	The concomitant use of <e10> ketoconazole </e10> with <e20> zalcitabine </e20> may lead to increased concentrations of zalcitabine.
mechanism	The concomitant use of <e10> cyclosporine </e10> with <e20> isoniazid </e20>, tacrolimus, terfenadine, dicumarol, or valproate resulted in an increase in cyclosporine plasma levels.
mechanism	The concomitant use of <e10> probenecid </e10> and a <e22> steroid </e22> may increase the clearance of the latter.
mechanism	The concomitant use of <e11> FOSCAVIR </e11> with other antacids, sucralfate, or quinine may decrease the absorption of <e20> acarbose </e20>, possibly resulting in an increased AUC of acarbose.
mechanism	The concomitant use of <e11> BREVIBLOC </e11> with <e20> dexamethasone </e20> resulted in an approximately 10% increase in dexamethasone concentrations.
mechanism	However, co administration of <e10> carbamazepine </e10> and <e20> zidovudine </e20> results in a 3-fold increase in zidovudine Cmax.
mechanism	However, co administration of <e10> lomefloxacin </e10> with <e20> cimetidine </e20> may have been responsible for an increased cimetidine exposure.
mechanism	These studies indicate that <e10> almotriptan </e10> may enhance the metabolism of <e20> lithium </e20> or other potentially potent lithium toxicants, which may potentially increase serum lithium concentrations and increase lithium toxicity.
mechanism	This observed increase in the plasma concentrations of <e10> aripiprazole </e10> after the administration of <e20> quinidine </e20> in the presence of fluvoxamine and fluvoxamine and/or fluvoxamine/fluvoxamine has been demonstrated by using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
mechanism	Drug Interactions with Carbamazepine : There have been reports of interactions of <e11> Gleevec </e11> with carbamazepine ( carbamazepine, ziconazole, felbamate, <e20> almotriptan </e20> ), with two other agents ( ziconazole and erythromycin ): The effect of carbamazepine on carbamazepine metabolism may be increased with concomitant administration of these agents with a high oral dose of Gleevec (approximately # mg every # hours).
mechanism	Drug Interactions with Concomitant Administration of <e11> EQUETROTM </e11> with <e20> valdecoxib </e20> : Patients treated concomitantly with EQUETROTM, who were on valdecoxib, were at an increased risk for gastrointestinal bleeding (Grade 4 or higher) when compared to patients who were not on valdecoxib.
mechanism	In a study in which healthy volunteers were treated with <e11> Gleevec </e11> and <e20> terfenadine </e20> concurrently, # of # subjects experienced an increase in blood concentrations of terfenadine.
mechanism	Limited data in nonhuman primates suggest that <e10> ketoconazole </e10>, when coadministered with <e20> rifampin </e20>, has additive effects on the pharmacokinetics of warfarin and similar anticoagulants.
mechanism	Limited data in rodents suggest a possible drug interaction between <e10> rifampin </e10> and <e20> isoniazid </e20>.
mechanism	Limited data in humans suggest that <e10> rifampin </e10> may interfere with the metabolism of warfarin and <e20> cisapride </e20>, resulting in elevated blood levels.
mechanism	In healthy subjects receiving <e10> lovastatin </e10> or <e20> fibrate </e20>, the concentrations of serum lithium were significantly lower, with a tendency to decrease in the presence of lovastatin.
mechanism	When <e10> amiodarone </e10> and <e20> cisplatin </e20> are administered concomitantly, blood levels of amiodarone may be increased.
mechanism	Drugs that inhibit platelet function, including acetylsalicylic_acid, dipyridamole, clofibrate, disopyramide, <e10> ethionamide </e10>, furosemide, halothane, ketoconazole, morphine, phenytoin, rifabutin, salicylates, sulfonamides, thiazide_diuretics, and vitamin_K_antagonists may increase the risk of bleeding when administered concomitantly with <e21> HER2_medication </e21>.
mechanism	<e12> Barbiturates </e12> inhibit <e20> fluvoxamine </e20> metabolism, and may increase the clearance of the drug.
mechanism	Barbiturates, <e10> phenytoin </e10>, and cyclosporine may reduce the clearance of <e20> ketoconazole </e20>.
mechanism	Barbiturates, phenytoin, and <e10> carbamazepine </e10> may increase the clearance of <e20> dofetilide </e20>.
mechanism	Aspirin : Concurrent administration of <e11> aspirin </e11> and <e20> cisapride </e20> results in an increase in blood levels of the latter drug.
mechanism	Cimetidine, Ranitidine, Dexamethasone and Phenobarbital : <e10> Cimetidine </e10>, <e20> Ranitidine </e20>, Dexamethasone, and Phenobarbital increase hepatic clearance of the vitamin and may therefore increase the plasma concentration of vitamin A.
mechanism	<e10> Terfenadine </e10> also inhibits the metabolism of theophylline, <e20> rifampin </e20>, and valproate, leading to a longer elimination half-life of these three drugs.
mechanism	Terfenadine, <e10> gemfibrozil </e10>, cisapride, disopyramide, and oral <e20> acetaminophen </e20> may enhance the absorption of cimetidine, increasing the blood levels by approximately 50%.
mechanism	Terfenadine, astemizole, indinavir, and <e10> clarithromycin </e10> may reduce the bioavailability of <e20> erythromycin </e20> by 50%.
mechanism	Other Potentially Important Drugs: <e10> Aprepitant </e10> and halothane have been reported to interact with the metabolism of <e20> diltiazem </e20> and halothane.
mechanism	Other Potentially Important Drug Interactions: Nonsteroidal_Anti-inflammatory_Drugs : Concurrent administration of <e10> erythromycin </e10> and other potentially important anti-inflammatory_drugs ( corticosteroids, indomethacin, <e20> aminosalicylic_acid </e20>, triamterene, bromocriptine, and terfenadine ) may result in decreased systemic exposure to a possible toxic dose of either of these drugs.
mechanism	Other Potentially Important Pharmacokinetics Adverse Drug Reactions (ARegion <e10> diltiazem </e10> : increase in AUC of <e20> cimetidine </e20> by #%, Cmax of cimetidine by #%, and AUC and Cmin of cimetidine by #%.
mechanism	Alprazolam : When administered concomitantly with <e10> alprazolam </e10>, the following drugs (including acetaminophen, Tylenol, Phenobarbital, Dilantin, Phenytoin, and <e20> Phenobarbital_sodium </e20> ) may result in a significantly increased absorption of alprazolam : Cimetidine, Phenobarbital, Dilantin, Phenytoin, and St. John's wort.
mechanism	Because <e10> fluvoxamine </e10> inhibits <e20> clofibrate </e20> s metabolism, the amount of clofibrate in the blood may be reduced by #%.
mechanism	Because <e10> fluvoxamine </e10> was found to have no significant effect on either <e20> zalcitabine </e20> or methotrexate concentrations, the mechanism by which fluvoxamine was responsible for the drug interaction with methotrexate is not known.
mechanism	Warfarin : When <e10> phenytoin </e10> is coadministered with <e20> warfarin </e20>, the prothrombin time (INR) increases and the dose of warfarin increases.
mechanism	Oral doses of <e10> astemizole </e10> # mg and # mg for # days each week were associated with a reduction of <e20> valdecoxib </e20> AUC by 10% and 40%, respectively.
mechanism	Similarly, <e10> ethanol </e10> caused a concentration-dependent decrease in the Cmax of <e20> phenytoin </e20> and a concentration-dependent increase in the AUC of phenytoin.
mechanism	Reciprocal interactions may occur if <e10> zalcitabine </e10> is coadministered with other anticonvulsants, <e22> antiepileptic_drugs </e22>, anticonvulsant_antidepressants, anticonvulsant_antifungals, anticonvulsant_antithiazines, or tricyclic_antidepressants.
mechanism	Reciprocal interactions may occur between <e10> tetracycline </e10> and carbamazepine or <e20> phenytoin </e20>.
mechanism	Reciprocal interactions may occur with <e10> terfenadine </e10>-<e20> terfenadine_hydrochloride </e20> or carbamazepine, and/or other nonsteroidal_anti-inflammatory_drugs.
mechanism	Antacids : In vitro studies of low-dose <e10> ibuprofen </e10> and low-dose <e20> calcium_channel_blockers </e20> showed that calcium_channel_blockers slow the absorption of ibuprofen and add an additional 25% increase in absorption of high-dose ibuprofen.
mechanism	Antacids : In vitro studies of antacids containing the <e10> diflunisal </e10> # mg/kg/day for # days, when compared to antacids with no <e20> diflunisal </e20>, showed an increase in diflunisal bioavailability of approximately 5%.
mechanism	The most commonly reported toxicities associated with coadministration of <e10> gentamicin </e10> and <e20> cimetidine </e20> are peripheral neuropathy and, to a limited extent, elevated serum creatinine.
mechanism	The most commonly reported drug interactions with <e11> INSPRA </e11> are with cyclosporine ( <e20> cyclosporine </e20> ), phenytoin ( phenytoin ), carbamazepine ( carbamazepine ), phenobarbital ( phenobarbital ), amiodarone ( amiodarone ), digoxin ( digoxin ), pimozide ( pimozide ), and warfarin ( warfarin ).
mechanism	The most commonly reported drug interactions with <e11> ELSPAR </e11> occur with the following:-<e20> phenytoin </e20> : Increased plasma concentrations of phenytoin may occur when the patient has concomitant use of other drugs with CYP 3A4 inhibitory activity, such as, for example, theophylline, clarithromycin, and nefazodone.
mechanism	The most commonly used drugs in combination with intravenous <e10> penicillin </e10> are the following: amphotericin_B, amiodarone, dapsone, <e20> furosemide </e20>, diazepam, digoxin, fluconazole, halothane, grapefruit juice, nelfinavir, norfloxacin, phenytoin, rifabutin, saquinavir, temazepam, theophylline, theophylline_HCl.
mechanism	The most commonly reported adverse experiences with <e11> Kineret </e11> in patients receiving a <e22> thiazide_diuretic </e22> include nausea, vomiting, and/or diarrhea.
mechanism	The most commonly occurring drug interactions with <e11> TRACRIUM </e11> include:-Aminoglutethimide : <e20> Aminoglutethimide </e20> may increase the plasma concentration of nonsteroidal_anti-inflammatory_drugs and may decrease the metabolism of anesthetics, anesthetics, barbiturates, clofibrate, diazepam, flecainide, and hexobarbital.
mechanism	The most commonly reported drug interactions with <e12> quinolones </e12> include increased CYP3A4 activity when coadministered with <e20> warfarin </e20>, anticoagulants, some fluconazole s, quinolones such as cimetidine and itraconazole, and macrolides such as rifampin.
mechanism	The most commonly reported drug interactions with concomitant use of <e10> sildenafil </e10> and <e20> lithium </e20> were hypertension and lithium toxicity.
mechanism	The most commonly occurring adverse reactions resulting from concomitant administration of <e10> lisinopril </e10> and <e20> lithium </e20> are hyperuricemia and, to a greater extent, hypercalcemia.
mechanism	The most commonly reported drug interactions associated with <e10> cyclosporine </e10> are hyperuricemic <e20> phenytoin </e20> and thiazide_diuretics.
mechanism	The most commonly reported drug interactions associated with <e10> doxycycline </e10> include increases in <e20> cyclosporine </e20> serum concentrations, which may result in a significant decrease in the half-life of doxycycline.
mechanism	The most commonly used oral <e12> anticoagulants </e12> in patients with HIV and liver cirrhosis are: enoxacin, <e20> warfarin </e20>, phenytoin, rifampin, propranolol, and warfarin_sodium.
mechanism	The most commonly reported drug interactions for <e11> FOSCAVIR </e11> are drug interactions with monoamine_oxidase_(MAO) inhibitors (e,g,, fluoxetine, fluvoxamine, <e20> sertraline </e20>, paroxetine, sertraline, venlafaxine ), an interaction with dopamine_antagonists (e,g,, alprazolam, theophylline ), and interactions with CYP3A4 inhibitors (e,g,, itraconazole, itraconazole, nelfinavir, ritonavir, saquinavir ).
mechanism	- Drugs that increase the clearance of drugs that are highly CYP3A4 substrates (eg, phenytoin, <e10> carbamazepine </e10>, tacrolimus, phenobarbital, phenytoin / cisapride, phenytoin, carbamazepine, digoxin, <e20> phenytoin </e20>, alfentanil, bromocriptine, diltiazem, disopyramide, disulfiram, disulfiram, disulfiram, itraconazole, itraconazole, phenytoin, rifampin, rifabutin, theophylline, warfarin, zidovudine, zidovudine, and lovastatin ), decreased the clearance of disopyramide, decreased the clearance of disulfiram, increased the clearance of zidovudine,
mechanism	- Drugs that inhibit CYP3A4 (e,g,, <e10> ritonavir </e10>, ketoconazole, nefazodone, clarithromycin, itraconazole, indinavir, nelfinavir, ritonavir, saquinavir, <e20> saquinavir </e20>, telithromycin, troleandomycin, clarithromycin ) may increase plasma levels of other potent CYP3A4 inhibitors such as ketoconazole and nelfinavir.
mechanism	- Drugs that may decrease the clearance of <e10> rifampin </e10> are listed:-Chlorpromazine (decreased <e20> rifampin </e20> clearance by 17% (9-30%, median))
mechanism	- Drugs that induce hepatic enzymes (eg, <e10> phenytoin </e10>, carbamazepine, cholestyramine, lovastatin ) may decrease the clearance of <e20> cisapride </e20>.
mechanism	- Drugs that may enhance the CYP3A4 activity of <e10> ketoconazole </e10> include: phenobarbital, <e20> diazepam </e20>, alprazolam, valdecoxib, furosemide, diazepam, disulfiram, alprazolam, disulfiram and phenytoin.
mechanism	Naproxen : Coadministration of <e10> naproxen </e10> and <e20> cisapride </e20> (80 mg on day #) increased serum cisapride concentrations by approximately 7%.
mechanism	<e10> Hydrocodone </e10> and <e20> carbamazepine </e20> interact pharmacologically and pharmacokinetically, with carbamazepine having the strongest effect on steady-state plasma concentrations and volume of distribution, as well as AUC and Cmax values.
mechanism	Cimetidine : In a single-dose study of healthy volunteers receiving <e10> cimetidine </e10> # mg and <e20> zalcitabine </e20> # mg, blood concentrations of cimetidine were higher in # mg than in # mg.
mechanism	Thus <e10> cimetidine </e10>. Cimetidine is a strong inhibitor of CYP3A4, thus may decrease the metabolism of <e20> ergotamine </e20>, potentially leading to toxicity.
mechanism	This small decrease in the plasma concentration of <e10> fluvoxamine </e10> may cause a significant decrease in its elimination rate, resulting in decreased exposure of <e20> fluvoxamine </e20> to the target organs.
mechanism	The Cmax of <e10> warfarin </e10> decreased by 38% and AUC by 38% when coadministered with <e20> warfarin </e20> and the drug was given # hours prior to, during, and after dosing with rifampin.
mechanism	This decrease in hepatic clearance of <e11> INDOCIN </e11> was observed with <e20> triazolam </e20> alone and with the concomitant administration of a low dose of indocyanine_oxidase_inhibitors (IDOI).
mechanism	Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole, itraconazole, itraconazole_dimethylester, ritonavir, <e10> clarithromycin </e10>, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin ) may be less effective with <e20> cimetidine </e20>.
mechanism	Substances that are CYP 3A4 substrates (eg, alfentanil, terfenadine, and <e10> disopyramide </e10> ) may increase plasma concentrations of <e20> erythromycin </e20>.
mechanism	Substances that are metabolized by CYP3A4 (eg, alprazolam, fluoxetine, fluvoxamine, paroxetine, sertraline, <e10> paroxetine </e10>, paroxetine_HCl ) may increase plasma levels of <e20> apomorphine </e20>, resulting in a reduction in efficacy of the drug.
mechanism	Substances that are effective in blocking the CYP3A4 activity of <e10> rifampin </e10> may be inhibited by <e20> nelfinavir </e20>.
mechanism	Drugs that cause CYP3A4 activity (eg, certain antidepressants, tricyclic_antidepressants, phenothiazines, barbiturates, barbiturates and <e10> phenytoin </e10> ) may decrease the efficacy of <e20> cyclosporine </e20> and may increase the half-life of cyclosporine.
mechanism	Drugs that cause hepatic enzyme levels to increase by interfering with hepatic metabolism of drugs that cause hepatic enzyme levels to decrease (eg, phenytoin, <e10> phenobarbital </e10>, carbamazepine ) may increase plasma <e20> valproic_acid </e20> concentrations and thus may require increased valproate doses to achieve the desired blood levels.
mechanism	Drugs that cause an increase in plasma concentrations of <e11> INDOCIN </e11> include certain antihistamines ( tricyclic_antidepressants, amitriptyline, nortriptyline, <e20> amiodarone </e20>, nisoldipine ), certain antihistamines ( bromocriptine ), some anticonvulsants ( carbamazepine, felbamate, phenobarbital, phenytoin, primidone, triazolam ), some tricyclic_antidepressants ( amitriptyline, nortriptyline, alprazolam ), some phenothiazines ( alprazolam, oxazolam ), and certain other psychotropic_agents ( theophylline, carbamazepine, alfentanil, fluoxetine, sertraline, alprazolam, bromocriptine, phenoth
mechanism	Concomitant administration of <e10> ketoconazole </e10> tablets with <e20> fluconazole </e20> tablets decreased the fluconazole AUC by 50% and increased the fluconazole AUC by 67%.
mechanism	Concomitant administration of <e10> fluvoxamine </e10> and <e20> loratadine </e20> produced a significant increase in loratadine and diazepam levels.
mechanism	Concomitant administration of <e10> ketoconazole </e10> with <e20> fluconazole </e20> at doses of # mg and # mg daily has been reported to reduce the clearance of fluconazole by approx. 40% in healthy volunteers.
mechanism	The absorption of <e11> ENBREL </e11> is decreased by the metabolism of <e20> erythromycin </e20> and the concomitant use of a cyclosporine_inhibitor or cyclosporine (previously known as enalapril ) with ENBREL.
mechanism	The mean percentage of patients who required <e10> ketoconazole </e10> and <e20> erythromycin </e20> increases of # to #% are increased by approximately #%.
mechanism	Concomitant administration of <e11> REVIA </e11> with <e20> cisapride </e20> produced a 1.6-fold increase in systemic exposure to cisapride.
mechanism	Administration of <e12> quinolones </e12> with <e20> warfarin </e20>, aspirin, and other nonsteroidal_anti-inflammatory_drugs may increase the effective half-life of these agents by decreasing the clearance of the quinolone.
mechanism	Administration of <e12> benzodiazepines </e12> in combination with <e20> cyclosporine </e20> results in an increased toxicity in renal tubules.
mechanism	Administration of <e12> quinolones </e12> with intravenous <e20> probenecid </e20> (40 mg q/wk) for # days did not significantly alter the plasma concentrations of a fluconazole and/or its derivatives or the oral bioavailability of fluconazole.
mechanism	Administration of <e12> NSAIDs </e12> may inhibit the metabolism of <e20> isoniazid </e20>, resulting in a lower plasma concentration of isoniazid.
mechanism	Administration of <e12> quinolones </e12> with antacids containing calcium, <e20> magnesium </e20>, or aluminum salts decreases absorption of quinolones.
mechanism	Administration of <e12> quinolones </e12> with <e20> cisapride </e20> and oral anticonvulsants may prolong and increase the plasma concentrations of cisapride.
mechanism	Caffeine Theobromine <e10> Theobromine </e10> can inhibit <e20> caffeine </e20> absorption.
mechanism	Caffeine Theobromine <e10> Caffeine </e10> inhibits <e20> theobromine </e20> metabolism by two steps: first, it decreases the renal excretion of theobromine by inhibiting cytochrome P450 3A4 (CYP3A4) activity; then, theobromine enters the body via the plasma or urine route.
mechanism	Caffeine Theobromine Grepafloxacin, a potential drug interaction for <e10> caffeine </e10>, resulted in an increased plasma <e20> theobromine </e20> level.
mechanism	Caffeine Theobromine Grepafloxacin Tablets Caffeine-<e10> Caffeine </e10> inhibits the metabolism of <e20> warfarin </e20> and therefore should be used with caution in patients on chronic renal dialysis.
mechanism	Theophylline : <e10> Theophylline </e10>, as well as other <e22> cationic_nitrates </e22>, may potentiate the effects of other agents which inhibit the enzyme system involved in the metabolism of theophylline or which interfere with the excretion of theophylline.
mechanism	Serum theophylline concentrations were significantly reduced by <e10> rifampicin </e10> and <e20> fluvoxamine </e20>, and in all cases by the concomitant administration of a thiazide_diuretic and a glucocorticoid.
mechanism	In addition, other agents that are metabolized by CYP3A4 (eg, quinolones, cimetidine, clarithromycin, nefazodone, troleandomycin, <e10> indinavir </e10>, isoniazid, ritonavir, saquinavir, telithromycin ) may decrease plasma concentrations of <e20> nelfinavir </e20>.
mechanism	The administration of <e10> levothyroxine </e10> is a risk factor for the clearance of <e20> furosemide </e20>.
mechanism	The administration of <e10> almotriptan </e10> increased the plasma concentration of <e20> disopyramide </e20> by approximately one-third to one-half.
mechanism	In a study in normolipidemic subjects with elevated liver ALT, a single oral dose of <e10> zalcitabine </e10> # mg was associated with a 28% decrease in plasma levels of <e20> diltiazem </e20> (400 mg).
mechanism	In # other patients, increased plasma levels of <e10> quinidine </e10> have been observed when <e20> anagrelide </e20> therapy was initiated, a possible drug interaction.
mechanism	<e10> Propranolol </e10> attenuates the hypotensive effect of <e20> gentamicin </e20>.
mechanism	Cholestyramine and colestipol (active ingredients in diet colestipol ) may interfere with absorption of <e10> digoxin </e10> or <e20> methotrexate </e20>.
mechanism	Single doses of <e11> TARCEVA </e11> significantly decreased the Cmax and AUC of <e20> rifampin </e20>.
mechanism	<e12> Antacids </e12> containing magnesium or aluminum may interfere with absorption of <e20> probenecid </e20>.
mechanism	Products containing calcium or aluminum containing <e10> iron </e10> (10 mg or more/kg) have been reported to decrease the plasma concentrations of <e20> probenecid </e20>, resulting in increased blood levels.
mechanism	Methotrexate : Ibuprofen : Increased clearance of <e10> methotrexate </e10> may be observed when <e20> erythromycin </e20> is coadministered with an oral metabolite of methotrexate (the active metabolite of methotrexate, the natriuretic effect of which is attributed to the reduction in the pH of the urine, and the induction of hepatic enzymes).
mechanism	Lithium : <e10> Lithium </e10> in a clinically relevant dose of # mg/day or # mg/day combined with <e20> propafenone </e20> in a dose of # mg/day decreased propafenone serum concentrations by 3.2% and 3.6%, respectively.
mechanism	There is a significant decrease in the plasma levels of <e10> fluvoxamine </e10> and <e20> escitalopram </e20> when administered concomitantly with these compounds.
mechanism	Pretreatment of healthy volunteers with <e10> phenytoin </e10> decreased the plasma levels of <e20> estradiol </e20> by approximately 50% and increased the plasma levels of 17beta-estradiol by approximately 20%.
mechanism	Drugs that may increase hepatic metabolism of <e11> FOSCAVIR </e11> include: <e20> Diflunisal </e20>, digoxin, indinavir, itraconazole, ketoconazole, methadone, phenytoin, rifampin, quinidine, saquinavir, valproate, warfarin.
mechanism	<e11> Gleevec </e11> can reduce the clearance of other oral <e22> anticoagulants </e22>, thus increasing the risk of systemic bleeding.
mechanism	<e11> Gleevec </e11> and <e20> digoxin </e20> may interact in vitro with warfarin or similar drugs, resulting in an increase in the clearance of the warfarin or other potent anticoagulant drugs.
mechanism	<e11> Gleevec </e11> prolongs and increases the blood levels of <e20> loperamide </e20>.
mechanism	Systemic exposure to <e10> enoxacin </e10> increases plasma <e20> furosemide </e20> levels and may increase the half-life of furosemide.
mechanism	The plasma concentration of <e10> furosemide </e10> is increased by oral <e20> ethionamide </e20>, but not by ethionamide in the presence of rifampin.
mechanism	The plasma concentration of <e10> loperamide </e10> was decreased by approximately 50% when administered in combination with <e20> isoniazid </e20>.
mechanism	The plasma concentration of <e10> cimetidine </e10> was decreased by approximately 38% when it was given concurrently with <e20> amphetamine </e20>.
mechanism	In normal volunteers, coadministration of <e10> diltiazem </e10> decreased plasma levels of <e20> digoxin </e20>.
mechanism	In a study in healthy volunteers, the effect of oral <e10> zalcitabine </e10> was reduced by approximately two-fold and increased by approximately tenfold by concomitant administration of <e20> amiodarone </e20>, a known aminoglycoside metabolite.
mechanism	When <e11> INDOCIN </e11> was administered with <e20> doxorubicin </e20>, the mean increase in plasma concentrations of INDOCIN from # to # micrograms/mL was -3% for # hours.
mechanism	<e11> INDOCIN </e11> decreased the AUC and Cmax of <e20> norfloxacin </e20> by 18% and 31%, respectively.
mechanism	Capsules <e11> INDOCIN </e11> containing <e20> diltiazem </e20> or succinylcholine were generally disintegrated within # days after administration.
mechanism	<e11> INDOCIN </e11> has been reported to reduce the plasma concentrations of <e20> phenytoin </e20> by up to 50%.
mechanism	<e11> Betaseron </e11> and <e20> clofibrate </e20> may interfere with the metabolism of warfarin or its derivatives.
mechanism	Furthermore it has been reported that <e10> flupenthixol </e10> at <e20> sumatriptan </e20> concentrations of # microM produced a #% increase in #-microM sumatriptan plasma concentrations.
mechanism	Carbamazepine : <e10> Carbamazepine </e10>, taken concomitantly with <e20> cimetidine </e20>, increases the clearance of cimetidine from approximately 40% to 60%.
mechanism	Phenytoin : <e10> Phenytoin </e10> decreases the elimination of <e20> atorvastatin </e20> by 50%.
mechanism	Valproate : A study of 5 healthy subjects revealed a strong reduction in serum <e10> valproate </e10> concentrations following coadministration with <e20> ethionamide </e20>.
mechanism	Cimetidine : In vitro data indicate that <e10> cimetidine </e10> inhibits the metabolism of <e20> diazoxide </e20> and that it may be possible to increase the oral bioavailability of cimetidine by altering its metabolism.
mechanism	Rifampicin : In vitro, <e10> rifampicin </e10>, alone or with other anticonvulsants, reduces <e20> atropine_sulfate </e20> binding to the cell surface and to plasma level.
mechanism	If <e10> rifampicin </e10> is given concomitantly with <e20> nevirapine </e20>, nevirapine clearance is increased.
mechanism	Coadministration of <e10> erythromycin </e10> with <e20> probenecid </e20> increased the clearance of probenecid.
mechanism	Another oral azole_antifungal such as <e11> FOSCAVIR </e11> has been reported to decrease the metabolism of <e20> fluvoxamine </e20>.
mechanism	In vitro data suggest that <e10> furosemide </e10> may have an additive effect on <e20> enoxacin </e20> absorption and that absorption may be enhanced by combination therapy with either ketoconazole or cimetidine.
mechanism	In vitro data suggest that <e10> cisapride </e10> may increase the clearance of some drugs, such as <e20> isoniazid </e20> and rifampin.
mechanism	Coadministration of <e10> gentamicin </e10> # mg and <e20> cimetidine </e20> # mg for # days had no significant effect on the Cmax and AUC of gentamicin.
mechanism	Coadministration of <e10> atorvastatin </e10> with <e20> furosemide </e20> resulted in a mean increase of -3% in AUC of furosemide.
mechanism	When <e10> Itraconazole </e10> is coadministered with <e20> warfarin </e20>, the increase in the AUC of warfarin is approximately 20%.
mechanism	When <e10> Itraconazole </e10> was given with a <e22> rifampin </e22>.
mechanism	Although no studies have evaluated the safety and efficacy of <e10> warfarin </e10> concomitantly with <e20> hydrocodone </e20>, the possibility of an additive interaction is of concern.
mechanism	Plasma concentrations of <e10> warfarin </e10> and <e20> furosemide </e20> are increased when administered concomitantly with oral hydralazine, as is the potential for interaction with other antihypertensive_drugs, including erythromycin and carbamazepine.
mechanism	The following drug interactions have been identified with concomitant administration of <e10> ketoconazole </e10> and <e20> indinavir </e20> : Drug Interaction: The following interactions have been identified with concomitant administration of indinavir and ketoconazole : Drug Interaction: Concomitant administration of indinavir with ketoconazole may increase plasma concentrations of indinavir by a mean of -0.4% and -5% for rifampin and clarithromycin, respectively, when these drugs are given at a dose of # mg daily on the ketoconazole preparation.
mechanism	Human pharmacokinetics data from healthy volunteers who received dosing with <e10> ketoconazole </e10> # mg once daily for # days have shown a significant increase in clearance of <e20> cisapride </e20> # mg daily, which would result in an approximately 30% increase in cisapride plasma levels.
mechanism	<e10> Ketoconazole </e10> inhibited the metabolism of <e20> ketoconazole </e20> to produce a drug concentration decrease in blood serum and a decreased half-life in urine.
mechanism	<e10> Ketoconazole </e10> has been reported to decrease the clearance of <e20> cisapride </e20>, resulting in increased serum cisapride levels.
mechanism	Coadministration of <e11> NUROMAX </e11> # mg with <e20> phenytoin </e20> at # mg reduced the AUC by 41% (p = 0.004) and the Cmax by 37% (p = 0.001) compared to placebo.
mechanism	Concomitant administration of <e10> dapsone </e10> and <e20> nelfinavir </e20> produced significant increases in both E1 and E2 in patients on dialysis and in serum E1 and E2 concentrations in those on hemodialysis.
mechanism	Concomitant administration of <e10> ketoconazole </e10> with <e20> cimetidine </e20> resulted in increased cimetidine concentrations in the serum.
mechanism	<e10> INH </e10> may increase the hepatic metabolism of phenytoin and other CYP3A4 inhibitors such as <e20> triazolam </e20>, fluoxetine, theophylline, and cimetidine.
mechanism	INH ( <e10> isoniazid </e10> ) metabolism may be inhibited by <e20> warfarin </e20> and other coumarin_anticoagulants.
mechanism	After the coadministration of <e10> cisapride </e10> and <e20> ketoconazole </e20> (an inhibitor of CYP2D6), a dose-dependent increase in the steady-state levels of ketoconazole was observed.
mechanism	however, in a double-blind study, the administration of <e10> ketoconazole </e10> alone or in combination with <e20> loratadine </e20> (Cerepirone ; 100 mg) resulted in a 4% increase in plasma loratadine concentrations.
mechanism	however, in a preliminary study with <e10> rifampin </e10> alone, <e20> ketoconazole </e20> markedly decreased the exposure of rifampin to the extent that rifampin was not required to reach the required plasma levels in patients treated with ketoconazole alone.
mechanism	Probenecid : <e10> Probenecid </e10> reduced the clearance of <e20> fluvoxamine </e20> by 25%.
mechanism	Methotrexate : <e10> Calcium </e10> (vitamin_D) -containing preparations, such as, for example, the multivitamins and vitamin_C preparations, may interfere with absorption of <e20> methotrexate </e20>.
mechanism	Methotrexate : Ketoprofen-<e10> Methotrexate </e10> (40 mg, qID) increased <e20> digoxin </e20> concentrations by 15% and approximately 50%.
mechanism	Lithium : <e12> Amphetamines </e12> may increase the clearance of <e22> lithium </e22>.
mechanism	Warfarin, Digoxin, and Phenytoin : <e10> Cimetidine </e10> potentiates the gastrointestinal absorption of <e20> warfarin </e20>, digoxin, and phenytoin, thus increasing the risk of gastrointestinal toxicity.
mechanism	In vitro studies have shown that <e10> dapsone </e10> reduced the absorption of <e20> dacarbazine </e20> by 50%.
mechanism	Probenecid : Concomitant administration of <e10> probenecid </e10> with <e20> bromocriptine_mesylate </e20> significantly increased its AUC and Cmax.
mechanism	Methotrexate : Concomitant administration of <e10> methotrexate </e10> with <e20> ketoconazole </e20> resulted in increased concentrations of methotrexate and decreased urinary excretion of methotrexate.
mechanism	Ibuprofen-<e10> ibuprofen </e10> increased <e20> erythromycin </e20> levels in vitro by 17%.
mechanism	Concomitant use of <e10> erythromycin </e10> with <e20> gentamicin </e20>, clarithromycin, amiodarone, carbamazepine, cyclosporine, dapsone, dipyridamole, efavirenz, fluoxetine, indinavir, itraconazole, itraconazole_citrate, itraconazole_sulfate, itraconazole_sulfate, itraconazole_thiazide, itraconazole_thiazide, itraconazole_ultraviolet_B, methadone, pimozide, quinidine, salicylates, salicylates_hydrochloride, succinimide, valproate, verapamil, voriconazole, and zidovudine may decrease the clearance of gentamicin, clar
mechanism	<e10> Cimetidine </e10> and carbamazepine are in vitro additive with <e20> doxepin </e20>, suggesting a possible pharmacokinetic interaction.
mechanism	Results of preliminary studies indicate that the clearance of <e10> ciprofloxacin </e10> can be significantly increased by the addition of <e20> carbamazepine </e20> to daily dosing, which was observed in volunteers taking either the single oral dose of ciprofloxacin or the recommended daily dose of carbamazepine for # days prior to the administration of the study drug.
mechanism	When <e10> lansoprazole </e10> was co-administered with <e20> halothane </e20>, halothane levels increased (by #% and #%, respectively).
mechanism	therefore, it is recommended that <e10> cyclosporine </e10> not be used concomitantly with other antipsychotic_agents, <e20> halothane </e20>, or other agents with known toxicity to the thyroid.
mechanism	therefore, it is recommended that <e12> NSAIDs </e12> be used with caution when <e20> methotrexate </e20> and/or cisplatin are used concurrently.
mechanism	therefore, it is recommended to avoid <e10> cholestyramine </e10> in patients receiving other <e22> quinolones </e22>, tricyclic_antidepressants, or other agents that inhibit CYP3A4 activity.
mechanism	therefore, it is likely that the extent of the <e12> diuretic </e12> action may be increased by the presence of this <e22> sulfonamide </e22>.
mechanism	Ketoconazole : In vitro data suggest a possible interaction between <e10> ketoconazole </e10> and <e20> ergotamine </e20> ( ergotamine HCl ) tablets (concurrent use of ergotamine tablets may decrease the efficacy of ergotamine HCl.
mechanism	Carbamazepine : In a study of # healthy volunteers, <e10> carbamazepine </e10> was found to decrease <e20> digoxin </e20> plasma concentrations by 5% when given # h following dosing with either # mg of digoxin or # mg of carbamazepine.
mechanism	Cholestyramine and Charcoal Tablets-Tablets that are used in combination with cholestyramine or charcoal (such as <e10> Cholestyramine </e10> ) are not likely to affect the absorption of <e20> sertraline </e20>.
mechanism	Cholestyramine and Charcoal are highly effective at blocking CYP3A4 activity, thus the potential exists for synergistic drug interactions with <e10> almotriptan </e10> when given concomitantly with or following concomitant <e20> chloroquine </e20>.
mechanism	Effect of AEDs and <e10> phenytoin </e10> on <e20> carbamazepine </e20> metabolism is unknown, but may result in decreased absorption.
mechanism	Although no clinical data were found to suggest a significant reduction in the plasma levels of <e10> terfenadine </e10> by <e20> cimetidine </e20>, there has been a steady increase in the frequency of adverse drug reactions associated with the concurrent use of both drugs.
mechanism	Although no clinical studies have been conducted to evaluate the potential drug interaction of <e10> gentamicin </e10> with <e20> amphotericin_B </e20>, it is expected that an increase in plasma concentrations of gentamicin will result in increased serum concentrations of amphotericin_B.
mechanism	Although no clinical studies have been conducted, <e10> rifampin </e10>-<e20> rifabutin </e20> concomitantly administered with atorvastatin has been shown to reduce the bioavailability of atorvastatin.
mechanism	However, the systemic exposure of <e10> ketoconazole </e10> in patients on cyclosporine A, tacrolimus, or <e20> digoxin </e20> may be increased, resulting in decreased antitumour activity of ketoconazole.
mechanism	However, the systemic administration of <e10> diltiazem </e10> at # mg/kg, twice daily for # days has been associated with a 2-fold increase in <e20> diltiazem </e20> AUC.
mechanism	Binding to Serum, Brain and Thymus: Because <e10> cisapride </e10> inhibits androgens and <e20> androgens </e20>, concurrent administration of either drug with other potentially potent (e,g,, terfenadine )androgens may lead to high plasma levels.
mechanism	Binding to Serum Albumin: Based on a pharmacokinetic study in healthy volunteers, <e10> probenecid </e10> was approximately # times less potent in binding to serum albumin than <e20> isoniazid </e20>.
mechanism	Binding to Serum Albumin and Injection of <e10> rifampin </e10>, as well as the plasma levels of <e20> dexamethasone </e20>, did not change significantly during rifampin administration.
mechanism	Binding to Serum: <e10> Cimetidine </e10> has been shown to have an affinity for <e20> serum </e20> that is very low.
mechanism	Binding to Serum:-<e10> Dexbrompheniramine </e10> has been reported to interfere with absorption of <e20> levothyroxine </e20> in some patients.
mechanism	Binding to Serum Albumin : <e10> Erythromycin </e10> attenuates the binding of <e20> serum albumin </e20> to human leukocytes and therefore the binding of Erythromycin and the other drugs to serum albumin.
mechanism	Binding to Serum Albumin or Plasma Proteins: Antacids (e,g,, vitamin_B-12, <e10> iron </e10> ) are known to decrease the binding of <e20> ketoconazole </e20> to serum albumin or plasma proteins, and antacids containing calcium (e,g,, calcium supplements or folic acid ), magnesium (e,g,, Magnesium supplements or folic acid ), or zinc (e,g,, zinc supplements or folic acid ) increase the binding of ketoconazole to serum albumin or plasma proteins.
mechanism	Binding to Serum Serum concentration of <e10> diclofenac </e10> decreased and duration of prothrombin time increased at low, mid and high <e20> diclofenac </e20> doses, but did not increase at high, moderate and very high diclofenac doses.
mechanism	Binding to Serum Serum Antibodies: Although the interaction between <e10> ciprofloxacin </e10> and serum antibody response to ciprofloxacin was not studied, it is possible that the low concentrations of ciprofloxacin needed to achieve an effect of <e20> nelfinavir </e20> may have been reached.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> may increase the clearance of <e20> terfenadine </e20>.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> significantly increased plasma concentrations of <e20> ethinyl_estradiol </e20> by 5-fold and plasma concentrations of estrogen by 2-fold.
mechanism	In a patient who was given a daily dose of # mg of <e10> clindamycin </e10> and # mg of <e20> rifampin </e20>, the rifampin dose was increased to # mg, which decreased the initial and maintenance steady state plasma concentrations of clindamycin by approximately 50% and approximately 40%, respectively.
mechanism	Urinary acidifying agents (e,g,, <e10> phenylbutazone </e10> ) increase the absorption of <e20> zidovudine </e20>.
mechanism	<e10> d-amphetamine </e10> increased the half-life of <e20> d-amphetamine </e20> by an average of # minutes.
mechanism	<e10> d-amphetamine </e10> inhibited <e20> aripiprazole </e20> binding with an EC50 of $15 mg/kg (approximately # mg of ARAVA/kg of body weight).
mechanism	<e10> d-amphetamine </e10> has been reported to increase <e20> carbamazepine </e20> plasma levels and may thus increase the likelihood of carbamazepine toxicity.
mechanism	MAO_inhibitors MAOI_antidepressants, tricyclic_antidepressants ( <e10> imipramine </e10>, nortriptyline ), and phenothiazines may increase <e20> haloperidol </e20> clearance.
mechanism	Methenamine therapy Urinary excretion of <e10> methenamine </e10> is increased by renal tubular secretion of <e20> phenytoin </e20>.
mechanism	Phenytoin : <e12> Amphetamines </e12> decrease the metabolism of phenytoin, increasing plasma levels of <e20> phenytoin </e20>.
mechanism	Antacids and sucralfate : <e10> Chlorotrianisene </e10> is metabolized by N-acetyltransferase-IV (NATIV), which converts <e20> chlorotrianisene </e20> to its glycosylated metabolite, which may increase the blood level of this antacids.
mechanism	Antacids and sucralfate : Since <e10> acetaminophen </e10>, cholestyramine, and <e20> sucralfate </e20> are the major components of multivitamins, and since multivitamins are likely to decrease the pH of your oral rinse, it is likely that you will need to decrease the pH of your oral rinse prior to taking these medications.
mechanism	Antacids and sucralfate : <e10> Magnesium </e10>, aluminum, and iron containing antacids may inhibit the absorption of <e20> cefdinir </e20>.
mechanism	Antacids and sucralfate : <e10> Acetazolamide </e10> may decrease the absorption of <e20> sucralfate </e20>.
mechanism	<e10> Sucralfate </e10> reduced the clearance of <e20> alfentanil </e20> by about 40%.
mechanism	<e10> Magnesium </e10> -containing preparations (eg, antacids ) may cause a decrease in the absorption of <e20> piperazine </e20> and therefore may increase the pharmacokinetics of piperazine.
mechanism	Magnesium-and aluminum -containing antacids, products containing ferrous_sulfate or <e10> iron </e10>, sulfasalazine, and some oral <e22> anticoagulants </e22> may decrease the bioavailability of coumarin.
mechanism	Separating the doses of <e11> ALFENTA </e11> by # mg/kg of theophylline significantly increased the plasma <e20> alfentanil </e20> AUC and Cmax and the time to peak plasma alfentanil (ALT).
mechanism	Other <e12> quinolones </e12> have been shown to interfere with <e20> cyclosporine </e20> metabolism and are therefore expected to decrease the clearance of cyclosporine.
mechanism	Cyclosporine : Elevated serum levels of cyclosporine were reported in a patient with a history of concomitant <e10> cyclosporine </e10> and <e20> diltiazem </e20>.
mechanism	Probenecid : As a consequence of <e10> probenecid </e10>, plasma concentrations of <e20> triazolam </e20> increased by a mean of 18% and 17%, respectively, resulting in a 16% and 18% increase in AUC values for triazolam and benzodiazepines, respectively.
mechanism	Plasma concentrations (AUC) of <e10> verapamil </e10> increased from # to #40% and # to #36% in the acute and maintenance phases, respectively, following concomitant administration of <e20> ergotamine </e20> and clarithromycin.
mechanism	<e10> Fluconazole </e10> significantly decreased the AUC of <e20> valdecoxib </e20> by 50% in a single dose, and increased the AUC of valdecoxib by 20% in a single dose.
mechanism	The absorption of <e10> ciprofloxacin </e10> is decreased by approximately 40% when <e20> furosemide </e20> is coadministered with the drug.
mechanism	The absorption of <e10> diazoxide </e10> was enhanced by the concomitant administration of <e20> ketoconazole </e20>, indicating that ketoconazole may have a role in increasing the absorption of diazoxide.
mechanism	Methotrexate : <e12> Quinolones </e12> inhibit the metabolism of <e20> methotrexate </e20>, leading to elevated plasma levels of methotrexate and prolongation of its half-life.
mechanism	Lithium : <e12> Amphetamines </e12> have been shown to decrease serum lithium levels and to increase <e20> lithium </e20> absorption.
mechanism	Antacids : In an open-label study in healthy subjects, a significant increase in the t(max) of <e10> diltiazem </e10> and <e20> sulfasalazine </e20> was observed when both drugs were administered with or prior to antacids containing magnesium or aluminum.
mechanism	Cholestyramine -Concomitant intake of <e10> cholestyramine </e10> with <e20> cimetidine </e20> decreased the clearance of cimetidine by approximately 7%.
mechanism	Colestipol -Concomitant intake of <e10> colestipol </e10> and <e20> methotrexate </e20> can result in elevated serum levels of methotrexate.
mechanism	Mineral_Oil -Concomitant intake of <e11> INDOCIN </e11> and a multivitamin containing <e20> vitamin_D </e20> or retinyl_acetate may lead to a decrease in serum vitamin_D levels.
mechanism	Elevated plasma levels of <e10> isoniazid </e10> and phenytoin have been reported with concomitant use of <e20> ketoconazole </e20>.
mechanism	<e12> Quinolones </e12> may also interfere with the metabolism of acetaminophen, corticosteroids, calcium supplements, <e20> calcium_antagonists </e20>, corticotropin, cyclosporine, darunavir, fluconazole, oral contraceptives, rifabutin, saquinavir, tamoxifen, and ulcer drugs.
mechanism	and <e11> Videx </e11> has been reported to decrease plasma <e20> phenytoin </e20> concentrations by blocking the hepatic metabolism of phenytoin.
mechanism	Elevated serum levels of <e10> carbamazepine </e10> have been reported in some patients taking <e20> phenytoin </e20> concomitantly.
mechanism	<e10> Probenecid </e10> has been reported to inhibit the metabolism of other <e22> anticonvulsant_drugs </e22>.
mechanism	<e10> Naproxen </e10> potentiates the acute, but not the chronic, renal toxicity of <e20> valdecoxib </e20>.
mechanism	Naproxen, <e10> Phenytoin </e10>, and Tetracycline may increase the clearance of <e20> gentamicin </e20>.
mechanism	Naproxen, naproxen_sodium, and <e10> fluvoxamine </e10> may decrease plasma levels of <e20> lovastatin </e20> and thus increase the effect of lovastatin.
mechanism	After multiple dosing, the <e12> quinolones </e12> demonstrated a tendency to increase the clearance of <e20> cimetidine </e20>.
mechanism	After multiple dosing, <e10> almotriptan </e10> decreased the AUC of <e20> valdecoxib </e20> by 48% and the Cmax by 46%, and the AUC and Cmax of almotriptan were reduced by 56% and 25%, respectively, compared with valdecoxib alone.
mechanism	<e11> Starlix </e11>, a calcium_channel_blocker, and <e20> verapamil </e20>, a calcium_channel_blocker, both increase the clearance of diltiazem.
mechanism	Indinavir : Coadministration of <e10> indinavir </e10> with <e20> dasatinib </e20> resulted in a reduction of # to #% AUC, corresponding to an approximately 50% decrease in AUC values of indinavir, with no significant changes in dasatinib AUC or Cmax values.
mechanism	Ritonavir : Coadministration of <e10> ritonavir </e10> and <e20> ritonavir </e20> has been reported to result in a slight increase in ritonavir plasma levels.
mechanism	Saquinavir : Coadministration of <e10> saquinavir </e10> with <e20> atazanavir </e20> # mg resulted in a 13% decrease in AUC, which was attenuated by # mg atazanavir.
mechanism	Ketoconazole : Coadministration of <e11> VIDEX </e11> with <e20> ketoconazole </e20> reduced its maximum plasma concentration by two-fold.
mechanism	Rifampin : Coadministration of <e10> rifampin </e10> # mg with # mg of <e20> zalcitabine </e20> resulted in a significant increase in zalcitabine exposure and a 50% decrease in plasma concentrations.
mechanism	Oral <e10> neomycin </e10> has been shown to reduce the clearance of <e20> indinavir </e20>, ritonavir, and nelfinavir.
mechanism	Oral <e10> neomycin </e10> has been shown to increase the absorption of <e20> zidovudine </e20>, indinavir, and nevirapine, possibly by interfering with the metabolism of these drugs.
mechanism	Oral <e10> neomycin </e10> may decrease the clearance of <e20> ethinyl_estradiol </e20> and its progesterone equivalent in postmenopausal women.
mechanism	Oral <e10> neomycin </e10> has been shown to decrease the absorption of oral <e20> cimetidine </e20>.
mechanism	<e10> Clarithromycin </e10> decreased the number of covalently closed capsules in days and the plasma level of <e20> warfarin </e20>.
mechanism	Aspirin : Concomitant administration of <e11> aspirin </e11> with <e20> zidovudine </e20> decreased zidovudine AUC by 36% (p = 0.005) and Cmax by 22% (p = 0.012) compared to zidovudine alone.
mechanism	Cimetidine : <e10> Cimetidine </e10> is converted to the active metabolite cimetidine in the liver and increased plasma levels of <e20> cisapride </e20> are expected.
mechanism	Digoxin : Some patients receiving <e10> digoxin </e10> concomitantly with <e20> lithium </e20> or warfarin, or with other medications known to prolong the QT interval, may develop ventricular tachycardia.
mechanism	Cimetidine : A review of a single institution's experience with <e10> cimetidine </e10> and <e20> halothane </e20> is reported.
mechanism	A study in dogs, in which <e10> methotrexate </e10> was given to two dogs with established renal tubular acidosis, found a significant increase in the renal clearance of <e20> cimetidine </e20> in one dog.
mechanism	A # to # mg dose of <e10> rifampin </e10> may decrease the plasma concentrations of <e20> clofibrate </e20> by 20% to 40%.
mechanism	Coadministration of <e10> carbamazepine </e10> # mg with <e20> lamivudine </e20> # mg was associated with a decrease in lamivudine AUC of 28% (from #/f to #/h).
mechanism	<e10> Quinidine </e10> inhibited <e20> acetaminophen </e20> metabolism to increase hepatic enzyme levels of the active metabolite.
mechanism	Therefore, caution should be exercised when <e10> rifabutin </e10> is coadministered with <e20> ketoconazole </e20>.
mechanism	Antacids containing <e10> magnesium </e10> ( mCem ), zinc ( Zn ), iron ( Fe ), calcium ( Ca ), or aluminum ( Al ) may interfere with absorption of <e20> warfarin </e20> and increase the plasma concentrations of warfarin.
mechanism	The mechanism for this is unknown, but it has been reported that <e10> carbamazepine </e10> may interfere with the metabolism of <e20> lovastatin </e20>, resulting in elevated levels of the parent and/or metabolite, lovastatin.
mechanism	Uricosuric_drugs, such as <e10> guanethidine </e10>, may have an increased exposure to the <e22> b-blocking_agent </e22>.
mechanism	Uricosuric_drugs, such as <e10> phenytoin </e10>, phenobarbital, carbamazepine, and others, reduce the renal clearance of <e20> cimetidine </e20>, resulting in a greater accumulation in the urine of the latter.
mechanism	In patients given concomitant <e10> diltiazem </e10> and <e20> astemizole </e20>, the astemizole requirement was greater.
mechanism	Elevated plasma levels of <e10> estradiol </e10> and <e20> progesterone </e20> have been reported with concomitant use of oral contraceptives containing drospirenone, ethinyl_estradiol or cyclosporine.
mechanism	Elevated serum levels of <e10> phenytoin </e10> have been reported in patients receiving concomitant <e20> cyclosporine </e20> and vitamin_K.
mechanism	Some <e12> quinolones </e12>, including ciprofloxacin, may have been inhibited by <e20> phenytoin </e20>.
mechanism	Steady-state serum concentrations of <e10> erythromycin </e10> are highly variable between patients and drug exposures may be increased by the following:-Concomitant administration of <e20> ciprofloxacin </e20> with the following: amiodarone, calcium_channel_blockers, corticosteroids, corticotropin, digoxin, diltiazem, estrogens, furosemide, fluconazole, hexobarbital, imipramine, lithium, methadone, phenobarbital, phenytoin, perphenazine, rifampin, quinine, saquinavir, theophylline, theophylline_hydrochloride, telithromycin, theophylline, terfenadine, theophylline_sulfate, tolbutamide, and vitamin_C.
mechanism	In addition, higher-than-recommended dose <e10> estazolam </e10> has been reported to reduce the plasma levels of <e20> ketoconazole </e20> by approximately 20%.
mechanism	In well-controlled patients, the antacids containing vitamin_C or <e10> allopurinol </e10> or any <e22> vitamin_K </e22> preparations (with or without sulfonamides ) are likely to reduce serum vitamin_K levels.
mechanism	There have been reports of enhanced absorption of <e10> diltiazem </e10> following concomitant administration of <e20> phenytoin </e20> with oral contraceptives containing estrogens and/or progestins (estrogen-containing oral contraceptives, Estrogen plus progestin (EGP)), compared to women not receiving these drugs.
mechanism	There have been reports of clinically significant increases in plasma levels of <e10> diazepam </e10> and <e20> ketoconazole </e20> when oral ketoconazole and diazepam are coadministered.
mechanism	1- nc denotes norethindrone ( <e10> norethindrone </e10> ) in vivo in <e20> erythromycin </e20> : (1) The concomitant administration of both drugs is associated with a decrease in bioavailability of erythromycin, a decrease in the amount of a norethindrone metabolized, and a decrease in the serum levels of norethindrone.
mechanism	The increase of <e10> erythromycin </e10> concentrations in the presence of <e20> fluvastatin </e20> may be potentiated.
mechanism	Hormonal contraceptives Co-administration of <e10> terfenadine </e10> and <e20> clofibrate </e20> significantly reduced the plasma levels of both medications.
mechanism	Calcium_Antagonist s: After <e10> fluvoxamine </e10> and <e20> warfarin </e20> are coadministered, prothrombin time increases and there is a significant increase in serum creatinine (3%).
mechanism	Pharmacokinetic data from an oral suspension of <e10> cyclosporine </e10> # mg once daily and # mg twice daily indicate that approximately 20% of the administered dose was excreted in the urine, and the elimination half-life of <e20> cyclosporine </e20> # mg twice daily was approximately # hours.
mechanism	Reports in the literature suggest that <e10> astemizole </e10> can inhibit the metabolism of ketoconazole and other strong CYP3A4 inhibitors ( <e20> quinidine </e20>, fluoxetine, paroxetine, and alfentanil ) and inhibitory effects of astemizole can be potentiated by high concentrations of these drugs.
mechanism	Treatment with <e11> COREG </e11> increases the clearance of <e20> guanfacine </e20> by twofold and increases the clearance of furosemide by approximately 30% with concomitant decreases in the renal excretion of these drugs.
mechanism	Methotrexate : <e10> Ketoconazole </e10> may decrease <e20> zalcitabine </e20> exposure.
mechanism	Cimetidine : Co-administration with <e11> CELEBREX </e11> caused a 3-fold increase in <e20> cimetidine </e20> plasma concentrations.
mechanism	Lithium : <e12> Amphetamines </e12> decrease the bioavailability of <e22> lithium </e22>.
mechanism	At higher than # micrograms/mL Clevid was the most effective at inhibiting the metabolism of <e10> methotrexate </e10> by inhibiting AUC(0-120) <e20> Clevid </e20> by > 50%.
mechanism	At # hours after intravenous <e10> ketoconazole </e10>, the intravenous infusion rate of <e20> indinavir </e20> was decreased by approximately 30%.
mechanism	Rifampin : Co-administration of <e10> ketoconazole </e10> with <e20> rifampin </e20> produced a 19% increase in the AUC of rifampin.
mechanism	Theophylline <e11> VIOXX </e11> increased <e20> vitamin_D </e20> by 39% and decreased calcium absorption by 36%.
mechanism	Although specific studies have not been conducted, the possibility of a drug interaction between <e11> WELLBUTRIN </e11> and <e20> digoxin </e20> or methotrexate has been suggested.
mechanism	Although specific studies have not been performed, it is likely that <e10> ketoconazole </e10> may interfere with the metabolism of <e20> fluconazole </e20> by inhibiting CYP2C9.
mechanism	Although specific studies are not available, <e10> cimetidine </e10> and other related drugs, including macrolide_antibiotics, may interfere with the metabolism of <e20> alfentanil </e20>, resulting in elevated plasma levels.
mechanism	Although specific studies have not been conducted, <e10> terfenadine </e10>, as well as other drugs, may decrease the clearance of certain corticosteroids and certain nonsteroidal_anti-inflammatory_drugs, and increase the clearance of the oral anticoagulant <e20> warfarin </e20>.
mechanism	Although specific studies have not been performed, it is likely that <e10> gentamicin </e10> and <e20> ketoconazole </e20> may interact to increase the toxicity of oral anticoagulants.
mechanism	Although specific studies have not been performed, data suggest that co-administration of <e10> zalcitabine </e10> with the following drugs may decrease zalcitabine pharmacokinetics: Ampicillin/Tazobactam, ciprofloxacin, ciprofloxacin, erythromycin, carbamazepine, cyclosporine, disulfiram, fluoxetine, pimozide, quinidine, <e20> zidovudine </e20>.
mechanism	Although specific studies have not been conducted, it is likely that co-administration of <e10> warfarin </e10> may increase the blood concentrations of <e20> cyclosporine </e20>.
mechanism	Although specific studies have not been conducted, <e10> tetracycline </e10> may increase the bioavailability of some oral <e22> anticonvulsants </e22>.
mechanism	Although specific studies have not been conducted, it is likely that coadministration of certain antibiotics (e,g,, ampicillin, tetracycline, clindamycin, erythromycin, <e10> clarithromycin </e10>, doxycycline, miconazole, nalidixic_acid, rifampin, troleandomycin, verapamil ) with <e21> VIDEX </e21> may have resulted in an increase in the bioavailability of the active ingredient.
mechanism	Although specific studies have not been performed, <e10> astemizole </e10> may decrease the absorption of <e20> cetirizine </e20>.
mechanism	Although specific studies have not been performed, there is the potential for significant interactions of <e10> quinidine </e10> with oral anticoagulants, <e20> warfarin </e20>, coumarin, corticosteroids, corticotropin, corticotropin_sulfate, cyclosporine, diltiazem, disopyramide, estrogens, furosemide, fluoroquinolones, glyburide, halothane, itraconazole, methadone, paroxetine, phenytoin, salicylates, tamoxifen, tolbutamide, warfarin (beta-adrenergic_blocking agent), and corticotropin.
mechanism	Although specific studies have not been performed, it is likely that an interaction between <e10> erythromycin </e10> and calcium_channel_blockers, such as <e20> verapamil </e20>, would decrease the clearance of the agent.
mechanism	Coadministration with compounds with weak renal metabolism (such as aminoglycosides, rifampin, indomethacin, <e10> clarithromycin </e10>, quinidine, methotrexate, valproate ) decreased serum <e20> gentamicin </e20> concentrations by approximately 20%.
mechanism	Coadministration with compounds that have secondary amine-type metabolites, such as neomycin, clarithromycin, or <e10> phenytoin </e10>, or that inhibit platelet function (such as <e20> clofibrate </e20>, dipyridamole, cholestyramine ), or that inhibit platelet aggregation (such as disopyramide ), significantly increased the amount of the target drug in plasma.
mechanism	Coadministration with compounds with antihypertensive activity, such as propranolol, <e10> isoniazid </e10>, carbamazepine, diazoxide, alfentanil, disopyramide, phenytoin, bromocriptine, valproate, and <e20> phenytoin </e20> resulted in a decrease in Cmax and AUC of cimetidine.
mechanism	Coadministration with compounds that are known to increase <e10> warfarin </e10> exposure (e,g,, phenytoin, <e20> phenobarbital </e20>, disopyramide, primidone ) did not increase the plasma concentrations of warfarin.
mechanism	Valproate : <e10> Cholestyramine </e10> decreased the clearance of <e20> valproate </e20> by approximately 50%.
mechanism	Effects of other <e12> phenothiazines </e12>, including cyclosporine, tacrolimus, hexobarbital, phenytoin, phenytoin_hydrochloride, and metoclopramide may be exacerbated by <e20> leucovorin </e20>.
mechanism	Phenytoin : Population pharmacokinetics (PK) studies suggest that <e10> phenytoin </e10> may reduce the clearance of <e20> atorvastatin </e20>.
mechanism	Phenobarbital ( Primidone ) and <e10> carbamazepine </e10> may reduce the clearance of <e20> barbiturates </e20> and phenytoin.
mechanism	Valproate : The extent to which <e10> valproate </e10> may alter the pharmacokinetics of <e20> lithium </e20> is unknown, but valproate has been reported to inhibit lithium metabolism.
mechanism	Anticonvulsants ( Phenytoin, Topiramate, Tegretol, Felbatol ) may decrease the clearance of <e10> digoxin </e10> and may require increases in <e20> digoxin </e20> dosage.
mechanism	Even so <e10> zalcitabine </e10> increased the <e20> zalcitabine </e20> plasma half-life (6 to 7 days) and decreased the half-life of the oral drug (approximately 7 days).
mechanism	Lithium : <e10> Lithium </e10> may prolong the pharmacokinetics of <e20> ergotamine </e20>.
mechanism	<e10> Valdecoxib </e10> may decrease the renal clearance of ketoconazole and other <e22> antifungals </e22>.
mechanism	<e10> Valdecoxib </e10> increases plasma levels of <e20> erythromycin </e20> by up to 50%.
mechanism	Concomitant single dose administration of <e10> terfenadine </e10> with <e20> carbamazepine </e20> resulted in a reduction of carbamazepine AUC and Cmax from # to # mg/mL and # to # mg/mL, respectively.
mechanism	Concomitant single dose administration of <e10> nevirapine </e10> (4 mg/kg) and <e20> clofibrate </e20> (20 mg/kg) significantly increased the nevirapine plasma concentration by approximately 5%.
mechanism	Plasma exposure (AUC) of <e10> rifabutin </e10> was decreased by approximately 40% when coadministered with <e20> rifabutin </e20> and a macrolide_antibiotic ( ciprofloxacin ).
mechanism	Plasma exposure (AUC) of <e10> celecoxib </e10> was higher with concomitant administration of <e20> omeprazole </e20> than with omeprazole alone (3-fold increase in celecoxib AUC).
mechanism	Coadministration of <e10> clofibrate </e10> and <e20> heparin_sodium </e20>, and concurrent use of triamterene or carbamazepine increased the half-life of heparin_sodium by approximately 20% and decreased the maximum plasma concentrations by approximately 22% for heparin_sodium.
mechanism	Coadministration with <e10> zalcitabine </e10> significantly increased the plasma level of <e20> zalcitabine </e20> by 15%.
mechanism	Coadministration of <e10> erythromycin </e10> with <e20> cefazolin </e20>, a potent inhibitor of CYP3A4 activity, resulted in a 15% increase in cefazolin AUC (p =.0016).
mechanism	Plasma exposure of <e10> clofibrate </e10> decreased when <e20> quinidine </e20> and sulfasalazine were coadministered.
mechanism	<e10> Erythromycin </e10> at a dose of # mg/day for # days may increase the plasma concentrations of <e20> nevirapine </e20> by 20%.
mechanism	<e10> Ketoconazole </e10> may decrease the bioavailability of <e20> fluvoxamine </e20>.
mechanism	<e10> Ritonavir </e10> in plasma significantly increased <e20> atazanavir </e20> (95% of atazanavir plasma concentrations were above # microM) and its R(+) isomer, atazanavir cis-3-C, aproximately.
mechanism	The interaction is likely to be significant since <e10> erythromycin </e10> inhibits <e20> carbamazepine </e20> metabolism by inhibiting CYP3A4.
mechanism	<e10> Ritonavir </e10> and <e20> ritonavir </e20> inhibit the metabolism of ritonavir to inhibit its clearance.
mechanism	Upon administration of <e10> warfarin </e10> and <e20> astemizole </e20> (500 mg qID) at # hours, a high rate of major gastrointestinal ulceration (36% of all patients) was observed.
mechanism	Amphotericin, Foscarnet, and Erythromycin : <e12> Aminoglycosides </e12>, especially <e20> amphotericin_B </e20>, produce severe and prolonged hypoglycemia.
mechanism	Amphotericin, Foscarnet, and Antacids Tablets Use <e10> Amphotericin </e10>, <e20> Foscarnet </e20>, and Antacids Tablets </e20> may decrease the serum levels of non-steroidal_anti-inflammatory_drugs (exercise-induced hypoglycemia, high-dose aspirin, salicylates, furosemide, triamterene, and certain barbiturates ), lithium, low-dose cimetidine, corticosteroids, bromocriptine, lithium, theophylline, decamethonium, diltiazem, lithium, lithium_hydrochloride, lithium_sulfate, methadone, phenytoin, rifampin, tacrolimus, theophylline, and vitamin_C.
mechanism	Probenecid or Cimetidine : A <e12> salicylate </e12> or Cimetidine : Cholestyramine : Benzodiazepines ( alprazolam, triazolam, diazepam ): Phenothiazines ( alprazolam, diazepam ): <e22> Amphetamines </e22> :
mechanism	Probenecid or Cimetidine : In a study in healthy volunteers, <e10> Probenecid </e10> or Cimetidine significantly decreased the plasma concentrations of <e20> amphetamines </e20> by approximately 34%.
mechanism	Metoclopramide : Bioavailability is reduced by <e10> metoclopramide </e10>, which may increase plasma concentrations of <e20> digoxin </e20> and other potent diuretics.
mechanism	Promethazine : Coadministration of <e10> ethoxzolamide </e10> and <e20> triazolam </e20> significantly reduced the rate of ethoxzolamide absorption.
mechanism	Multiple-dose administration of <e10> flupenthixol </e10> # mg twice daily, # mg daily, and # mg two times daily (40-mg subcutaneous pellets) for # days and <e20> ketoconazole </e20> # mg once daily for # days increased the fluconazole AUC by 26%, 36%, and 40%, respectively.
mechanism	Other strong selective_serotonin_reuptake_inhibitors, such as <e10> sertraline </e10>, citalopram, and venlafaxine, can interact with <e20> citalopram </e20>, causing elevated citalopram levels.
mechanism	Concurrent administration of <e10> doxorubicin </e10> with <e20> rifampin </e20> has been reported to increase doxorubicin plasma levels.
mechanism	However, <e10> halothane </e10> has been reported to produce respiratory depression when administered with either <e20> carbamazepine </e20>, valdecoxib, or zidovudine.
mechanism	The half-life of <e10> terfenadine </e10> was reduced by about two-thirds when coadministered with <e20> atorvastatin </e20>.
mechanism	<e10> Rifampin </e10>, warfarin, phenytoin, or carbamazepine decreased the clearance of <e20> ketoconazole </e20> by approximately 10%, and the amount of active metabolite (up to # mg/day) decreased by approximately 40%.
mechanism	The concomitant administration of <e10> erythromycin </e10> and <e20> clarithromycin </e20> decreased the elimination of clarithromycin, but did not significantly affect the metabolism of clarithromycin.
mechanism	Withdrawal of <e10> levodopa </e10> from the diet may increase the clearance of <e20> phenytoin </e20>.
mechanism	<e10> Amprenavir </e10> was used at # mg/kg/day and <e20> nelfinavir </e20> at # mg/kg/day, in a 6-day regimen, in # healthy male volunteers.
mechanism	<e10> Amprenavir </e10> reduced the AUC of <e20> indinavir </e20> by 19%, decreased the AUC of rifabutin by 17%, and increased the AUC of rifabutin by 9%.
mechanism	<e10> Rifampin </e10> reduced the plasma levels of <e20> terfenadine </e20> by 50% but did not significantly affect the plasma levels of either the hydrochlorothiazide or levodopa.
mechanism	<e10> Rifampin </e10> reduced the clearance of <e20> rifabutin </e20> by 17% (P = 0.0001).
mechanism	<e10> Amprenavir </e10> can interact with <e20> ritonavir </e20>, increasing plasma concentrations and AUC of ritonavir.
mechanism	<e10> Amprenavir </e10> and <e20> ritonavir </e20> inhibited the metabolism of amprenavir and ritonavir to produce plasma levels of amprenavir that were approximately twofold lower than plasma levels observed with normal-functioning ritonavir.
mechanism	RESULTS: The geometric mean fluconazole AUC of <e11> ZYVOX </e11> # mg and <e20> astemizole </e20> # mg were # and # times higher, respectively, when the two drugs were coadministered than when the drugs were given alone.
mechanism	Apparent oral clearance was determined to be significantly increased when <e10> cyclosporine </e10> was coadministered with <e20> cisapride </e20>.
mechanism	<e10> Fluvoxamine </e10>, <e20> quinine </e20>, and chloroquine increase CYP3A4 activity by inhibiting the enzyme and the cofactor for CYP3A4 activity, respectively.
mechanism	DISCUSSION: <e10> Clarithromycin </e10> may be potentiated when given with <e20> digoxin </e20>, triazolam, metoclopramide, and some other protease_inhibitors.
mechanism	<e10> Acetaminophen </e10> s increase in <e20> lithium </e20> may have resulted in less lithium absorption, which may have resulted in a decrease in lithium plasma levels and the tendency to develop lithium toxicity.
mechanism	<e10> Theophylline </e10> has been reported to inhibit the metabolism of <e20> cyclosporine </e20>, leading to a decrease in the serum levels of cyclosporine.
mechanism	Previous studies have demonstrated that <e10> naloxone </e10> has an effect on <e20> lorazepam </e20>.
mechanism	Previous studies have shown that <e10> clofibrate </e10> in combination with vitamin_K2 may increase the clearance of <e20> atorvastatin </e20>, possibly increasing the risk of vitamin K deficiency.
mechanism	Previous studies have shown that <e10> ketoconazole </e10> decreased the clearance of <e20> cisapride </e20> by 27% (IC50 = 47 mg/kg).
mechanism	<e10> Azithromycin </e10> and clarithromycin inhibited <e20> cisapride </e20> metabolism in vitro, with azithromycin being more potent than clarithromycin.
mechanism	<e10> Azithromycin </e10> inhibits the metabolism of <e20> fluconazole </e20>.
mechanism	Coadministration of <e10> clofibrate </e10> with <e20> zidovudine </e20> results in a 22% increase in zidovudine clearance.
mechanism	(1968, 1970), the AUC of <e10> doxapram </e10> was significantly increased by #% and #% for diltiazem and <e20> indomethacin </e20>, respectively.
mechanism	This might be an indirect effect of co-administration of <e10> ketoconazole </e10> and <e20> indinavir </e20>.
mechanism	<e10> Amiodarone </e10> (10 mg QID) decreased the AUC of <e20> aripiprazole </e20> by 50% and the Cmax by 30%.
mechanism	These alterations in CYP3A4 activity may, in part, explain the increased plasma concentrations of <e10> cyclosporine </e10> after initiation of <e20> ampicillin </e20> therapy.
mechanism	<e13> Misonidazole </e13> may inhibit the metabolism of <e20> ketoconazole </e20>.
mechanism	Enhanced <e10> theophylline </e10> plasma levels are seen with the combination of <e20> alfentanil </e20> with fentayl in vitro.
mechanism	This study demonstrates that <e10> fluvoxamine </e10>, an intravenous (i.v.) MAO_inhibitor, may interfere with the metabolism of <e20> fluvoxamine </e20>.
mechanism	Additional <e10> iron </e10> -containing supplements may be required during the first few days after initiation of treatment with <e20> niacin </e20> in the presence of increased serum iron levels.
mechanism	Additional <e10> iron </e10> exposure, which may be produced in response to chronic zinc depletion, may increase the potential for systemic effects of <e20> digoxin </e20>.
mechanism	Consequently, the effect of <e10> amphetamine </e10> on <e20> dopamine </e20> and norepinephrine concentrations is potentiated.
mechanism	[The effect of <e10> furosemide </e10> on <e20> cimetidine </e20> is greater in the central nervous system than in the peripheral.
mechanism	In addition to this observed interaction, <e10> isoniazid </e10> increased the levels of <e20> furosemide </e20> and decreased the plasma levels of cimetidine in normal subjects.
mechanism	The results raise the possibility that the <e12> benzodiazepines </e12> may have a drug interaction with <e20> diazepam </e20>.
mechanism	Co-administration of <e10> quinidine </e10> with <e20> warfarin </e20> has been reported to increase warfarin AUC by 38%.
mechanism	<e10> Acarbose </e10> enhances absorption of <e20> digoxin </e20> and other strong CYP3A4 inhibitors such as atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin.
mechanism	However, the peak plasma concentrations of <e10> digoxin </e10> are increased by approximately 50% when <e20> cimetidine </e20> is coadministered.
mechanism	However, the peak plasma concentrations of <e10> nevirapine </e10> are approximately 10-fold greater when coadministered with <e20> nevirapine </e20>.
mechanism	<e11> DIAMOX </e11> blocks <e20> lofexidine </e20> -induced (4 mg) renal tubular secretion of indocyanine green and inhibits lofexidine-induced (20 mg) renal tubular secretion of indocyanine green in vitro.
mechanism	<e10> Acetazolamide </e10> increased the plasma concentrations of <e20> doxorubicin </e20> and the intracellular half-life of doxorubicin.
mechanism	<e10> Acetazolamide </e10> produced a small, but statistically significant, increase in plasma levels of <e20> dexamethasone </e20>.
mechanism	<e10> Acetazolamide </e10> has been reported to increase the clearance of oral <e20> fluconazole </e20> and the elimination half-life of ketoconazole by approximately 50%.
mechanism	<e10> Acetazolamide </e10> has been shown to inhibit <e20> diazoxide </e20> and chloroquine absorption and to increase diazoxide and chloroquine serum concentrations.
mechanism	Co-administration of <e10> loratadine </e10> and <e20> phenytoin </e20> resulted in a significant decrease in the mean plasma levels of loratadine.
mechanism	Ethanol :Clinical evidence indicates that <e10> ethanol </e10> increases the plasma concentrations of <e20> phenytoin </e20>, clarithromycin, propranolol, phenobarbital, and some cephalosporins.
mechanism	Phenytoin : If <e10> phenytoin </e10> is administered concomitantly with <e20> ergotamine </e20>, it increases the clearance of ergotamine, resulting in decreased plasma concentrations.
mechanism	Cimetidine : <e10> Cimetidine </e10> may increase plasma levels of <e20> ketoconazole </e20> and cimetidine.
mechanism	Intravenous <e10> ranitidine </e10> and oral <e20> lisinopril </e20> significantly reduced the amount of cilostazol required.
mechanism	Products containing <e10> quinine </e10> may decrease plasma concentrations of <e20> digoxin </e20> and some nonsteroidal_anti-inflammatory_drugs.
mechanism	Limited clinical experience with <e10> dapsone </e10> has identified an additional rare clinical observation, involving <e20> zidovudine </e20> in a patient on oral corticosteroids.
mechanism	Limited clinical experience with <e11> NUROMAX </e11> indicates that, in some patients, the <e20> warfarin </e20> dosage may be reduced by up to 50% when given with NUROMAX.
mechanism	<e10> Cimetidine </e10>, diazepam, haloperidol, phenothiazines, and barbiturates may enhance the renal clearance of <e20> ketoconazole </e20> and may increase serum and urine levels of ketoconazole.
mechanism	Co-administration of <e10> nelfinavir </e10> with carbamazepine, cyclosporine, tacrolimus, and <e20> alfentanil </e20>, causing an increase in AUC of nelfinavir by 40%, did not result in an increase in nelfinavir AUC.
mechanism	Co-administration of <e10> furosemide </e10> with a <e22> sympathomimetic </e22> may decrease the effective dosage of furosemide.
mechanism	Ketoconazole : Co-administration of <e10> ketoconazole </e10> and <e20> cisapride </e20> decreased AUC values by a mean of 6%.
mechanism	Furosemide : When <e10> Furosemide </e10> is administered with <e20> bromocriptine_mesylate </e20>, serum bromocriptine_mesylate levels increase and the blood concentration of bromocriptine_mesylate is reduced.
mechanism	Mercaptopurine / Azathioprine : <e10> Mercaptopurine </e10> -related drugs such as <e20> azathioprine </e20> and its derivatives, including N,N-dimethylmercapturine (DMA), may decrease the clearance of mercaptopurine.
mechanism	Mercaptopurine / Azathioprine : An increase in plasma concentrations of mercaptopurine or azathioprine may occur when <e11> PROLEUKIN </e11> is administered concomitantly with <e20> mercaptopurine </e20> or azathioprine.
mechanism	Dicumarol : It is known that <e10> dexamethasone </e10> may reduce the metabolism of <e20> astemizole </e20> and increase the clearance of cisplatin.
mechanism	Uricosuric_Agents : Since <e10> erythromycin </e10> is reported to inhibit CYP2D6, it is expected that agents with similar pharmacology, including <e20> cyclosporine </e20>, may also be inhibitors of CYP2D6.
mechanism	The concomitant administration of <e10> valdecoxib </e10> and <e20> quinidine </e20> decreased the oral clearance of valdecoxib by approximately 22% and resulted in a 24% decrease in the AUC of valdecoxib.
mechanism	Chlorpropamide : <e10> Chlorpropamide </e10> may increase the serum concentrations of <e20> digoxin </e20>.
mechanism	Cyclosporin : Reports suggest that <e12> quinolones </e12>, including <e20> ciprofloxacin </e20>, may decrease the pharmacokinetics of oral anticoagulants, such as warfarin and its derivatives and its derivatives, phenytoin, carbamazepine, and corticosteroids.
mechanism	Verapamil : Coadministration of <e11> PRECEDEX </e11> with <e20> verapamil </e20> (100 mg) resulted in a mean reduction in plasma concentrations of 15% and a mean increase in a creatinine clearance of 8% (P = #) at # hours postdose.
mechanism	Coadministration of <e10> valdecoxib </e10> with oral <e20> carbamazepine </e20>, phenytoin, or almotriptan resulted in elevated valdecoxib plasma concentrations.
mechanism	<e10> Fluvoxamine </e10> or fluvoxamine can reduce the clearance of <e20> ketoconazole </e20> by up to 70% and reduce the plasma levels of ketoconazole by up to 46%.
mechanism	<e10> Ketoconazole </e10>, by-products of the metabolism of <e20> ketoconazole </e20>, have been reported to inhibit the metabolism of other strong inhibitors of CYP3A4 ( such as diltiazem, clarithromycin, nefazodone, pimozide, fluconazole, indinavir, itraconazole, ritonavir, saquinavir, telithromycin, troleandomycin, troleandomycin, zidovudine ) with half-maximal inhibitory concentrations (IC(50)) in the low to high mg/mL range.
mechanism	The steady state plasma levels of <e10> ketoconazole </e10> and <e20> ketoconazole_succinate </e20> were reduced by approximately 45% and approximately 70%, respectively, following administration of a single dose of 10,000 mg of both drugs.
mechanism	The steady state plasma concentration of <e10> rifabutin </e10> decreased by 20% when <e20> erythromycin </e20> was coadministered.
mechanism	Drugs Demonstrated to be Increased by Coadministration of Antacids or Enemas With Calcium <e10> Acetazolamide </e10> or calcium carbonate tablets (previously used with <e20> vitamin_D </e20> ) may decrease the absorption of these drugs.
mechanism	Coadministration of <e10> diazepam </e10> # mg daily with <e20> carbamazepine </e20> # mg daily for # days did not produce significant changes in AUC or Cmax of carbamazepine, nor did it result in a significant increase in AUC or Cmax of cimetidine.
mechanism	Coadministration of oral <e10> cyclosporine </e10> and <e20> levothyroxine </e20> may prolong the blood levels of levothyroxine.
mechanism	<e11> Cytadren </e11> may increase the effect of <e20> epirubicin </e20>.
mechanism	A case report of severe clinical deterioration associated with concomitant administration of <e10> almotriptan </e10> and a <e20> valdecoxib </e20> is reported.
mechanism	<e10> Cimetidine </e10> decreased the <e20> phenytoin </e20> plasma concentrations by 53%.
mechanism	Discontinuation of cimetidine dosage in patients taking warfarin or <e10> phenytoin </e10> concurrently with <e20> cimetidine </e20> may result in significant decreases in AUC and Cmax of cimetidine.
mechanism	<e10> Probenecid </e10> increased the clearance of <e20> bromocriptine_mesylate </e20> by about twofold, and the clearance of ketoconazole and phenytoin by about 20% and 60%, respectively.
mechanism	<e10> Indinavir </e10> and <e20> ritonavir </e20> have been shown to interfere with the metabolism of ritonavir, resulting in decreased plasma concentrations.
mechanism	<e10> Saquinavir </e10> # mg once daily for # days produced # mg and # mg of # and # mg of # HIV, respectively, and an increase of <e20> ketoconazole </e20> AUC by #%.
mechanism	<e10> Nelfinavir </e10> may increase the plasma concentration of some <e22> cephalosporins </e22> and inhibit their metabolism.
mechanism	Coadministration of <e10> methotrexate </e10> ( # mg, # days) with <e20> diflunisal </e20> ( # mg, # days) resulted in a reduction in Cmax of diflunisal of approximately 25% and in AUC of diflunisal by approximately 36% when compared to a similar dosing schedule without diflunisal.
mechanism	<e10> Anagrelide </e10> may enhance the absorption of <e20> warfarin </e20> or its derivatives, especially in patients taking cyclosporine or tacrolimus.
mechanism	There is a 3-fold increase in plasma concentrations of <e10> rifampin </e10> when a single # mg dose of <e20> digoxin </e20> is given with rifampin # mg.
mechanism	Co-administration of <e10> lopinavir </e10> with <e20> zidovudine </e20> significantly increased zidovudine concentrations.
mechanism	For example, since <e10> terfenadine </e10> inhibits <e20> chloroquine </e20>, its elimination may result in less chloroquine in the urine.
mechanism	Oral <e12> anticoagulants </e12>, such as warfarin, use of oral <e22> coumarin </e22> ( phenytoin ), and blood clotting agents may result in increased platelet inhibition by PAS.
mechanism	Oral <e12> anticoagulants </e12>, such as warfarin and its derivatives, prolong the half-life of <e20> zidovudine </e20> and increase its half-life by ~10%.
mechanism	Oral <e12> anticoagulants </e12> ( tricyclic_antidepressants, amitriptyline, <e20> fluoxetine </e20>, paroxetine ) may decrease the plasma levels of warfarin or its derivatives and therefore increase the risk of bleeding.
mechanism	Because oral <e12> anticoagulants </e12> cause a significant increase in heparin and <e20> warfarin </e20> concentrations, co-administration of these anticoagulants with warfarin has the potential to increase its therapeutic effect.
mechanism	<e10> Aprepitant </e10> reduces <e20> clofibrate </e20> serum concentrations by lowering the rate of platelet inhibition by clofibrate.
mechanism	<e10> Aprepitant </e10> significantly reduced the rate of <e20> ethinyl_estradiol </e20> metabolism.
mechanism	Coadministration of <e10> cholestyramine </e10> and <e20> astemizole </e20> resulted in a mean reduction in AUC of about 20%.
mechanism	The daily dose of <e10> erythromycin </e10> was increased by approximately #% to # mg when <e20> quinine </e20> and ciprofloxacin were coadministered.
mechanism	<e10> Aprepitant </e10> may inhibit <e20> cyclosporine </e20> metabolism in renal tubular epithelium.
mechanism	Although there was a time period of up to # weeks between the initiation of concomitant <e10> ketoconazole </e10> therapy and the time of ketoconazole withdrawal, concomitant administration of <e20> digoxin </e20>, erythromycin, and nelfinavir in a patient with a periodontitis-related inflammatory disease did not result in significant increases in serum digoxin levels.
mechanism	Midazolam : <e10> Ketoconazole </e10> increased the clearance of <e20> midazolam </e20> by 20% and decreased its bioavailability by 35%.
mechanism	Ketoconazole : When <e10> ketoconazole </e10> is coadministered with <e20> quinine </e20>, the effect of quinine on ketoconazole pharmacokinetics may be enhanced.
mechanism	Rifampin : When administered concurrently with <e10> rifampin </e10>, <e20> probenecid </e20> may inhibit the metabolism of rifampin and its sulfonamides and thus prolong its half-life.
mechanism	Diltiazem : In the case of <e10> digoxin </e10> toxicity, <e20> diltiazem </e20> is found to inhibit the metabolism of digoxin to produce a low molecular weight steroid hormone which, in turn, may inhibit blood glucose levels.
mechanism	Agents that induce hepatic enzyme activity (such as <e10> phenobarbital </e10>, phenytoin, or phenytoin_sulfate ) may reduce the clearance of <e20> dofetilide </e20> and increase dofetilide blood levels.
mechanism	Inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, nefazodone, <e10> troleandomycin </e10>, ritonavir, nelfinavir ) have been reported to decrease the metabolism of <e20> clarithromycin </e20>, resulting in higher plasma levels.
mechanism	Inhibitors of CYP3A4, including ketoconazole, may inhibit the metabolism of <e10> erythromycin </e10> and reduce the bioavailability of other <e22> NSAIDs </e22>.
mechanism	Inhibitors of CYP3A4 (eg, ketoconazole, itraconazole, <e10> ritonavir </e10>, erythromycin, clarithromycin ) may increase the clearance of <e20> acitretin </e20>.
mechanism	Inhibitors of CYP3A4 (such as ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, <e10> nefazodone </e10>, nelfinavir, saquinavir, indinavir, saquinavir, erythromycin, troleandomycin, didanosine, troleandomycin, zidovudine ) have been reported to decrease plasma levels of <e20> cilostazol </e20>.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> with <e20> zalcitabine </e20> # mg was associated with a #-fold increase in zalcitabine exposure.
mechanism	Quinidine : Coadministration of <e10> cimetidine </e10> and <e20> quinidine </e20> (25 micrograms per kilogram of body weight/day for # days) in healthy volunteers resulted in a significant decrease in plasma quinidine concentrations and a significant increase in its pharmacodynamic index, the QT interval (mean +/- SD; time interval from drug administration to the Tc-95 concentration, s interval), from # minutes to # minutes after administration of quinidine.
mechanism	<e10> Phenobarbital </e10> or other anticonvulsants, barbiturates, and other CNS_depressants may decrease the clearance of <e20> cimetidine </e20> and may increase the clearance of other intravenous anesthetics.
mechanism	In EM individuals, administration of <e10> lopinavir </e10> in combination with <e20> erythromycin </e20> resulted in a mean increase in steady-state plasma levels of lopinavir from 526 to 740 mg/L.
mechanism	In EM individuals, the dose of <e10> Cisapride </e10> required to achieve # mg of <e20> diltiazem </e20> clearance was increased by #% (approximately #%) and the Cmax was increased by #%.
mechanism	Antacid : When <e10> asparaginase </e10> was administered with <e20> anhydrotetracycline </e20>, there was a decrease in asparaginase activity.
mechanism	Colestipol : Plasma concentrations of <e10> colestipol </e10> were approximately #% higher when administered concurrently with <e20> indinavir </e20>.
mechanism	Digoxin : When <e10> digoxin </e10> is given with <e20> carbamazepine </e20>, a 3-fold increase in the digoxin concentration is seen.
mechanism	Erythromycin : In vitro data indicate that <e10> erythromycin </e10> may decrease the pharmacokinetics of <e20> nifedipine </e20>, resulting in a higher plasma concentration.
mechanism	Oral Contraceptives : An increase in the exposure to the <e12> progestins </e12> metabolized by CYP3A4 has been observed during the use of oral contraceptives with estrogens and progestins (such as <e20> anafranil </e20> ) as the active ingredients.
mechanism	<e12> Antacids </e12>, as well as magnesium and calcium supplements, may increase the absorption of <e20> digoxin </e20> and other anticholinesterase_agents.
mechanism	Use with Allopurinol : <e10> Acetazolamide </e10> may increase the plasma concentrations of <e20> allopurinol </e20>.
mechanism	When used in a single daily dose of <e10> loperamide </e10> # mg, <e20> levothyroxine </e20> # mg decreased by approximately 50% and loperamide # mg decreased by approximately 30%.
mechanism	When used in combination with oral <e10> astemizole </e10>, <e20> colestipol_HCl </e20> resulted in a decrease in AUC of both colestipol_HCl and its active metabolite colestipol by 42% and 20%, respectively.
mechanism	When used in combination with <e10> levothyroxine </e10>, <e20> cyclosporine </e20> reduced levothyroxine metabolism by about 50% (approximately # micrograms per kilogram of body weight).
mechanism	When used in combination, <e10> ketoconazole </e10> and <e20> ketoconazole </e20> increase the binding of ketoconazole to drugs that are substrates for CYP2D6 and, consequently, may decrease the bioavailability of ketoconazole.
mechanism	When used in combination with either <e10> cisplatin </e10>, <e20> gentamicin </e20>, or oxaliplatin, doxorubicin can inhibit the metabolism of vitamin_D, resulting in decreased serum levels of vitamin_D and potentially decreased bone metabolism.
mechanism	When used in combination with <e11> CRIXIVAN </e11>, the following medications may increase the clearance of <e20> fluconazole </e20> :-Antacids, certain vitamin_B-containing preparations, certain antacids, cholestyramine, carbamazepine, dicumarol, disulfiram, ergot_derivatives, fluvoxamine, grapefruit juice, leucovorin, midazolam, morphine, phenylbutazone, theophylline, thiazide_diuretics, and warfarin.
mechanism	When used in combination with <e10> cypermethrin </e10>, there is a reduction in the clearance of <e20> nifedipine </e20>.
mechanism	Co-administration with <e10> cimetidine </e10> (200 mg/day) increased the hepatic clearance of <e20> acitretin </e20> by approx. 35% (p < #) and reduced the clearance of cimetidine by approx. 50% (p < #) at the high dose of # mg/day.
mechanism	Total body clearance of <e10> pentobarbital </e10> was decreased by approximately 38% after concomitant administration of aripiprazole and <e20> atorvastatin </e20>.
mechanism	Total body clearance of <e10> fluvoxamine </e10> is increased approximately 5-fold by combination with a high dose of <e20> cimetidine </e20>.
mechanism	Lithium : Increased plasma lithium levels and decreased lithium clearance have been reported in patients treated with <e10> lithium </e10> and <e20> ketoconazole </e20>.
mechanism	Digoxin : In vitro, <e10> rifampin </e10> markedly decreased <e20> digoxin </e20> binding to in vitro phosphorylated extracellular domains of p53, with a possible relevance to the pharmacokinetics of digoxin.
mechanism	On the basis of in vitro data and in vivo data, it is suggested that <e10> nifedipine </e10> may have a competitive interaction with <e20> cisapride </e20> in some drug combinations, and it is suggested that cisapride may be competitive with nifedipine in some drug combinations.
mechanism	On the basis of the results of in vitro studies of <e10> clindamycin </e10>, a possible drug interaction for <e20> dapsone </e20> with chronic high levels of clindamycin was considered to occur when dapsone was given at least # times a day for # days after dapsone was given.
mechanism	On the basis of its pharmacokinetic properties and the known interactions of <e10> amprenavir </e10> with <e20> phenytoin </e20>, and especially with macrolide_antibiotics like erythromycin, the possibility of a drug interaction with the metabolism of amprenavir by the human hepatic system is considered.
mechanism	Furthermore, <e10> rifampin </e10>, a known inducer of the CYP2D6 enzyme, increased the concentration of <e20> valproate </e20> by a mean of 7% and the dose requirement by 18% (2 mg/day).
mechanism	Furthermore, rifampin, phenytoin, and carbamazepine, which are known to increase <e10> indinavir </e10> levels, may decrease <e20> indinavir </e20> serum concentrations.
mechanism	Furthermore, rifampin, phenytoin, and <e10> warfarin </e10> may interfere with the metabolism of <e20> probenecid </e20>, resulting in lower plasma concentrations and increased toxicity.
mechanism	Concomitant administration of <e10> rifampin </e10> with <e20> cimetidine </e20>, macrolide_antibiotics ( macrolide_antibiotics such as erythromycin, clarithromycin, etc), anticonvulsants ( carbamazepine, felbamate, phenobarbital, phenytoin ), antihistamines ( mecamylamine, midazolam ), and tricyclic_antidepressants ( amitriptyline, imipramine, imipramine_HCl, nortriptyline, sertraline, theophylline, alprazolam, nisoldipine ), all produce significant increases in rifampin serum levels.
mechanism	In vitro studies indicate that the <e12> sulfonamides </e12> produce inhibitory effects on the metabolism of <e20> methotrexate </e20>, which is an active metabolite of a single dose of methotrexate.
mechanism	In vitro studies of <e10> warfarin </e10> suggest a possible drug interaction with significant increase in AUC values and significant decrease in Cmax values for <e20> fluvoxamine </e20> # mg/day compared to # mg/day.
mechanism	Concurrent use of <e10> cimetidine </e10> with other oral anticoagulants ( <e20> warfarin </e20>, phenytoin, or diazepam ) may prolong prothrombin time.
mechanism	Steady-state <e10> bosentan </e10> plasma concentrations of <e20> cyclosporine </e20> were decreased by 47% and 59% with concomitant administration of the CYP3A4 inhibitor ketoconazole, and the decrease was concentration-dependent.
mechanism	Co-administration of <e10> rifabutin </e10> (500 mg orally and twice daily) and <e20> indinavir </e20> in patients on combination therapy for HIV infection was associated with a decrease in indinavir steady-state concentrations from # to # ng/mL.
mechanism	Co-administration of <e10> cyclosporine </e10> decreased the plasma levels of <e20> carbamazepine </e20> by 50% on the seventh day of co-administration.
mechanism	Co-administration of <e10> doxycycline </e10> and an <e22> aminoglycoside </e22> increases the clearance of the latter drug.
mechanism	<e10> Bosentan </e10> may decrease serum levels of <e20> cimetidine </e20> and its metabolism, and therefore may increase the risk of liver enzyme abnormalities, and the potential for drug interactions with cimetidine.
mechanism	Ketoconazole : Co-administration with <e10> ketoconazole </e10> has been shown to significantly decrease the plasma concentrations of <e20> atorvastatin </e20>.
mechanism	<e10> Bosentan </e10> may potentiate the metabolism of <e20> warfarin </e20>.
mechanism	<e10> Bosentan </e10> may decrease plasma <e20> warfarin </e20> concentrations and increase the half-life of warfarin.
mechanism	Warfarin : Co-administration of <e10> warfarin </e10> with <e20> cyclosporine_A </e20> decreased the AUC of cyclosporine by about 35% and the Cmax by about 50%.
mechanism	Concomitant oral administration of <e10> levothyroxine </e10> with <e20> digoxin </e20> or with other thyroid_products increases the clearance of digoxin, resulting in increased serum levels of digoxin.
mechanism	- Indomethacin : <e10> Indomethacin </e10> reduces the absorption of <e20> amphetamine </e20>.
mechanism	In a study in healthy volunteers, co-administration of <e10> erythromycin </e10> with <e20> clarithromycin </e20> was associated with an increase in plasma concentrations of clarithromycin (approximately # microM higher) than with either drug alone.
mechanism	In a study in a human model, coadministration of <e10> diltiazem </e10> with <e20> warfarin </e20> resulted in an increase in mean warfarin plasma concentrations of approximately #%.
mechanism	In vitro, <e10> ketoconazole </e10> reduces the exposure of <e20> furosemide </e20> and ampicillin to 3% and 4%, respectively.
mechanism	<e10> Itraconazole </e10>, a strong inhibitor of CYP3A4, increased the plasma concentration of <e20> zalcitabine </e20> by 17%.
mechanism	<e10> Phenytoin </e10> has been reported to reduce the clearance of triazolam, which may increase the blood levels of <e20> carbamazepine </e20>.
mechanism	Because busulfan is a hepatic enzyme, <e10> warfarin </e10> administration may cause a decrease in the clearance of <e20> busulfan </e20>.
mechanism	However, in another study, co-administration of <e10> chloramphenicol </e10> with <e20> astemizole </e20> resulted in a decrease in the AUC and Cmax of astemizole.
mechanism	Phenytoin / Phenobarbital : <e10> Leucovorin </e10> may decrease the renal clearance of <e20> phenobarbital </e20> and may increase the renal clearance of phenytoin and phenobarbital.
mechanism	Phenytoin / Phenobarbital : Decreased plasma concentrations of <e10> phenytoin </e10> have been reported when <e20> phenobarbital </e20> is administered concurrently.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> can cause elevated plasma concentrations of <e20> aripiprazole </e20>.
mechanism	Phenytoin / Phenobarbital / Aprepitant : <e10> Phenytoin </e10> and phenobarbital may interact with <e22> anticoagulant_agents </e22>, and hence, should be used with caution when used with these agents.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> may inhibit metabolism of <e20> doxorubicin </e20> by blocking the cytochrome P450 3A4 (CYP3A4) pathway.
mechanism	Corticosteroids : A 10-day regimen of <e10> doxapram </e10> # mg daily resulted in a decrease of <e20> dexamethasone </e20> from # mg to # mg and a decrease of alprazolam from # mg to # mg.
mechanism	Lithium Reversible increases in serum lithium levels were observed when <e10> lithium </e10> was administered concomitantly with <e20> aprepitant </e20>.
mechanism	Leucovorin : The combination of <e10> ciprofloxacin </e10> and <e20> levodopa </e20> resulted in the following values for plasma concentrations of ciprofloxacin : levodopa : levodopa = (2.16 +/- 0.16) x 10(-3) mg/L, ciprofloxacin = (2.30 +/- 0.19) x 10(-3) mg/L.
mechanism	Agents that are orally bioavailable such as <e10> chloramphenicol </e10>, cholestyramine, cholestyramine with <e20> amphotericin_B </e20>, clarithromycin, fluconazole, indomethacin, itraconazole, ketoconazole, methotrexate, nefazodone, nelfinavir, ritonavir, saquinavir, theophylline, troleandomycin, and zidovudine may reduce the elimination of rifampin.
mechanism	Agents with Increased Release of <e10> Furosemide </e10> (eg, <e20> verapamil </e20>, diazepam, diltiazem, and nifedipine ) may increase the rate of elimination of Furosemide by altering its pH.
mechanism	<e11> Geocillin </e11> has been shown to increase the bioavailability of <e20> amphetamines </e20>.
mechanism	Geocillin ( <e10> tetracycline </e10> ) has been shown to reduce the absorption of <e20> dapsone </e20> and other oral anticoagulants.
mechanism	<e10> Iron </e10> -containing preparations may interfere with absorption of <e20> caffeine </e20> -containing preparations.
mechanism	<e10> Iron </e10> salts reduce the renal clearance of <e20> cyclosporine </e20>, but increase the renal clearance of disopyramide and phenytoin.
mechanism	Serum concentration of <e10> doxorubicin </e10> was increased by a mean of 3-fold and the AUC of doxorubicin was increased by a mean of 8-fold when <e20> doxorubicin </e20> was coadministered with rifabutin, erythromycin, cyclosporine, diltiazem, or indinavir.
mechanism	Inducers and Inhibitors of Aminoglycoside Proteases: In a study in healthy volunteers, <e10> indinavir </e10> decreased the steady-state plasma concentration of <e20> gentamicin </e20> by a mean of 50% and reduced the plasma concentration of a selective cyclosporine A inhibitor by a mean of 30% at # mg/day.
mechanism	<e11> CANCIDAS </e11> administered concurrently with <e20> phenytoin </e20> in healthy volunteers did not decrease blood levels of phenytoin.
mechanism	In two clinical studies, the concomitant administration of <e10> phenytoin </e10> and <e20> fluvoxamine </e20> resulted in an increase in fluvoxamine serum AUC values by 5% to 40%.
mechanism	A drug-drug interaction study of <e10> nevirapine </e10> and pimozide with rifampin, clarithromycin, and <e20> warfarin </e20> found that nevirapine was # to # times more likely to increase the clearance of rifampin and clarithromycin.
mechanism	In addition, results from in vitro studies of <e10> nevirapine </e10> or <e20> lopinavir </e20> were consistent with an additive effect of protease inhibitors ( nevirapine or lopinavir ) on the extent of reduction of plasma levels of zidovudine by nevirapine.
mechanism	In addition, results from in vitro studies of <e10> verapamil </e10> suggest that the metabolic metabolism of <e20> digoxin </e20> may be enhanced by the administration of low-dose digoxin.
mechanism	<e10> Probenecid </e10> has been shown to increase the absorption of cimetidine and <e20> erythromycin </e20>.
mechanism	H2-Receptor_Antagonists : Co-administration of <e10> erythromycin </e10> with <e20> methotrexate </e20> increases methotrexate serum concentrations by approximately 50%.
mechanism	Carbamazepine : Elevated serum carbamazepine levels have been reported when <e10> carbamazepine </e10> is co-administered with <e20> fluconazole </e20>.
mechanism	Concomitant administration of <e11> COREG </e11> and a <e22> serine_antibiotic </e22>, ampicillin, has been shown to decrease COREG plasma concentrations and half-life.
mechanism	however, # mg <e10> ketoconazole </e10> tablets increased <e20> erythromycin </e20> AUC from # to # ng/mL.
mechanism	Fluconazole : Concomitant use of <e10> fluconazole </e10> (30-200 mg/day) with <e20> ergotamine </e20> (30-200 mg/day) (50 mg every 6 hours) increased fluconazole plasma levels by 30% (mean +/- SD, fluconazole: ergotamine: 3,961 +/- 3,722 ng/mL; P =.003) and ERG increased fluconazole plasma levels by 15% (mean +/- SD, fluconazole: ergotamine: 3,721 +/- 4,948 ng/mL; P =.0022).
mechanism	Metformin : In vitro studies in cells transfected with the <e12> TCA </e12> plasmid indicate that <e20> ketoconazole </e20> decreases the hepatic metabolism of CPT-11 and ARAVA (CYP3A4 substrate).
mechanism	Although not observed in patients with ALFACAM, <e10> ketoconazole </e10> may potentiate the in vitro effect of <e20> fluconazole </e20>, thereby increasing the risk of gastrointestinal complications.
mechanism	Probenecid : As with other <e12> tetracyclines </e12>, it should be noted that the possibility of interaction with probenecid has been increased by the introduction of <e20> probenecid </e20> in this report.
mechanism	In the first study, the <e10> warfarin </e10> and <e20> rifampin </e20> salts exhibited different levels of Cmax and AUC in the plasma of healthy volunteers. In a study in healthy volunteers, there were strong interactions of # mg/day of rifampin with # mg/day of warfarin.
mechanism	In a multiple-dose study, # mg of <e10> rifampin </e10> administered with # mg of <e20> clarithromycin </e20> # mg resulted in a reduction in plasma rifampin concentration of 20% compared with clarithromycin administered with # mg of clarithromycin.
mechanism	There was a tendency for the <e10> lithium </e10> to decrease the serum lithium levels in the following weeks following <e20> valdecoxib </e20> administration.
mechanism	Cimetidine : <e10> Cimetidine </e10> may inhibit the metabolism of some <e22> cephalosporins </e22>, including ceftazidime, resulting in elevated serum levels.
mechanism	Ampicillin : In vitro studies of <e10> ampicillin </e10> have shown that there is a slight increase in pharmacokinetics with co-administration of <e20> indinavir </e20> and the inhibitor of HIV-1 reverse transcriptase, ritonavir.
mechanism	Cyclosporin : After administration of <e10> cyclosporin </e10> to anesthetized rats, <e20> ethambutol </e20>, phenobarbital, and digoxin were eliminated in a dose-dependent manner.
mechanism	<e10> Chlorprothixene </e10> may increase plasma concentrations of <e20> fluconazole </e20> and other known inhibitors of cytochrome P450.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> increases the clearance of cisplatin and <e20> cisplatin </e20> and may increase the half-life of these drugs.
mechanism	<e10> Cholestyramine </e10>-<e20> warfarin </e20>-Cimetidine Interactions are rare and not expected with the cyclosporine_anticonvulsants and with the combination of the cyclosporine_anticonvulsants with amiodarone, dofetilide, or terfenadine.
mechanism	<e10> Cholestyramine </e10>, carbamazepine, felbamate, and phenobarbital : The concomitant administration of <e20> rifampin </e20> and Cholestyramine, Carbamazepine, Felbamate, or Phenobarbital may decrease the half-life of rifampin and cause increased plasma levels.
mechanism	<e10> Cholestyramine </e10> and bromocriptine_mesylate (e,g,, Cholestyramine ) enhance <e20> acitretin </e20> metabolism and produce a 5-fold increase in AUC and Cmax.
mechanism	Probenecid : <e10> Probenecid </e10> may increase plasma concentrations of <e20> diazepam </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> has been shown to decrease the pharmacokinetics of other <e22> anticholinesterase_agents </e22>, including carbamazepine, phenobarbital, and alfentanil.
mechanism	Probenecid : <e10> Probenecid </e10>, and other azole_antifungals, such as <e20> itraconazole </e20>, produce in vitro inhibition of growth of all known bacteria and yeasts.
mechanism	Probenecid : <e10> Probenecid </e10> decreased the AUC of <e20> warfarin </e20> by approximately 50%.
mechanism	Probenecid : <e10> Probenecid </e10>, like other drugs, can decrease the absorption of <e20> norethindrone </e20>, and therefore, the effective dose of the parent drug.
mechanism	Probenecid : <e10> Probenecid </e10> reduces the hepatic metabolism of <e20> ketoconazole </e20> by increasing the levels of triazolam, alprazolam, and triazolam_hydrochloride.
mechanism	Probenecid : <e10> Probenecid </e10>, the active metabolite of <e20> amphetamines </e20>, has been reported to decrease plasma levels of amphetamines in rats and dogs, with little effect on plasma cAMP concentrations.
mechanism	Probenecid : <e10> Probenecid </e10> decreases the bioavailability of <e20> digoxin </e20>, isoniazid, phenytoin, and theophylline.
mechanism	Probenecid : <e10> Probenecid </e10> (40 mg once daily for # days) significantly reduced the natriuresis to <e20> nisoldipine </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> significantly increased the half-life of <e20> amphetamine </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> has been reported to decrease the metabolism of <e20> indinavir </e20>, thus decreasing the half-life of the active compound.
mechanism	Pharmacokinetic studies have demonstrated that <e10> carbamazepine </e10> increases the exposure of <e20> disopyramide </e20> and that carbamazepine increases the rate of disopyramide elimination.
mechanism	<e11> Tagamet </e11> increases the clearance of indinavir, <e20> ritonavir </e20>, saquinavir, and cimetidine.
mechanism	<e11> Tagamet </e11>, and similar agents, have been reported to cause the metabolism of intravenous <e20> guanfacine </e20> to guanfacine and to a lesser extent to cimetidine, suggesting a possible drug interaction with these agents.
mechanism	<e11> Tagamet </e11>, alone, had a maximum reduction of 24% in the urinary excretion of phenytoin and <e20> levodopa </e20>.
mechanism	<e11> Tagamet </e11>, an oral <e22> macrolide_antibiotic </e22>, increases the prothrombin time and increases the level of coagulation factors, including fibrinogen and prothrombin time, by about 50%.
mechanism	<e11> Tagamet </e11>, in addition to its antihypertensive effect, also increases plasma levels of <e20> losartan </e20>.
mechanism	<e11> Tagamet </e11>, a Cys-Acylo_Tyr (CysTyr) analog, inhibited the in vitro metabolism of <e20> diltiazem </e20> and, as a result, increased the plasma levels of diltiazem.
mechanism	<e11> Tagamet </e11>, tetracycline, and <e20> levamisole_hydrochloride </e20> may increase the metabolism of oral contraceptives, certain antibiotics, calcium supplements, corticosteroids, corticotropin, cyclosporine, disopyramide, fluconazole, halothane, morphine, phenytoin, risperidone, methadone, quinidine, theophylline, theophylline_HCl, theophylline_HCl_b-D-glucarate, theophylline_HCl_D-mannitol, and warfarin.
mechanism	<e11> Tagamet </e11> inhibits <e20> levodopa </e20> metabolism in vivo and prevents the increase in levodopa clearance observed when metoclopramide is coadministered.
mechanism	<e11> Tagamet </e11> did not affect the pharmacokinetics of cisapride and carbamazepine in subjects with normal renal function, however, subjects with impaired renal function were observed to have reduced blood levels of <e20> cisapride </e20> and carbamazepine.
mechanism	However, a crossover study of oral <e10> phenytoin </e10> and carbamazepine tablets (1 g once daily for # days) in healthy subjects demonstrated an increase in plasma concentrations of <e20> phenytoin </e20> from # to #.5 microM when carbamazepine was coadministered.
mechanism	However, a crossover study with theophylline did not reveal an effect of <e10> theophylline </e10> on the bioavailability of <e20> phenytoin </e20> or lovastatin.
mechanism	Co-administration of <e10> ketoconazole </e10>, ketoconazole_b-ring, <e20> rifampin </e20>, and aripiprazole significantly reduced the plasma concentrations of aripiprazole.
mechanism	<e12> Quinolones </e12>, including rifabutin, <e20> ciprofloxacin </e20>, and rifabutin, may inhibit the metabolism of certain antibiotics or drugs of abuse (e,g,, oxytocin, ampicillin, cimetidine, morphine, succinylcholine, and barbiturates ).
mechanism	Antacids or <e10> sucralfate </e10> that interfere with absorption of <e20> levothyroxine </e20> may decrease serum and urine levothyroxine levels and result in elevated thyroidal antibody levels.
mechanism	Also, concomitant administration of <e10> diltiazem </e10> with <e20> atorvastatin </e20> has resulted in a marked reduction in the AUC of atorvastatin, an increase in the Cmax of atorvastatin and a decrease in the AUC/F ( AUC/F ( a %) of atorvastatin).
mechanism	Also, concomitant administration of <e10> diflunisal </e10> with oral <e22> anticoagulants </e22> increased the risk of bleeding.
mechanism	Also, concomitant administration of <e10> quinidine </e10>, which has a highly binding affinity for <e20> vitamin_D </e20>, also weakens vitamin_D binding to the active site of the receptor and thus causes a reduction in the serum concentration of vitamin_D.
mechanism	Also, concomitant administration of <e10> warfarin </e10> with <e20> piperazine </e20>, a potent diuretic, increased the renal excretion of piperazine.
mechanism	Some <e12> quinolones </e12> have been reported to decrease the clearance of digoxin and <e20> insulin </e20>, resulting in a concomitant rise in blood levels.
mechanism	Some quinolones, including ciprofloxacin, exhibit a strong tendency to interact with <e10> chloramphenicol </e10>, a bacterial-antibiotic, causing a loss of clearance of <e20> chloramphenicol </e20>.
mechanism	Methotrexate Renal tubular secretion was reduced by <e10> warfarin </e10> and <e20> ketoconazole </e20>, and increased by fluconazole, methotrexate, cisapride, cimetidine, phenytoin, and diazepam.
mechanism	Multivalent Cation-Containing Products: In vitro data indicate that the clearance of <e10> probenecid </e10> may be reduced by concomitant use of <e20> methylprednisolone </e20> and some multivalent cation-containing products.
mechanism	Multivalent Cation-Containing Products: Since the metabolism of multivalent cations can be altered by concomitant administration of drugs such as methotrexate, <e10> doxorubicin </e10>, carbamazepine, cyclosporine, dexamethasone, disopyramide, fentanyl, indomethacin, and <e20> interferon-alfa </e20>, careful monitoring of the patient is advised.
mechanism	Multivalent Cation-Containing Products: <e10> Chlorotrianisene </e10> is known to have a significant effect on the pharmacokinetics of a number of multivalent cation-containing products, such as the following: <e20> Acetaminophen </e20> and other nonsteroidal_anti-inflammatory_drugs, salicylates, some bile salts, some corticosteroids, and bromocriptine.
mechanism	Multivalent Cation-Containing Products: Clinical studies, as well as postmarketing observations, have shown that multivalent cation-containing products (such as aspirin, ketoprofen, <e10> lisinopril </e10>, diclofenac, clofibrate ) have been shown to increase the absorption of <e20> warfarin </e20>, and therefore may increase the risk of warfarin-related adverse events.
mechanism	Multivalent Cation-Containing Products: Concomitant administration of <e10> lithium </e10> with multivalent cation-containing products (eg, lithium carbonate, lithium sulfate, lithium-containing products with a positive lithium ion gradient such as anion-exchange_plasma-reducing_agents or cyclosporine, triazolam, <e20> phenytoin </e20> ) may lead to an elevation in serum lithium concentrations.
mechanism	Multivalent Cation-Containing Products: When <e10> carbamazepine </e10> and <e20> lithium </e20> are used concomitantly, patients should be closely observed for signs and symptoms of lithium toxicity.
mechanism	Multivalent Cation-Containing Products: Experience with multivalent cation-containing products such as alcohol and succinylcholine suggests that these products may increase the renal clearance of <e10> amprenavir </e10> and <e20> atazanavir </e20>.
mechanism	Multivalent Cation-Containing Products: Caffeine Tablets, decaffeinated coffee, and energy drinks containing <e10> caffeine </e10> (a caffeine metabolite) may reduce the absorption of <e20> warfarin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> may increase the metabolism of <e20> digoxin </e20>.
mechanism	Probenecid : <e10> Probenecid </e10> markedly inhibits the in vitro metabolism of <e20> dexamethasone </e20> and other glucocorticoids.
mechanism	Theophylline : As <e10> theophylline </e10> has been reported to decrease the absorption of <e20> warfarin </e20>, the increase in the half-life of warfarin is likely to reduce the pharmacologic effect of warfarin.
mechanism	Antibiotics : In vitro data suggest that oral <e12> antibiotics </e12>, including ampicillin and tetracycline, may diminish the renal clearance of <e20> warfarin </e20>.
mechanism	Antidepressants : In one study, the addition of <e10> ketoconazole </e10> # mg to an SSRI (e,g,, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine ) significantly increased the plasma concentration of <e20> desipramine </e20>, a serotonin reuptake inhibitor.
mechanism	Human pharmacokinetic data suggest that the AUC of <e10> fluvoxamine </e10> is reduced by the extent of renal clearance and the metabolism of <e20> lovastatin </e20> may increase its hepatic exposure.
mechanism	The gastrointestinal absorption of <e10> ketoconazole </e10> is decreased when administered concurrently with <e20> carbamazepine </e20>.
mechanism	<e11> Atromid-S </e11> significantly increased the absorption of <e20> ergotamine </e20> and norethindrone.
mechanism	plasma levels of <e10> diltiazem </e10> are increased when patients are treated with an <e22> cephalosporin </e22>.
mechanism	plasma levels of theophylline, a potent inhibitor of CYP3A4 activity, are increased by coadministration of <e10> ciprofloxacin </e10> and <e20> simvastatin </e20>.
mechanism	plasma levels of <e10> rifampin </e10>, dexamethasone, corticosteroids, corticotropin, corticotropin_sulfate, and <e20> ethinyl_estradiol </e20> were decreased significantly by addition of furosemide or by using rifampin-corticotropin (or dexamethasone ) supplements during a period of at least # weeks.
mechanism	Administration of <e10> ketoconazole </e10> at doses of # mg/day and # mg/day for # days did not inhibit <e20> ergotamine </e20> metabolism.
mechanism	<e10> Fluvoxamine </e10> decreased the clearance of <e20> cimetidine </e20> by approximately 50%.
mechanism	In a study in healthy volunteers, coadministration of <e10> terfenadine </e10> # mg and a <e22> drug </e22> with narrow therapeutic index, such as ketoconazole (4%), fluconazole (40%), or cimetidine (10%), was associated with a mean increase in the plasma concentrations of ergotamine, a CYP3A4 substrate, of #-fold, whereas concomitant administration of the CYP3A4 inducer ergotamine and a CYP3A4 inhibitor, atazanavir, resulted in a mean decrease in the plasma concentrations of ergotamine by 8-fold.
mechanism	In a study of healthy volunteers, <e10> probenecid </e10> given concomitantly with <e20> rifampin </e20> was found to decrease rifampin plasma concentrations by a mean of -20% and increase rifampin AUC by a mean of 34%.
mechanism	Cytochrome P-450 inducers, including cyclosporine, tacrolimus, phenytoin, phenobarbital, carbamazepine, phenytoin_hydrochloride, phenytoin, primidone, <e10> felbamate </e10>, phenytoin_hydrochloride, phenytoin, diazepam, triazolam, chlordiazepoxide, diltiazem, cimetidine, dextromethorphan, eszopiclone, fluoxetine, haloperidol, pimozide, quinidine, theophylline, <e20> warfarin </e20>, and zidovudine inhibit the metabolism of a single high dose of zidovudine and may result in decreased plasma levels of zidovudine.
mechanism	Cytochrome P-450 inducers, including <e10> ketoconazole </e10>, cimetidine, itraconazole, and ketoconazole, inhibit <e20> acitretin </e20> metabolism, resulting in a decrease in serum and urine levels of acitretin.
mechanism	<e10> Phenytoin </e10> has been reported to increase the plasma levels of <e20> ketoconazole </e20>.
mechanism	Phenytoin, <e10> carbamazepine </e10>, and tacrolimus decrease <e20> norfloxacin </e20> serum concentrations by inhibiting CYP3A4 activity.
mechanism	<e10> Cimetidine </e10>, but not other NSAIDs, decreased the bioavailability of <e20> cimetidine </e20> in healthy volunteers by approximately 17%.
mechanism	Cimetidine, caffeine, and <e10> acetaminophen </e10> may increase <e20> cyclosporine </e20> levels by inhibiting sulfate-reducing enzymes.
mechanism	Although concomitant use of <e10> isoniazid </e10> and <e20> rifampin </e20> increases the risk of rifampin nephrotoxicity, the impact of rifampin nephrotoxicity on isoniazid metabolism is unknown.
mechanism	<e10> Paroxetine </e10> has been reported to decrease <e20> cimetidine </e20> plasma concentrations, and thus an increase in the AUC of cimetidine may occur.
mechanism	However, other published reports have shown that the AUC of <e10> cimetidine </e10> was significantly decreased in patients receiving <e20> ketoconazole </e20>.
mechanism	However, other published reports have demonstrated a decrease in plasma <e10> lithium </e10> concentrations when <e20> lithium </e20> was given concurrently with oral contraceptives containing progestins, a common cause of amenorrhea.
mechanism	However, other published reports have shown that <e10> phenytoin </e10> and phenobarbital, when given concomitantly with <e20> estradiol </e20>, had a tendency to increase the plasma levels of estradiol.
mechanism	<e10> Colchicine </e10> may decrease the bioavailability of <e20> furosemide </e20>, propranolol, barbiturates, or other drugs that cause elimination of bile acids (eg, vitamin_B6 ).
mechanism	<e11> WelChol </e11> can inhibit the metabolism of <e20> ethinyl_estradiol </e20>, progestins, and progestins_with-alkyl side-chains (withanol, cholestyramine, triestin, tamoxifen, etc).
mechanism	<e11> WelChol </e11> may interfere with the absorption of certain drugs (e,g,, furosemide, nonsteroidal_anti-inflammatory_drugs, salicylates, <e20> vitamin_D </e20> ) by decreasing the serum levels of these drugs.
mechanism	Repeated doses of <e10> dapsone </e10> may decrease the serum concentrations of <e20> adenosine </e20>.
mechanism	The absorption of <e10> terfenadine </e10> is reduced by <e20> warfarin </e20>, phenytoin, tacrolimus, or carbamazepine.
mechanism	The absorption of <e10> nevirapine </e10> decreased by 62% with <e20> efavirenz </e20> coadministration, and the AUC of nevirapine increased by 18% and the Cmax by 14%.
mechanism	The absorption of <e10> rifampin </e10> is increased by <e20> phenytoin </e20>.
mechanism	The absorption of <e10> cefazolin </e10> is enhanced by <e20> methotrexate </e20>.
mechanism	Particular caution should be exercised when <e10> cimetidine </e10> is administered concomitantly with <e20> warfarin </e20>, which may cause clinically significant increases in serum creatinine.
mechanism	Particular caution should be exercised when <e10> loxapine </e10> is administered with <e20> alcohol </e20> or other CNS_depressants, as these agents may potentiate the CNS depressant effect of loxapine.
mechanism	Digoxin : Coadministration of <e11> COREG </e11> and <e20> digoxin </e20> increased serum digoxin levels by 28%.
mechanism	Therefore, if <e10> furosemide </e10> is to be used concomitantly with <e20> ketoconazole </e20>, the ketoconazole dose should be increased to # mg/day.
mechanism	Drugs that induce hepatic enzyme systems (e,g,, amiodarone, <e10> cypermethrin </e10> ) may increase the clearance of <e20> erythromycin </e20>.
mechanism	Drugs such as digoxin, theophylline, phenobarbital, <e10> phenytoin </e10>, and corticosteroids that are highly expressed in the prostate and that inhibit the metabolism of <e20> prostate_specific_antibody </e20> s (PSA) by raising serum levels of the hormone may increase the plasma concentration of PSA and increase the risk of prostate cancer.
mechanism	<e10> Colchicine </e10> injection increases the clearance of (e,g,, <e20> phenytoin </e20> ) by about two-fold and the half-life of (e,g,, phenytoin ) by about two-fold.
mechanism	Colchicine para-aminosalicylic_acid and digoxin levels may be increased when <e11> VIOXX </e11> is administered concomitantly with <e20> colchicine </e20> or digoxin.
mechanism	Concomitant use of <e10> ketoconazole </e10> and <e20> terfenadine </e20> increased AUC of terfenadine by about two-fold, but did not affect the pharmacokinetic profile of terfenadine.
mechanism	Concomitant use of <e10> chloroquine </e10> may reduce the effectiveness of other anticonvulsants, <e20> cyclosporine </e20>, carbamazepine, gabapentin, indomethacin, and phenytoin.
mechanism	Concomitant use of <e11> VIOXX </e11> and <e20> isoniazid </e20> is reported to result in a 25% increase in the serum concentration of isoniazid.
mechanism	Concomitant use of <e11> FOSCAVIR </e11> with all antacids containing magnesium, calcium, or iron has been associated with increased serum levels of <e20> magnesium </e20> or calcium.
mechanism	Concomitant use of <e10> phenytoin </e10> and <e20> phenobarbital </e20> may result in an increased clearance of the former and increased clearance of the latter.
mechanism	Concomitant use of <e10> chlorpromazine </e10> with <e20> warfarin </e20> (international normalised ratio of warfarin to ethinyl_estradiol) and/or hormonal contraceptives may lead to significant increases in ethinyl_estradiol concentrations.
mechanism	Concomitant use of <e10> quinine </e10> and <e20> acitretin </e20> increases the absorption of quinine from the intestine and may potentiate the potential of gastrointestinal side effects.
mechanism	Concomitant use of <e10> diltiazem </e10> tablets and other potent CYP3A4 inhibitors, such as ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin ( TAO ), and <e20> troleandomycin </e20>, may increase the plasma concentrations of the desired drug.
mechanism	Concomitant use of <e10> ketoconazole </e10> with <e20> methotrexate </e20> significantly increases the plasma concentrations of methotrexate.
mechanism	Concurrent administration of <e11> ENABLEX </e11> and <e20> amphetamine </e20> has been reported to result in a marked increase in plasma amphetamine levels, and, therefore, it is not recommended.
mechanism	Conversely, decreases in body weight and increased appetite have been reported when <e11> LEVSIN </e11> is coadministered with antihypertensive_drugs that have either metabolic effects or weak metabolism (e,g,, <e20> losartan </e20>, fluoxetine, amiodarone, guanethidine ).
mechanism	There have been reports of interactions between <e10> doxorubicin </e10> and other <e22> quinolones </e22>, including carbamazepine, rifabutin, and erythromycin.
mechanism	Ephedrine : <e10> Ephedrine </e10> increased plasma <e20> cimetidine </e20> concentrations (p = 0.008) and induced a 50% increase in cimetidine exposure at the AUC of cimetidine (0, 60, and 120 minutes).
mechanism	Hepatic Enzyme Inducers, such as <e10> warfarin </e10>, may increase the plasma levels of <e20> cyclosporine </e20>.
mechanism	Hepatic Enzyme Inducers, Interferon-G, and Indinavir : <e10> Indinavir </e10> increased the metabolism of <e20> cypermethrin </e20> by increasing cypermethrin elimination and increasing plasma concentrations of cypermethrin.
mechanism	Drugs which inhibit CYP3A4 (eg, ketoconazole, itraconazole, ritonavir, erythromycin, indinavir, <e10> erythromycin </e10>, clarithromycin, saquinavir, telithromycin, troleandomycin, troleandomycin s, troleandomycin s, indinavir, ritonavir, saquinavir, troleandomycin, indinavir ) may reduce the bioavailability of <e20> atazanavir </e20>.
mechanism	Drugs which inhibit the CYP3A4 activity of <e10> ketoconazole </e10> include: atazanavir, clarithromycin, diltiazem, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, <e20> telithromycin </e20>, troleandomycin, voriconazole.
mechanism	Ketoconazole : <e10> Ketoconazole </e10> significantly inhibits <e20> nelfinavir </e20> metabolism, resulting in lower plasma levels of nelfinavir and higher AUCs of nelfinavir.
mechanism	The clearance of <e10> valdecoxib </e10> has been reported to be enhanced by <e20> caffeine </e20>.
mechanism	<e10> d-amphetamine </e10> and ketamine exhibit additive depressant effects on both blood pressure and heart rate when given to healthy volunteers receiving <e20> fluvoxamine </e20>.
mechanism	<e10> d-amphetamine </e10> increased <e20> d-amphetamine </e20> AUC, however, and halothane decreased d-amphetamine AUC, suggesting that AUC may be a poor indicator of exposure to d-amphetamine.
mechanism	<e10> d-amphetamine </e10> may interact with adrenergic or <e22> serotonergic_agents </e22> to increase the clearance of these medications.
mechanism	Methenamine therapy: Urinary excretion of methenamine decreased significantly in rats given <e10> methenamine </e10> when compared to rats given <e20> phenytoin </e20>.
mechanism	Phenytoin : <e12> Amphetamines </e12>, like other stimulants, may increase the absorption of <e20> phenytoin </e20>.
mechanism	Ingestion of <e10> phenytoin </e10> or alfentanil, which inhibit CYP3A4, results in a 5- to 8-fold increase in plasma concentrations of <e20> rifabutin </e20> and has no effect on rifabutin pharmacokinetics.
mechanism	Ingestion of <e10> colestipol </e10> # mg decreased plasma <e20> dantrolene </e20> levels by 15%, whereas no such effect was observed with # mg of bromocriptine_mesylate.
mechanism	Lithium : <e10> Lithium </e10> may decrease the renal clearance of <e20> phenytoin </e20>, and therefore the dose requirement.
mechanism	Lithium : <e10> Lithium </e10> is a potent inhibitor of the CYP3A4-mediated metabolism of <e20> cimetidine </e20>.
mechanism	Protein Binding In vitro studies have shown that <e10> prazosin </e10> increases the binding of <e20> terfenadine </e20>, carbamazepine, and cisapride to protein.
mechanism	Protein Binding In vitro studies of (1) <e10> phenytoin </e10>, (2) <e20> doxycycline </e20>, and (3) indinavir against bovine serum albumin (BSA) suggest that these drugs have similar binding parameters to BSA.
mechanism	Because <e12> antacids </e12> may interfere with vitamin_D metabolism, it is recommended that <e20> vitamin_D </e20> be administered concomitantly with antacids.
mechanism	Allopurinol : The pharmacokinetics of <e10> allopurinol </e10> is increased by <e20> cisapride </e20>, likely because of increased absorption resulting in lower levels of allopurinol and, possibly, increased serum cisapride levels.
mechanism	Ganciclovir : Administration of <e10> Ganciclovir </e10> may prolong the half-life of <e20> ergotamine </e20>.
mechanism	A # (17)% decrease in diuretic clearance occurred with <e10> digoxin </e10> # mg q10b; this result was also observed with <e20> potassium-sparing_diuretics </e20>.
mechanism	In eight HIV-infected patients, the plasma concentrations of <e10> zalcitabine </e10> were increased by 4.1-fold (median: # micrograms/mL) after coadministration with <e20> erythromycin </e20>.
mechanism	The AUC of <e10> phenytoin </e10> was reduced by 40% and 50% in patients who were co-administered <e20> furosemide </e20> and vitamin_B-12.
mechanism	In a single case report, a patient with chronic renal insufficiency receiving <e10> digoxin </e10> therapy concurrently with a plasma <e20> isoniazid </e20> dose of 16 mg increased the serum isoniazid concentration by 15%.
mechanism	Plasma concentrations of <e10> nevirapine </e10> increased during concomitant administration of <e20> atazanavir </e20>.
mechanism	Plasma concentrations of <e10> digoxin </e10> are increased by <e20> phenytoin </e20> and decreased by the digoxin protease_inhibitor diltiazem, suggesting that digoxin is a target of the enzyme inhibitors for the treatment of diabetes.
mechanism	Plasma concentrations of <e10> levothyroxine </e10> and <e20> triamterene </e20> are enhanced when administered concurrently with a high-dose (5 g) dose of the diuretic, allopurinol, or a daily dose of C-peptide (300 micrograms per kilogram of body weight).
mechanism	Interactions with Other Drugs and Other Hazards: Concomitant administration of <e11> HUMORSOL </e11> with other central_nervous_system_depressants (eg, <e20> benzodiazepines </e20>, barbiturates, barbiturates_sodium, barbiturates_sodium_phenylbutazone, barbiturates_sodium_phenylbutazone, bumetanide, diazepam, diazepam_sodium, diazepam_sodium, ethanol, propoxyphene, quinidine, zopiclone, zopiclone_sodium, and disulfiram ) may increase the clearance of HUMORSOL.
mechanism	Interactions with Other Drugs: Concomitant administration of <e10> cyclosporine </e10> and other potent anticonvulsants ( phenytoin, <e20> carbamazepine </e20>, felbamate, phenobarbital, phenytoin_sodium, phenytoin, primidone, rifampin, spironolactone, valproate ) may increase serum concentrations of cyclosporine.
mechanism	This may occur if <e10> cimetidine </e10> is co-administered with potent inhibitors of CYP2D6 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, <e20> nefazodone </e20>, ritonavir, nelfinavir, saquinavir, telithromycin ) or with drugs that induce CYP2D6 (eg, progestins, progestin-only analogues, coumarin, valproate, terfenadine ).
mechanism	Hydrochlorothiazide : In vitro studies have demonstrated that <e10> hydrochlorothiazide </e10> can inhibit <e20> dapsone </e20> -induced apoptosis of liver and prostate epithelium in a dose-dependent manner.
mechanism	Acetaminophen : In vitro data indicate that <e10> ketoprofen </e10> inhibits the metabolism of <e20> acetaminophen </e20> by inducing a two-fold decrease in the steady-state plasma concentrations of (i) the phenolic metabolites of acetaminophen ( phenylbutazone, phenylacetylsalicylate, and salicylate ) and (ii) the oxidized products of phenylbutazone and salicylate.
mechanism	Cyclosporine : Administration of <e10> cyclosporine </e10> decreased the clearance of <e20> phenytoin </e20>, and an increase in phenytoin concentrations occurred when cyclosporine was given concurrently with the study drugs.
mechanism	Aspirin : In an in vitro study, <e10> diclofenac </e10> significantly decreased the clearance of <e20> aspirin </e20>, and the half-life was increased by approximately 40%.
mechanism	Naproxen : The elimination half-life of <e10> naproxen </e10> was increased by 6- to 8-fold when administered concomitantly with <e20> probenecid </e20> and vitamin_K.
mechanism	<e10> Quinidine </e10>, when administered concomitantly with <e20> phenytoin </e20>, produced a slightly greater effect on the blood concentration of phenytoin.
mechanism	<e10> Erythromycin </e10> may decrease the bioavailability of <e20> colestipol_sodium </e20>.
mechanism	Erythromycin and <e10> terfenadine </e10> inhibited the metabolism of <e20> ciprofloxacin </e20>.
mechanism	<e10> Propantheline </e10> increases the rate of drug metabolism by altering the metabolism of its primary metabolite <e20> levothyroxine </e20>.
mechanism	Propantheline and <e10> phenytoin </e10> may interfere with the metabolism of <e20> caffeine </e20>, leading to decreased blood levels.
mechanism	<e12> Antacids </e12>, sucralfate, and theophylline reduce the absorption of <e20> furosemide </e20>.
mechanism	Antacids, <e10> sucralfate </e10>, and allophycetin -containing preparations may interfere with the absorption of <e20> probenecid </e20>.
mechanism	<e10> Rifampin </e10> increased the AUC of <e20> cisapride </e20> by 62%.
mechanism	Macrolide_Antibiotics (e, g, ampicillin, <e10> tetracycline </e10>, bacitracin, erythromycin, clarithromycin ) and salicylates reduce <e20> verapamil </e20> clearance by approximately 50% and decrease serum levels by approximately 50%.
mechanism	In vitro, <e10> cholestyramine </e10> and erythromycin inhibit <e20> warfarin </e20> uptake and in vivo, the combination of warfarin with the CYP3A4 inhibitor, cisapride, results in an increase in clearance of warfarin.
mechanism	A study in normal volunteers demonstrated that <e10> phenytoin </e10> (10 mg) significantly reduced the AUC of <e20> phenobarbital </e20> by a mean of 30%.
mechanism	In renal and cardiac transplant patients, <e10> carbamazepine </e10> increases plasma concentrations of <e20> fluvoxamine </e20>.
mechanism	Concomitant administration of <e10> amprenavir </e10> and <e20> ritonavir </e20> is associated with a significant increase in plasma levels of the latter drug.
mechanism	Studies showed that <e10> zalcitabine </e10> inhibited the absorption of both <e20> furosemide </e20> and cyclosporine, which resulted in high blood levels of furosemide.
mechanism	Studies showed that <e10> lithium </e10> reduced the half-life of <e20> pentobarbital </e20> by 50%.
mechanism	The elimination half-life of <e10> ketoconazole </e10> was increased to 10 days when administered with <e20> cimetidine </e20>.
mechanism	The elimination half-life of <e10> levodopa </e10> was reduced by about 30% when <e20> lorazepam </e20> was coadministered with itraconazole and the mean maximum plasma levels of lorazepam were significantly lower than the levodopa values at steady state.
mechanism	Adenosine : <e10> Adenosine </e10> (40 mg/kg bw, s,c,) had a strong and sustained effect on the elimination of <e20> estradiol </e20>, with the resulting increase in estradiol levels being #% of that observed with other SSRIs.
mechanism	Antacids or H_2_receptor_antagonists such as phenytoin, tacrolimus, or <e10> phenobarbital </e10> may inhibit the absorption of <e20> CMI </e20> or, in some patients, cause a marked increase in the plasma levels of CMI.
mechanism	Digoxin : Concomitant administration of <e10> furosemide </e10> with <e20> digoxin </e20> results in an increase in digoxin concentrations from 50 to 70%.
mechanism	If <e10> phenytoin </e10> is coadministered with <e20> levothyroxine </e20>, an increase in the metabolism of levothyroxine by the thyroid gland may occur.
mechanism	If <e10> phenytoin </e10> is co-administered with <e20> ketoconazole </e20>, there is a high likelihood of significant increases in urinary ketoconazole levels and, thus, ketoconazole clearance.
mechanism	Concomitant administration of <e10> azithromycin </e10> and <e20> nelfinavir </e20> has been reported to result in decreased levels of azithromycin.
mechanism	Patients taking <e10> fluvoxamine </e10> and <e20> erythromycin </e20> concomitantly have a decreased efficacy of erythromycin.
mechanism	In vitro studies have demonstrated that <e10> gentamicin </e10> increases the absorption of <e20> ampicillin </e20>.
mechanism	In vitro studies with <e10> acetaminophen </e10> and cimetidine revealed that <e20> N-(1,3,5-trimethoxyphenyl)-amine </e20> significantly inhibits both N-acetyltransferase activity and N-acetyltransferase metabolism of acetaminophen.
mechanism	In vitro studies have shown that <e10> buprenorphine </e10> increased the clearance of <e20> fluvoxamine </e20> by approximately 3-fold, whereas the elimination of fluvoxamine was unaffected by buprenorphine.
mechanism	<e10> Cimetidine </e10>, however, did not increase <e20> cyclosporine </e20> serum concentrations.
mechanism	Co-administration of <e11> FOSCAVIR </e11> with other drugs that are known to alter plasma concentrations of <e20> ethinyl_estradiol </e20>, such as triazolam, phenobarbital, carbamazepine, alfentanil, and cisapride, has resulted in increases in the exposure of ethinyl_estradiol to #-fold and #-fold, respectively.
mechanism	<e10> Ketoconazole </e10> was reported to decrease the metabolism of <e20> ketoconazole </e20>.
mechanism	In patients receiving anticoagulants or other agents with anticoagulant activity such as warfarin, clofibrate, heparin, corticosteroids, or <e10> warfarin </e10>, the concomitant administration of <e20> ketoconazole </e20> may reduce the anticoagulant effect.
mechanism	The mean clearances of <e10> ketoconazole </e10> and <e20> atorvastatin </e20> were found to be higher with ketoconazole than with atorvastatin.
mechanism	Isoflurane, <e10> enflurane </e10>, halothane, and halothane in combination with <e20> ethinyl_estradiol </e20> (20 mg b.i.d.) decreased the exposure of ethinyl_estradiol to 15%, whereas the exposure of valdecoxib was increased by the combination.
mechanism	In a placebo-controlled study, intravenous <e10> fluvoxamine </e10> decreased the <e20> cimetidine </e20> plasma levels by 31% (95% CI, -50% to -12%), and in a randomized trial, an increase of cimetidine plasma levels by 30% (95% CI, -22% to 50%) was observed.
mechanism	Inhibitors or substrates of CYP2C9 (such as <e10> ketoconazole </e10>, itraconazole, ritonavir, nelfinavir, clarithromycin, indinavir, nefazodone, ritonavir, saquinavir, <e20> troleandomycin </e20>, telithromycin, troleandomycin, and erythromycin ) inhibit the metabolism of oral contraceptives containing ethinyl_estradiol and may increase exposure of these products to the oral cavity.
mechanism	Inhibitors or substrates of CYP3A4 (such as ketoconazole, <e10> erythromycin </e10>, itraconazole, clarithromycin, nefazodone, ritonavir, saquinavir, telithromycin, troleandomycin, nelfinavir ) may decrease the metabolism of <e20> doxorubicin </e20>.
mechanism	Cimetidine : <e10> Cimetidine </e10> was reported to inhibit the metabolism of <e20> methotrexate </e20>.
mechanism	Additionally, higher than expected levels of <e10> cyclosporine </e10> were observed when <e20> lithium </e20> was added to the diet of the sheep.
mechanism	Absorption of <e12> quinolones </e12> is enhanced by <e20> probenecid </e20>, a cationic cationic binding protein (and by a number of quinolones and other cationic_binding_agents ).
mechanism	Absorption of <e12> quinolones </e12> is impaired by fluconazole and certain other quinolones, and the concomitant administration of <e20> fluconazole </e20> may result in increases in plasma concentrations of quinolones.
mechanism	Absorption of <e10> cisapride </e10> may be enhanced by concurrent administration of <e20> chloramphenicol </e20>, an immunosuppressive drug, and theophylline, a diuretic.
mechanism	<e12> Barbiturates </e12>, quinidine, lithium salts, phenothiazines, quinine, barbiturates, and quinidine may decrease the clearance of <e20> amiodarone </e20>.
mechanism	Barbiturates, <e10> phenytoin </e10>, rifampin, quinine, theophylline, triazolam, and other anticonvulsants : Concomitant administration with <e20> zidovudine </e20> results in a significant reduction in zidovudine metabolism.
mechanism	Concurrent administration of <e10> digoxin </e10> with <e20> dexamethasone </e20> may cause a decrease in dexamethasone absorption and increase the clearance of digoxin.
mechanism	<e10> Paroxetine </e10> may also interact with antidepressant, barbiturates, anticonvulsants, antifungals, <e20> atorvastatin </e20>, clofibrate, corticosteroids, corticotropin, diazepam, diltiazem, efavirenz, enoxacin, efuran_sulfate, grapefruit juice, grapefruit juice plus vitamin_E, grapefruit juice plus vitamin_C, grapefruit juice plus vitamin_B12, grapefruit juice plus vitamin_B12 plus quinine, grapefruit juice plus vitamin_C plus vitamin_B12, grapefruit juice plus vitamin_C plus vitamin_B12, grapefruit juice plus vitamin_C plus vitamin_B12 plus quinine, grapefruit juice plus vitamin_B12 plus vitamin_C plus vitamin_C plus vitamin_B12 plus quinine, grapefruit juice plus vitamin_B12 plus vitamin
mechanism	When <e10> duloxetine </e10> was coadministered with <e20> enoxacin </e20>, the AUC and Cmax of duloxetine were increased by approximately 40% and 25%, respectively, and the elimination half-life was shortened by approximately 30%.
mechanism	Concurrent administration of <e10> methotrexate </e10> with <e20> ketoconazole </e20> resulted in a 40% increase in the cumulative exposure of methotrexate.
mechanism	Drugs which induce hepatic metabolism of <e11> Levo-Dromoran </e11> include: carbamazepine, cyclosporine, tacrolimus, disopyramide, diazepam, diltiazem, haloperidol, methadone, phenytoin, <e20> quinidine </e20>, theophylline, triazolam, theophylline_HCl, and isoniazid.
mechanism	Drugs which induce hepatic metabolism of <e11> INDOCIN </e11> include: alcohol, nonsteroidal_anti-inflammatory_drugs, <e20> cyclosporine </e20>, disulfiram, sulfasalazine, tricyclic_antidepressants, methadone, theophylline, warfarin, and nonsteroidal_anti-inflammatory_drugs.
mechanism	Drugs which induce CYP3A4 activity (eg, alprazolam, cyclosporine, carbamazepine, <e10> phenytoin </e10>, bromocriptine, clarithromycin, flecainide, lovastatin, pimozide, quinine, saquinavir, telithromycin, triazolam ) may increase the clearance of <e20> ketoconazole </e20>, resulting in a decrease in serum concentrations of ketoconazole.
mechanism	When <e10> indinavir </e10> and <e20> ritonavir </e20> were coadministered, the plasma concentrations of indinavir decreased, and the half-life of indinavir increased.
mechanism	Potential for reduction in plasma concentrations of <e10> ketoconazole </e10> and cimetidine when coadministered with <e20> alfentanil </e20>.
mechanism	<e11> SUSTIVA </e11> can reduce the clearance of <e20> diltiazem </e20> by 46%.
mechanism	<e11> SUSTIVA </e11> may decrease the effectiveness of oral contraceptives, corticosteroids, certain blood_thinner s, phenytoin, <e20> carbamazepine </e20>, valproic_acid, and aspirin.
mechanism	Caffeine : <e10> Caffeine </e10> may reduce the absorption of <e20> quinine </e20> and may reduce the activity of other quinine -containing preparations.
mechanism	In a multiple-dose study in healthy volunteers receiving a single <e10> ketoconazole </e10> dose of # mg or # mg or a single <e20> cisapride </e20> dose of # mg, cisapride AUC0-16 were increased by approximately 50% (p = #) and approximately 40% (p = #) compared to subjects not receiving cisapride.
mechanism	Cyclosporine : Elevated plasma concentrations of <e10> cyclosporine </e10> may interfere with clearance of <e20> cisapride </e20>.
mechanism	Digoxin : <e10> Doxorubicin </e10> -induced phosphorylation of P450 enzyme isoforms CYP1A2, CYP1A2, and CYP1B1 was not inhibited by <e20> digoxin </e20>.
mechanism	<e10> Enoxacin </e10>, fluconazole, and probenecid decrease <e20> furosemide </e20> absorption by the following orders: enoxacin, fluconazole, probenecid.
mechanism	Warfarin : Quinolones, such as <e10> cimetidine </e10>, should be administered with caution to patients receiving oral <e22> anticoagulants </e22>.
mechanism	<e10> Cimetidine </e10> may increase the clearance of triazolam, ketoconazole, phenobarbital, and <e20> phenytoin </e20>.
mechanism	A pharmacokinetic study of the oral <e12> contraceptive </e12> with clofibrate, a metabolite of vitamin_C, showed that the concentration of <e20> clofibrate </e20> increased by 2-fold in patients taking oral contraceptives with high clofibrate exposure.
mechanism	Administration of <e10> clozapine </e10> to patients on two different dosage regimens (containing either # mg or # mg of <e20> clozapine </e20> per day for # days and # mg or # mg of clozapine per day for # days or # days, respectively) resulted in a 16% increase in AUC and a 14% increase in Cmax and a 15% increase in AUC and Cmax of # mg of clozapine.
mechanism	Administration of <e10> ketoconazole </e10> # mg # days prior to <e20> valdecoxib </e20> # mg daily decreased the serum valdecoxib levels by 27% compared to valdecoxib alone.
mechanism	Administration of <e10> ketoconazole </e10> to patients with chronic renal insufficiency has been shown to reduce plasma concentrations of <e20> nelfinavir </e20> and ethinyl_estradiol by approximately 50% and approximately 30%, respectively.
mechanism	In clinical trials, co-administration of <e11> VIDEX </e11> was associated with a reduced duration of response (5.8%) compared to placebo (23%) in patients treated with a dose of <e20> cisapride </e20> # mg, # mg/day for # days.
mechanism	In clinical trials, <e10> diltiazem </e10> caused a 25% increase in <e20> warfarin </e20> clearance and a 22% increase in warfarin blood levels.
mechanism	The effects of <e10> cyclosporine </e10> and <e20> cisapride </e20> on the activity of digoxin, insulin, and furosemide are reversed by coadministration with high doses of these drugs.
mechanism	Co-treatment with the protease inhibitor <e10> clofibrate </e10> (5 mg q24h) decreased the plasma level of <e20> rifabutin </e20> by 40%.
mechanism	Pre-treatment with the <e12> quinolones </e12> sainurin, macrolide_antibiotics such as erythromycin, or salicylates or corticosteroids may diminish the bactericidal effect of <e20> ciprofloxacin </e20>.
mechanism	When ertapenem is coadministered with <e10> metronidazole </e10>, an increase in plasma concentrations of <e20> ertapenem </e20> is observed.
mechanism	Based on total-body clearance data, the metabolism of <e10> levodopa </e10> is altered by <e20> propafenone </e20>.
mechanism	Concomitant administration of <e11> CELEBREX </e11> and <e20> diazepam </e20> resulted in a decrease in mean #% AUC and a decrease in mean #% Cmax of CELEBREX compared to concurrent administration of CELEBREX and diazepam.
mechanism	<e10> Erythromycin </e10> may increase plasma concentrations of oral <e20> ciprofloxacin </e20> by inhibiting the hepatic metabolism of ciprofloxacin.
mechanism	<e10> Erythromycin </e10> may increase the absorption of some <e22> macrolide_antibiotics </e22>.
mechanism	There have been reports of concomitant administration of <e10> quinidine </e10> and <e20> gentamicin </e20> in dogs.
mechanism	Although trough citalopram levels are not affected by <e10> terfenadine </e10>, discontinuation of <e20> terfenadine </e20> may result in lower citalopram levels than if the drug was not discontinued.
mechanism	Metoprolol-Administration of <e10> metoprolol </e10> may reduce the plasma concentration of <e20> zalcitabine </e20>.
mechanism	<e11> BREVIBLOC </e11> (3 microM) inhibited the hepatic metabolism of oral <e20> ethinyl_estradiol </e20>.
mechanism	When <e10> digoxin </e10> is added to the diet of rats, the rate of digoxin absorption is decreased, the extent of renal excretion is increased, and <e20> digoxin </e20> concentrations are increased.
mechanism	Coadministration of <e10> dapsone </e10> with <e20> diflunisal </e20> caused a rapid decrease in diflunisal exposure.
mechanism	Therefore, <e10> esomeprazole </e10> may decrease the clearance of corticosteroids and/or <e20> warfarin </e20>.
mechanism	Therefore, <e10> esomeprazole </e10> has been reported to increase plasma concentrations of <e20> cisapride </e20> and dipyridamole by several times.
mechanism	While no in vitro studies have shown an interaction of <e10> gentamicin </e10> and <e20> lithium </e20>, it is possible that the metabolism of lithium may be impaired by the addition of gentamicin to lithium therapy.
mechanism	While no in vitro studies have shown a decrease in the bioavailability of <e11> PRINIVIL </e11> following coadministration of <e20> cyclosporine </e20>, the possibility of a potential pharmacokinetic interaction of increased exposures of PRINIVIL with cyclosporine or other antipsychotic_agents (eg, risperidone, thiothixene, and risperidone-like_agents ) is possible.
mechanism	Drugs That Induce Hepatic Cytochrome P450 3A4 Expression: Drugs that induce hepatic cytochrome P450 3A4 expression (eg, <e10> phenytoin </e10>, carbamazepine, phenobarbital, cimetidine, theophylline, diazepam, barbiturates, benzodiazepines, barbiturates, clozapine, diltiazem, disulfiram, eszopiclone, fluoxetine, fluvoxamine, furosemide, <e20> grapefruit juice </e20>, itraconazole, itraconazole hydrochloride, ketoconazole, loratadine, methadone, methotrexate, nifedipine, phenytoin, quinine, rifabutin, rifabutin sulfate, St, Johns wort, sucral
mechanism	<e10> Lithium </e10> in combination with <e20> carbamazepine </e20> or warfarin resulted in an increase in the renal clearance of lithium, while increasing plasma levels of lithium were associated with decreased renal clearance.
mechanism	The results of in vitro studies of <e10> ketoconazole </e10> indicate that <e20> clindamycin </e20> may inhibit the metabolism of ketoconazole by increasing the formation of its active metabolite, which is a potent inducer of drug clearance.
mechanism	<e11> Trecator </e11>, like other antidepressants, reduces the clearance of <e20> citalopram </e20>.
mechanism	<e10> Ethopropazine </e10> increases <e20> lofexidine </e20> metabolism and prolongs the half-life of lofexidine by 20%.
mechanism	Presumably, <e10> phenytoin </e10> and possibly other <e22> MAO_inhibitors </e22>, potentiate the antihypertensive effect of concomitant nifedipine, atorvastatin, or other oral antihypertensive_drugs.
mechanism	Presumably, <e10> phenytoin </e10> may also decrease the metabolism of <e20> furosemide </e20> and therefore, its effectiveness.
mechanism	<e10> Acetaminophen </e10>, morphine, and <e20> phenobarbital </e20> can inhibit the metabolism of norethindrone, resulting in higher plasma levels.
mechanism	<e10> Aminoglutethimide </e10>, an inhibitor of hepatic metabolism, significantly decreased the elimination of <e20> digoxin </e20> and the clearance of carbamazepine.
mechanism	Anticonvulsants ( <e10> phenytoin </e10>, carbamazepine, phenobarbital, triazolam ): Concomitant administration with <e20> ethchlorvynol </e20> (EtVYN ) increases the hepatic metabolism of Eth and increases plasma concentrations of Eth.
mechanism	Anticonvulsants ( <e10> phenobarbital </e10>, phenytoin, carbamazepine ): Co-administration with <e20> nevirapine </e20> is associated with a significant reduction in nevirapine exposure.
mechanism	Atorvastatin : <e10> Atorvastatin </e10> has been shown to decrease the absorption of <e20> efavirenz </e20> and its metabolites, thereby potentially increasing the systemic exposure of efavirenz and its active metabolite.
mechanism	Griseofulvin : <e10> Griseofulvin </e10> inhibits the absorption of <e20> quinidine </e20>, thus lowering the systemic exposure of quinidine.
mechanism	Prednisolone : <e10> Erythromycin </e10> significantly increased the <e20> phenytoin </e20> AUC by 23% (p = 0.009).
mechanism	Protease_inhibitors : Amprenavir, <e10> ritonavir </e10>, indinavir, saquinavir, indinavir, troleandomycin, and clarithromycin may reduce plasma levels of <e20> troleandomycin </e20>.
mechanism	<e10> Indinavir </e10>, ritonavir, and indinavir have additive or potentiating effects with <e20> ketoconazole </e20> in inhibiting the metabolism of ketoconazole.
mechanism	Rifampin : <e10> Rifampin </e10> increased the serum concentration of <e20> clofibrate </e20> and decreased the plasma levels of cilostazol.
mechanism	Rifampin : <e10> Rifampin </e10> is a methylprednisolone_antagonist that increases the metabolism of <e20> rifampin </e20> and may increase its pharmacokinetic profile.
mechanism	Selegiline : <e12> Amphetamines </e12> may interfere with the absorption of <e20> selegiline </e20>.
mechanism	Theophylline : <e10> Theophylline </e10> inhibits the metabolism of <e20> ketoconazole </e20>.
mechanism	Tricyclic_antidepressants ( <e10> amitriptyline </e10>, fluoxetine, sertraline ): The clearance of <e20> clonidine </e20> is increased when it is administered with antidepressants such as fluoxetine or sertraline.
mechanism	Tricyclic_antidepressants ( amitriptyline, imipramine, <e10> fluoxetine </e10>, sertraline ) have been reported to decrease plasma concentrations of <e20> buprenorphine </e20>.
mechanism	Tricyclic_antidepressants ( amitriptyline, <e10> nortriptyline </e10>, imipramine ) and carbamazepine, as well as some <e22> barbiturates </e22>, produce concomitant increases in the plasma levels of digoxin and digoxin-d,l-methyldopa.
mechanism	Aspirin : When coadministered with <e10> atorvastatin </e10> (100 mg), the <e20> fluvastatin </e20> AUC increased from 20.4 to 28.4%, whereas the Cmax increased from 44 to 83%.
mechanism	Cyclosporine, Digoxin, Methotrexate and <e10> Phenytoin </e10> may interact with <e20> Nabilone </e20> ;
mechanism	Phenylbutazone : <e10> Phenylbutazone </e10> has been reported to inhibit the metabolism of <e20> carbamazepine </e20> by interfering with CYP3A4, resulting in decreased plasma levels of carbamazepine.
mechanism	Short-term pharmacokinetic studies in healthy subjects revealed a 20% reduction in Cmax and a 40% decrease in AUC with <e10> ketoconazole </e10> and <e20> ketoconazole </e20> coadministration.
mechanism	Co-medications that induce hepatic enzymes such as <e10> isoniazid </e10>, carbamazepine, or cyclosporine may increase the clearance of <e20> levodopa </e20>.
mechanism	Co-medications that induce hepatic enzymes such as <e10> cyclosporine </e10> or tacrolimus have the potential to increase the clearance of <e20> cefditoren_mesylate </e20>.
mechanism	Concurrent use with oral <e10> nifedipine </e10> increased the niacin plasma levels by approximately 40% in subjects with <e20> efavirenz </e20> plasma concentrations below # mg/L.
mechanism	Increasing the <e10> acetaminophen </e10> dose increases the clearance of <e20> cimetidine </e20>, resulting in an increase in plasma levels and concomitant increase in half-life.
mechanism	The <e10> carbamazepine </e10> interaction has been demonstrated with data from a clinical study in which patients on long-term <e20> carbamazepine </e20> therapy were concomitantly receiving either of two oral anticonvulsants ( carbamazepine and phenytoin ) and were monitored for an average of 5 years.
mechanism	Increasing the <e10> levothyroxine </e10> dose to # mg/day increased the serum <e20> thyroid_stimulating_hormone </e20> level by 50% and resulted in a 20% increase in the levothyroxine -stimulated serum T3 level in healthy volunteers.
mechanism	Phenobarbital : Coadministration of <e11> SUSTIVA </e11> # mg and <e20> phenobarbital </e20> # mg decreased mean fluency scores by 46%.
mechanism	Effects of Other Drugs with Anticholinergic Activities <e10> Phenobarbital </e10> has been reported to decrease the pharmacologic effects of other <e22> anticholinergic_agents </e22>.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> increases the plasma concentrations of <e20> valdecoxib </e20>.
mechanism	Carbamazepine : Carbamazepine increases <e10> norethindrone </e10> plasma concentrations by concomitant administration of <e20> carbamazepine </e20> and the methylxanthines retinyl_acetate and retinyl_gamma_conjugate.
mechanism	Phenobarbital : It has been reported that <e10> phenobarbital </e10> may inhibit the metabolism of <e20> cefazolin </e20>.
mechanism	<e10> Felbamate </e10> significantly inhibits <e20> diazepam </e20> elimination (P = 0.00005) in a dose-dependent manner.
mechanism	Anticonvulsants : In clinical studies of <e10> warfarin </e10> co-administration with <e20> diazepam </e20> and aripiprazole, a rise in plasma concentrations of warfarin has been observed.
mechanism	Anticonvulsants : In patients taking <e10> ketoconazole </e10> and who have been treated with either <e20> cisapride </e20> or phenytoin, increased serum levels of cisapride may occur.
mechanism	Anticonvulsants : In patients receiving concomitant <e10> carbamazepine </e10> and <e20> cyclosporine </e20>, there has been one reported case of a patient with elevated carbamazepine levels resulting in a decrease in carbamazepine effectiveness.
mechanism	Concomitant administration of <e10> rifampin </e10> with <e20> aripiprazole </e20> increases AUC of rifampin by 34%.
mechanism	Concomitant administration of <e10> cholestyramine </e10> and <e20> anastrozole </e20> was associated with a greater increase in plasma concentrations of cholestyramine.
mechanism	Concomitant administration of <e10> digoxin </e10> with <e20> sodium_thiosulfate </e20> may increase serum digoxin levels.
mechanism	Concomitant administration of <e10> fluvoxamine </e10> and <e20> diltiazem </e20> resulted in a mean increase in AUC of ~14% for both drugs, whereas cimetidine resulted in a 20% decrease in AUC of diltiazem.
mechanism	The coadministration of <e11> aspirin </e11> with carbamazepine, <e20> lithium </e20>, carbamazepine with calcium supplements, or lithium with carbamazepine has not been studied, but it is likely that these agents interfere with the absorption of carbamazepine.
mechanism	Chronic administration of <e10> chloramphenicol </e10> reduced the antimicrobial activity of <e20> sulfadiazine </e20> by 38%.
mechanism	The concomitant use of <e10> ketoconazole </e10> and <e20> rifampin </e20> may decrease the clearance of rifampin, resulting in an increase in rifampin concentrations and decreased rifampin efficacy.
mechanism	The concomitant use of <e11> TORADOL </e11> (e,g,, diltiazem ) and <e20> zidovudine </e20> (e,g,, zidovudine ) may increase the pharmacokinetics of zidovudine and should be avoided because of possible synergistic elevations of zidovudine in plasma and/or serum.
mechanism	The concomitant use of <e10> ketoconazole </e10> with <e20> nalidixic_acid </e20> has resulted in a significant reduction of nalidixic_acid absorption and serum ketoconazole concentrations.
mechanism	However, co administration of <e10> loratadine </e10> and <e20> rifampin </e20> (a substrate of CYP3A4) was found to have a modest effect on the hepatic metabolism of loratadine and its concomitant CYP3A4 substrates, therefore potentially reducing the plasma concentrations of loratadine and its metabolite (5-fluorouracil ) and increasing the exposure of other antacids containing a single 5-fluorouracil carbamazepine moiety.
mechanism	However, co administration of <e10> ketoconazole </e10> to <e20> celecoxib </e20> decreased the renal clearance of celecoxib by about 50% (about #% increase in AUC).
mechanism	These studies indicate that <e10> cimetidine </e10> may have a significant effect on the metabolism of <e20> vitamin_D </e20>.
mechanism	This observed increase in clearance of <e10> rifampin </e10> and <e20> isoniazid </e20> was likely due to the inhibition of the CYP2C9 metabolism.
mechanism	Drug Interactions with Methotrexate : <e10> Methotrexate </e10> may interact with certain drugs, such as phenytoin, carbamazepine, clofibrate, disopyramide, triazolam, <e20> indomethacin </e20>, cyclosporine, fluconazole, itraconazole, nelfinavir, rifampin, saquinavir, telithromycin, troleandomycin, troleandomycin plus clarithromycin, and zidovudine.
mechanism	Drug Interactions with D,H,E,_45: A single oral dose of <e11> VIDEX </e11> # mg in healthy volunteers produced a mean decrease of 38% in plasma <e20> fluvoxamine </e20> levels, which was most pronounced at # mg (P = #).
mechanism	During administration of <e10> astemizole </e10>, <e20> ketoconazole </e20> and cimetidine plasma concentrations are decreased by approx. 50%, and a reduction of approx. 30% in the AUC of cimetidine is observed, compared to the plasma concentrations at # mg/kg.
mechanism	In a study of subjects with moderate to severe migraine, the daily dosage of <e10> cimetidine </e10> was reduced by approximately 50% when <e20> nefazodone </e20> was used as a prodrug.
mechanism	Limited data in rats indicate that <e10> nevirapine </e10> at # mg/day decreased the clearance of <e20> probenecid </e20> and increased the clearance of ketoconazole.
mechanism	Limited data in humans suggest that concomitant use of <e10> nelfinavir </e10> with <e20> ritonavir </e20>, a commonly used HIV protease inhibitor, may increase the risk of severe diarrhea or the likelihood of vomiting.
mechanism	In healthy subjects, <e10> nelfinavir </e10> coadministration with a single dose of <e20> valdecoxib </e20> # mg resulted in a 50% decrease in plasma valdecoxib exposure (4-fold).
mechanism	When <e10> amiodarone </e10> was added to the daily regimen of two women who were receiving <e20> carbamazepine </e20>, the two combined-dose oral plasma concentrations of amiodarone were significantly higher than when carbamazepine was administered alone.
mechanism	<e12> Barbiturates </e12>, sulfonamides, and corticosteroids may interfere with the metabolism of <e20> cetirizine </e20>, resulting in elevated plasma levels.
mechanism	Barbiturates, <e10> phenytoin </e10>, amiodarone, carbamazepine, carbamazepine sulfate, doxorubicin, famotidine, felbatol, ibuprofen, erythromycin, <e20> terfenadine </e20>, telithromycin, and voriconazole may increase plasma concentrations of cimetidine.
mechanism	Cimetidine, Ranitidine : <e10> Cimetidine </e10> may increase the clearance of <e20> valdecoxib </e20>.
mechanism	<e10> Terfenadine </e10>, rifampin, tacrolimus, and disopyramide decrease the clearance of <e20> warfarin </e20>.
mechanism	Terfenadine, <e10> erythromycin </e10>, and indinavir inhibit <e20> terfenadine </e20> metabolism by inhibiting cytochrome P450 3A4 activity.
mechanism	Terfenadine, astemizole, <e10> terfenadine </e10>, fluvoxamine, and <e20> fluvoxamine </e20> may reduce the clearance of the agent and may increase the toxicity of the agent.
mechanism	Other Potentially Important Pharmacokinetic Interactions of Carbamazepine : Carbamazepine has been shown to enhance the absorption of <e11> Bezalip </e11>, <e20> triazolam </e20>, and primidone, resulting in increases in Cmax, AUC, and AUMC.
mechanism	Alprazolam : When given in combination with <e10> alprazolam </e10>, <e20> ketamine </e20> may induce severe hypoglycemia.
mechanism	Because <e10> fluvoxamine </e10> significantly increased the clearance of <e20> cisapride </e20>, the increase in plasma cisapride concentrations may have resulted in an increased plasma level of theophylline.
mechanism	Because <e10> fluvoxamine </e10> decreases dopamine release and serotonin release, it may have clinical effects on <e20> cimetidine </e20>, dopamine, and serotonin levels.
mechanism	Warfarin : When administered concurrently with <e11> BREVIBLOC </e11>, warfarin : results in increased clearance of <e20> phenytoin </e20> and may lead to severe hypophosphorylation.
mechanism	Oral doses of <e10> enoxacin </e10> # mg BID and # mg CID significantly increased the Cmax and AUC of <e20> diltiazem </e20>.
mechanism	Similarly, <e10> ethanol </e10>, the active component of <e20> ketoprofen </e20>, causes an increase in both the mean and maximum volume of distribution of cefdinir in patients.
mechanism	Reciprocal interactions may occur between <e10> gentamicin </e10> and <e20> quinidine </e20> ;
mechanism	Reciprocal interactions may occur when <e10> levothyroxine </e10> is given concomitantly with <e20> warfarin </e20>.
mechanism	In an in vitro study, <e10> cefdinir </e10> at # to # micrograms/mL was found to inhibit <e20> cefdinir </e20> at # micrograms/mL to a maximum of 3% (compared to C. # to # micrograms/mL).
mechanism	Metoclopramide : When <e10> ketoconazole </e10> and <e20> metoclopramide </e20> were given concomitantly, there was a slight increase in plasma ketoconazole levels.
mechanism	Antacids : In a study of oral antacids containing various magnesium, calcium, and aluminum contents, <e10> magnesium </e10> (0.058 mg/mL) increased the <e20> furosemide </e20> effective dose by 17%.
mechanism	Antacids : In vitro, <e10> colestipol </e10> caused a concentration-dependent inhibition of <e20> colestipol_hydrochloride </e20> (corticotropin, 50 micrograms/mL) absorption, while it did not affect the absorption of either dexamethasone (1 micrograms/mL) or 5-fluorouracil (100 micrograms/mL).
mechanism	- Drugs that induce hepatic metabolism of <e10> celecoxib </e10> may result in decreased plasma concentrations of <e20> valdecoxib </e20>.
mechanism	- Drugs that induce hepatic enzymes such as <e10> indomethacin </e10>, phenytoin, amiodarone, phenobarbital, carbamazepine, and phenytoin may increase <e20> phenytoin </e20> plasma levels and decrease the efficacy of phenytoin.
mechanism	- Drugs that induce hepatic enzymes such as <e10> phenytoin </e10>, carbamazepine, and phenobarbital may reduce the clearance of <e20> diltiazem </e20>.
mechanism	- Drugs that induce CYP3A4 activity (eg, <e10> carbamazepine </e10>, phenobarbital, phenytoin, alfentanil, phenytoin_hydrochloride, and rifampin ) increase the plasma concentration of <e20> propafenone </e20>.
mechanism	- Drugs that reduce hepatic enzyme activity by inhibiting metabolism of drugs (eg, <e10> phenytoin </e10>, phenobarbital, carbamazepine, diazepam, alfentanil, disopyramide, <e20> phenytoin_succinate </e20>, phenobarbital-sulfate, phenytoin sulfate ) may decrease plasma levels of alfentanil, resulting in lower alfentanil serum levels.
mechanism	Naproxen : Coadministration of <e11> SUSTIVA </e11> and <e20> naproxen </e20> has been shown to result in elevated plasma concentrations of naproxen, as well as a reduced elimination half-life.
mechanism	<e10> Hydrocodone </e10> : Coadministration of <e20> hydrocodone </e20> with oral contraceptives, carbamazepine, methotrexate, certain azoles and tricyclic_antidepressants decreased the AUC of hydrocodone by 43%.
mechanism	Cimetidine : In patients receiving <e10> cimetidine </e10> concurrently with <e20> carbamazepine </e20>, the following variables were reduced: (1) the AUC of carbamazepine, the primary metabolite of cimetidine, was reduced by approximately #% (47% decrease).
mechanism	Thus <e10> cimetidine </e10> may have a potential for pharmacokinetic interactions with <e20> cyclosporine </e20>, especially during the initial period of cyclosporine administration.
mechanism	This small decrease in maximum Cmax of <e10> norethindrone </e10> suggests that coadministration of <e20> ketoconazole </e20> may have increased the risk of gastrointestinal absorption of norethindrone.
mechanism	Antacid ( Maalox ) use has been reported to increase the serum concentrations of <e10> amiodarone </e10> and the elimination half-life of <e20> cyclosporine </e20>.
mechanism	Substances that are potent inhibitors of CYP2C9 (e,g,, ketoconazole, itraconazole, ritonavir, erythromycin, clarithromycin, <e10> erythromycin </e10>, indinavir, nelfinavir ) may increase the clearance of <e20> cyclosporine </e20>.
mechanism	Substances that are CYP3A4 inhibitors (eg, ketoconazole, itraconazole, ritonavir, erythromycin, clarithromycin, <e10> indinavir </e10>, saquinavir, indinavir, indinavir, saquinavir, telithromycin ) are expected to decrease <e20> saquinavir </e20> concentrations.
mechanism	Drugs that cause a rise in serum creatinine (eg, <e10> phenytoin </e10>, doxycycline, amiodarone, phenytoin sulfate ) may decrease the renal clearance of <e20> cefazolin </e20>.
mechanism	Drugs that cause metabolism of <e10> quinine </e10> by CYP3A4 are inhibitors of hepatic CYP3A4 and therefore not likely to have a significant effect on <e20> quinine </e20> plasma concentrations.
mechanism	Concomitant administration of <e10> quinidine </e10> and <e20> cimetidine </e20> produced a 2-fold increase in cimetidine AUC.
mechanism	Concomitant administration of <e10> ketoconazole </e10> with <e20> digoxin </e20>, phenytoin, carbamazepine, diazepam, or cyclosporine may increase the plasma concentrations of these drugs and may potentially increase the clearance of digoxin and phenytoin.
mechanism	Concomitant administration of <e10> digoxin </e10> with <e20> ketoconazole </e20> results in increased concentrations of digoxin in the urine and increased serum levels of digoxin.
mechanism	Concomitant administration of <e10> diltiazem </e10> (20 mg BID) and <e20> digoxin </e20> (20 mg BID) resulted in a 13% decrease in blood concentration of digoxin.
mechanism	The absorption of <e10> phenytoin </e10> is enhanced by co-administration of <e20> cyclosporine </e20> and/or azithromycin.
mechanism	The absorption of <e10> probenecid </e10> is impaired by <e20> indomethacin </e20>, fluvastatin, and aripiprazole.
mechanism	The mean percentage change in the plasma prothrombin time (PT) in the placebo group (12.5%) was significantly higher than in the <e10> rifampin </e10> group (4%), and this increase was significantly greater in the <e20> rifampin </e20> group (17%) than in the placebo group (1%).
mechanism	Concomitant administration of <e11> PRINIVIL </e11> with <e20> diazepam </e20> (90 mg) caused a 3-fold increase in diazepam clearance.
mechanism	Caffeine Theobromine <e10> Caffeine </e10> may inhibit the metabolism of <e20> isoniazid </e20>.
mechanism	Caffeine Theobromine Grepafloxacin, with or without <e10> carbamazepine </e10>, and thus likely to be ingested concurrently with <e20> caffeine </e20>, increased caffeine plasma levels by approximately 17%.
mechanism	Serum theophylline concentrations may be elevated by <e10> furosemide </e10> administration and by the concomitant use of <e20> warfarin </e20> or warfarin_sodium.
mechanism	Drugs Metabolized by CYP3A4 (Bupropion, fluoxetine, <e10> quinidine </e10>, paroxetine, sertraline ): Quinidine exposure was reduced by 58% (AUC) when <e20> quinidine </e20> was coadministered.
mechanism	In addition, other drugs that are potent inhibitors of CYP3A4 activity (eg, fluconazole, ketoconazole, <e10> itraconazole </e10>, rifampin, nefazodone, troleandomycin, clarithromycin, clarithromycin, erythromycin, terfenadine, bromocriptine, bromocriptine, valdecoxib ) have been reported to decrease the extent of <e20> indinavir </e20> plasma exposure.
mechanism	The administration of <e10> lithium </e10> with <e20> guanethidine </e20> tablets may cause a rise in serum lithium levels.
mechanism	In a study in diabetic subjects, co-administration of <e10> enalapril </e10> and <e20> indinavir </e20> for # weeks increased the mean (+/-sd) enalapril and indinavir levels by 15% and 8%, respectively, and resulted in a 20% increase in the plasma levels of enalapril.
mechanism	In # other studies, <e10> ketoconazole </e10> has been shown to decrease the metabolism of <e20> fluvoxamine </e20> in the liver.
mechanism	<e10> Propranolol </e10> has been shown to increase the clearance of <e20> pentamidine </e20> by about 50%.
mechanism	Cholestyramine and colestipol : <e10> Cholestyramine </e10> and colestipol, like other <e22> nonsteroidal_anti-inflammatory_drugs </e22>, may decrease the hepatic metabolism of some drugs (such as warfarin ) and increase the metabolism of others (such as bromocriptine ).
mechanism	Single doses of <e10> valdecoxib </e10> # mg and <e20> isoniazid </e20> # mg decreased the clearance of valdecoxib by #% and 20%, respectively.
mechanism	<e12> Antacids </e12> or other digestive products may reduce the absorption of <e20> ketoconazole </e20>, a cationic metallo-beta-lactamase inhibitor.
mechanism	Products containing <e10> diazepam </e10>, barbiturates, barbiturates and certain other <e22> anticonvulsants </e22>, cholestyramine, lithium, magnesium salts, triazolam, and certain other antidepressants may increase the clearance of barbiturates, barbiturates and lithium, magnesium salts, triazolam, and certain other antidepressants.
mechanism	Products containing calcium or aluminum are known to inhibit <e10> diltiazem </e10> absorption and, thus, will decrease plasma levels of <e20> diltiazem </e20>.
mechanism	Products containing calcium and <e10> iron </e10> may inhibit the absorption of <e20> phenytoin </e20>.
mechanism	Products containing calcium, <e10> magnesium </e10>, or iron are reported to inhibit <e20> erythromycin </e20> activity.
mechanism	Methotrexate : <e10> Ethopropazine </e10> may reduce the clearance of <e20> methotrexate </e20>.
mechanism	Drugs that may increase plasma concentrations of <e10> diltiazem </e10> include certain antibiotics (e, g,, ampicillin, tetracycline, <e20> bacitracin </e20>, clindamycin, colistin, clindamycin, chloramphenicol, cisapride, dapsone, dipyridamole, diflunisal, flecainide, miconazole, nelfinavir, ritonavir, saquinavir, troleandomycin, telithromycin, tobramycin, theophylline, and zidovudine ) and monoamine_oxidase_inhibitors, as well as some tricyclic_antidepressants and certain quinidine_derivatives.
mechanism	<e11> Gleevec </e11> may inhibit the absorption of <e20> digoxin </e20>, diazepam, phenobarbital, paroxetine, and some other antidepressants.
mechanism	<e11> Gleevec </e11> and <e20> carbamazepine </e20> may interact with cyclosporine, tacrolimus, digoxin, lithium, methylprednisolone, nifedipine, phenobarbital, phenytoin, quinidine, theophylline, or warfarin.
mechanism	Systemic exposure to <e10> probenecid </e10> may be reduced by concurrent administration of <e20> carbamazepine </e20>.
mechanism	The plasma concentration of <e10> diazepam </e10> decreased by approximately 20% when coadministered with <e20> ketoconazole </e20> and by approximately 50% when coadministered with Cd-DTPA.
mechanism	The plasma concentration of <e10> diltiazem </e10> is increased by the following: # mg/day of <e20> indinavir </e20> and # mg/day of ritonavir.
mechanism	The plasma concentration of <e10> isoniazid </e10> is reduced by approximately 40% in patients receiving <e20> valdecoxib </e20>.
mechanism	<e10> Indinavir </e10> reduced the steady-state plasma concentrations of dideoxynal by approximately 50% and significantly increased the plasma concentrations of <e20> dideoxynal </e20>.
mechanism	In normal volunteers, coadministration of <e10> fluvoxamine </e10> with <e20> aprepitant </e20> decreased plasma levels of fluvoxamine.
mechanism	When <e11> INDOCIN </e11> was coadministered with <e20> tetracycline </e20>, a significant increase in the Cmax and AUC of INDOCIN was observed.
mechanism	<e11> INDOCIN </e11> may increase the plasma concentrations of <e20> dopamine </e20>, therefore, dopamine may increase the response to the dopamine agonist, phenytoin, when administered concomitantly.
mechanism	Capsules <e11> INDOCIN </e11> may increase the bioavailability of <e20> bromocriptine_mesylate </e20> and other potent CYP3A4 inhibitors such as, but not limited to, isoniazid, phenytoin, carbamazepine, cimetidine, cyclosporine, tacrolimus, disopyramide, ketoconazole, phenytoin, alfentanyl, cisapride, disulfiram, ergot_derivatives, ketoconazole, lovastatin, rifampin, saquinavir, theophylline, temazepam, and theophylline_citrate.
mechanism	<e11> INDOCIN </e11>-a <e22> TNF-blocking_agent </e22>, has been reported to reduce plasma levels of indocyanine_green, which is a TNF-blocking_agent.
mechanism	<e11> Betaseron </e11> can enhance the pharmacokinetics of <e20> succinylcholine </e20> by increasing the volume of distribution of succinylcholine.
mechanism	Furthermore it has been reported that <e10> astemizole </e10> causes an increase in serum <e20> cyclosporine </e20> concentrations.
mechanism	Carbamazepine : <e10> Carbamazepine </e10> increases the clearance of <e20> dofetilide </e20>.
mechanism	Valproate : A 5-mg oral dose of <e10> valproate </e10> significantly increased the AUC and Cmax of <e20> erythromycin </e20> by 29% and 21%, respectively.
mechanism	Cimetidine : In a dose-dependent study in healthy volunteers, # mg of <e10> cimetidine </e10> daily for # days increased the <e20> lamivudine </e20> AUC from # to #.5 times and the AUC from # to # times, respectively.
mechanism	Rifampicin : In vitro data indicate that <e10> rifampicin </e10> may increase the <e20> zalcitabine </e20> exposure in healthy volunteers when administered concurrently with zalcitabine.
mechanism	If <e10> rifampicin </e10> is administered concomitantly with <e20> loratadine </e20>, serum concentrations of loratadine may be reduced.
mechanism	Coadministration of <e10> erythromycin </e10> with <e20> terfenadine </e20> resulted in a significant decrease in plasma concentrations of terfenadine.
mechanism	Another oral azole_antifungal, ketoconazole, increases the systemic exposure of <e11> COREG </e11> by <e20> furosemide </e20>.
mechanism	Human pharmacokinetics data suggest that a single <e10> nelfinavir </e10> dose of # mg would not be effective for <e20> valdecoxib </e20>.
mechanism	In vitro data suggest that <e10> carbamazepine </e10> may decrease the metabolism of <e20> methotrexate </e20>.
mechanism	Coadministration of <e10> valdecoxib </e10> with other known CYP3A4 inhibitors, including <e20> ketoconazole </e20>, itraconazole, nefazodone, troleandomycin, clarithromycin, and ritonavir, did not increase plasma concentrations of valdecoxib.
mechanism	When <e10> Itraconazole </e10> is administered concomitantly with <e20> cyclosporine </e20>, the maximum rate of Itraconazole elimination will be approximately doubled compared to when Itraconazole is given concomitantly with cyclosporine.
mechanism	When <e10> Itraconazole </e10> is added to <e20> phenytoin </e20> therapy, the patient may require an increase in phenytoin dosage to achieve and maintain the target serum phenytoin concentration.
mechanism	Plasma concentrations of <e10> fluvoxamine </e10> are increased when <e20> diazepam </e20> is used concomitantly.
mechanism	The following drug interactions have been identified in studies in subjects taking <e10> ketoconazole </e10> concomitantly with <e20> cimetidine </e20> : Acetazolamide : There have been reports of significant increases in the AUC of the cimetidine metabolite on concomitant administration of ketoconazole and cimetidine with carbamazepine, diazepam, fluoxetine, fluvoxamine, paroxetine, and quinidine.
mechanism	<e10> Ketoconazole </e10> (10 mg/day for # days) has a greater effect than <e20> cimetidine </e20> (25 mg/day for # days).
mechanism	<e10> Ketoconazole </e10> in doses of # mg/kg twice daily (50% reduction in blood concentrations) decreased the AUC of <e20> digoxin </e20> by 69% and the Cmax by 42% on # mg/kg twice daily and reduced the AUC of digoxin by 41% on # mg/kg once daily.
mechanism	<e10> Ketoconazole </e10> markedly inhibited <e20> atorvastatin </e20> metabolism, resulting in a 3- to 5-fold increase in AUC and Cmax.
mechanism	Coadministration of <e11> FOSCAVIR </e11> # mg daily with <e20> ketoconazole </e20> # mg daily decreased the peak plasma concentration of FOSCAVIR by approximately 50%.
mechanism	Coadministration of <e11> INSPRA </e11> # hours after <e20> fluvoxamine </e20> # hours produced a mean increase in fluvoxamine plasma concentration of 4% compared to a decrease of 5% in the same dose given alone.
mechanism	Concomitant administration of <e11> COREG </e11> with potent serotonergic_agents (e,g,, <e20> clozapine </e20>, amiodarone, fluoxetine, sertraline, venlafaxine, paroxetine, sertraline, trazodone ) may result in an increase in catecholamine levels and may result in an increase in respiratory depression.
mechanism	Concomitant administration of <e11> INOmax </e11> with a protease_inhibitor, macrolide_antibiotics, or other agents with high aminoglycoside binding such as clarithromycin, <e20> erythromycin </e20>, indomethacin, rifabutin, or carbamazepine may increase INOmax serum levels and therefore inhibit its efficacy.
mechanism	INH ( <e10> estradiol </e10> ) binding to the INH receptor is inhibited by <e20> alfentanil </e20>.
mechanism	After the coadministration of <e10> isoniazid </e10>, <e20> bromocriptine_mesylate </e20> and valproate, the peak plasma concentrations of valproate were significantly decreased by 20% and 18%, respectively.
mechanism	however, in a single study, <e10> piperazine </e10> was reported to decrease the <e20> lorazepam </e20> clearance by about #%.
mechanism	however, in a single-dose study, <e10> ketoconazole </e10> was found to reduce the plasma concentrations of <e20> disulfiram </e20> by approximately 40% and the rate of disulfiram metabolism by approximately 40%.
mechanism	Probenecid : <e10> Probenecid </e10> significantly decreased the in vitro anticoagulation effect of warfarin and its derivatives (e,g,, <e20> phenytoin </e20>, rifampin, and valproate ).
mechanism	Methotrexate : <e10> Chlorotrianisene </e10> can inhibit the metabolism of <e20> methotrexate </e20>.
mechanism	Methotrexate : Ketoprofen, <e10> fluvoxamine </e10>, indomethacin, and sodium_valproate may decrease the bioavailability of <e20> methotrexate </e20>.
mechanism	The effect of <e10> acetaminophen </e10> is reported to be less potent with <e20> lithium </e20> than with ethanol.
mechanism	Methotrexate : Concomitant use of <e10> digoxin </e10> and <e20> methotrexate </e20> may increase the metabolism of digoxin and cause elevated serum digoxin levels.
mechanism	Ibuprofen-<e10> ibuprofen </e10> significantly decreased plasma concentrations of <e20> cisapride </e20>.
mechanism	Concomitant use of <e10> nevirapine </e10> with <e20> azithromycin </e20> decreased azithromycin plasma levels by 50%.
mechanism	<e10> Cimetidine </e10>, a cyclosporine analog, has been reported to decrease <e20> terfenadine </e20> plasma levels.
mechanism	Results of preliminary studies of patients receiving <e10> indinavir </e10>, nevirapine, or other HIV drugs concurrently with <e20> dasatinib </e20> indicate an increase in Cmax and AUC.
mechanism	When <e10> lansoprazole </e10> is administered concomitantly with a <e22> MAO_inhibitor </e22>, there is a tendency for the maximum concentration of lansoprazole to be lower than with lansoprazole alone, but that is not significant.
mechanism	therefore, it is recommended that <e10> ketoconazole </e10> be used with caution in patients receiving long-term <e20> lithium </e20> therapy because of the possibility that lithium may cause imbalances in the liver.
mechanism	therefore, it is recommended that <e10> ketoconazole </e10> be used with caution in patients on a <e22> anticoagulant </e22>, as there may be an increase in exposure to other prothrombotic_agents.
mechanism	therefore, it is recommended that <e10> chlorothiazide </e10> be used with caution in patients receiving <e20> cisapride </e20> because of the potential for severe hypoglycemia.
mechanism	Carbamazepine : In an animal study, # mg/kg of carbamazepine # times a week for # weeks significantly increased <e10> Aprepitant </e10> exposure in # rats exposed to <e20> acetaminophen </e20> (35 mg/kg for # days).
mechanism	Cholestyramine and Charcoal or <e10> Colestipol </e10> may inhibit hepatic metabolism of <e20> acetaminophen </e20>.
mechanism	Cholestyramine and Charcoal, administered concurrently, did not alter the clearance of <e10> cholestyramine </e10>, and conversely increased the clearance of <e20> cimetidine </e20>.
mechanism	Rifampin : Following administration of # mg <e10> rifampin </e10>, plasma concentrations of <e20> ethinyl_estradiol </e20> increased by approximately 43% and that of progestin decreased by approximately 17%.
mechanism	Effect of AEDs that inhibit CYP3A4 activity (e,g,, ketoconazole, itraconazole, alfentanil, terfenadine, cisapride, <e10> dasatinib </e10>, nelfinavir, ritonavir, saquinavir, indinavir ) have been reported to be increased by concomitant <e20> ketoconazole </e20>.
mechanism	Although no clinical studies have been conducted with the use of <e10> warfarin </e10> # mg and # mg once daily, it is believed that the administration of <e20> ethchlorvynol </e20> # mg once daily with warfarin # mg may result in a significant increase in the serum ethchlorvynol level.
mechanism	However, the systemic clearance of <e10> fluvoxamine </e10> was significantly higher than that of <e20> ketoconazole </e20>, and the systemic clearance of fluvoxamine is likely to be decreased when concomitantly administered with ketoconazole.
mechanism	However, the systemic absorption of <e10> almotriptan </e10> is increased by several-fold when administered with <e20> lithium </e20>, suggesting a possible mechanism for lithium toxicity.
mechanism	Levothyroxine_Sodium Absorption: The absorption of <e11> COREG </e11> is significantly reduced when it is administered with <e20> levothyroxine_sodium </e20>.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> decreased the amount of <e20> warfarin </e20> needed to inhibit platelet aggregation by about 30%.
mechanism	Cholestyramine : <e10> Cholestyramine </e10> (10 mg/kg/day) was given orally to <e20> phenytoin </e20> -treated rats for # days, followed by a 3-day washout period. Phenytoin treatment was associated with a significant increase in plasma and urinary levels of the AUGMENTIN_X_receptor_antagonist (AUGMENTIN_XR).
mechanism	<e10> d-amphetamine </e10>, like other <e22> psychotropic_agents </e22>, has the potential to alter blood concentrations of the main active metabolite amphetamine, 3,4-methylenedioxymethamphetamine (MDMA), and its metabolite methylamphetamine (MA).
mechanism	<e10> d-amphetamine </e10> decreases the clearance of <e20> fluvoxamine </e20> and its concomitant administration increases its clearance.
mechanism	Ethosuximide : <e12> Quinolones </e12>, including <e20> ethosuximide </e20>, have been reported to inhibit the metabolism of this drug and cause hypokalemia.
mechanism	Methenamine therapy Urinary excretion of <e10> methenamine </e10> decreased in <e20> nifedipine </e20> treated rats and healthy volunteers when it was given concurrently with the drug.
mechanism	Phenytoin : <e12> Quinolones </e12> may inhibit the metabolism of <e20> phenytoin </e20>, resulting in a decrease in the serum concentrations of phenytoin.
mechanism	Antacids and sucralfate : Caffeine and sucralfate are reported to reduce <e10> colestipol </e10> absorption in a dose-dependent manner, and <e20> colestipol </e20> may be absorbed by mucous membranes.
mechanism	Antacids and sucralfate : <e10> Cholestyramine </e10> and sucralfate decrease absorption of <e20> acetaminophen </e20> and phenobarbital.
mechanism	<e10> Sucralfate </e10> significantly reduced <e20> digoxin </e20> -induced increases in creatinine and tmax, and the extent of renal toxicity.
mechanism	<e10> Magnesium </e10>-and/or aluminum -containing antacids may interfere with absorption of <e20> probenecid </e20>.
mechanism	Magnesium-and aluminum -containing antacids, including <e10> Magnesium </e10>, aluminum, and calcium -containing antacids, may interfere with absorption of <e20> erythromycin </e20> and cause low serum concentrations of this drug.
mechanism	Separating the doses of <e10> alprazolam </e10> and <e20> ampicillin </e20> at # to # mg/kg for # days in male and female rats, respectively, decreased the ampicillin AUC by approximately 20% to 30%.
mechanism	Other <e12> quinolones </e12> ( <e20> norfloxacin </e20>, ciprofloxacin, clarithromycin, clindamycin, colistin, and warfarin ) have been reported to increase the metabolism of a single dose of ciprofloxacin and may have a cumulative effect on the pharmacokinetics of ciprofloxacin.
mechanism	Cimetidine : <e10> Cimetidine </e10> significantly reduced the plasma level of <e20> amphetamines </e20> and amphetamine_derivatives in healthy volunteers and in patients with Parkinson disease.
mechanism	<e10> Rifampin </e10> may enhance the metabolism of <e20> piperidine </e20>.
mechanism	<e10> Fluconazole </e10>, given concurrently with <e20> digoxin </e20>, significantly decreased serum levels of digoxin.
mechanism	Cholestyramine -Concomitant intake of <e10> cholestyramine </e10> and <e20> furosemide </e20> has been reported to result in high plasma concentrations of furosemide.
mechanism	Colestipol -Concomitant intake of <e10> colestipol </e10> with <e20> estrogens </e20>, oral contraceptives, and oral progestins may decrease the efficacy of estrogens.
mechanism	Orlistat-<e10> Cholestyramine </e10> did not inhibit the hepatic metabolism of <e20> orlistat </e20>, but reduced the elimination of the active metabolite, the acetaminophen metabolite of orlistat.
mechanism	Elevated plasma levels of <e10> gentamicin </e10> have been reported with the concomitant administration of oral <e20> sulfasalazine </e20> and some other oral anticoagulants.
mechanism	<e12> Quinolones </e12> may interfere with the metabolism of oral <e22> anticoagulants </e22>.
mechanism	and <e11> Videx </e11> may reduce the bioavailability of <e20> methotrexate </e20> and carbamazepine.
mechanism	<e10> Probenecid </e10>, a <e22> quinolone </e22>, may interfere with oral anticoagulants, resulting in an increase in prothrombin time.
mechanism	<e10> Naproxen </e10>-Caffeine or <e20> cholestyramine </e20> tablets may decrease the absorption of naproxen, resulting in lower concentrations and serum levels.
mechanism	After multiple dosing, the serum concentrations of <e10> digoxin </e10> were reduced by 43% in patients receiving high-dose <e20> dexamethasone </e20> and increased by 25% in patients receiving low-dose dexamethasone.
mechanism	<e11> Starlix </e11>, cimetidine, clarithromycin, indinavir, itraconazole, itraconazole + cisapride, itraconazole, lomefloxacin, nelfinavir, ritonavir, saquinavir, <e20> troleandomycin </e20>, tetracycline
mechanism	Ritonavir : Coadministration of <e10> ritonavir </e10> # hours prior to dosing with <e20> dasatinib </e20> resulted in a 40% increase in ritonavir exposure.
mechanism	Ketoconazole : Coadministration of <e10> ketoconazole </e10> and <e20> rifampin </e20> for # days caused a 20% reduction in rifampin AUC, as did coadministration of rifampin and a prothrombin time-resolved dye.
mechanism	Rifabutin : Coadministration of <e10> rifabutin </e10> with <e20> simvastatin </e20> resulted in a 13% increase in rifabutin AUC and a 39% decrease in Cmax.
mechanism	Rifampin : Coadministration of <e11> CRIXIVAN </e11> and <e20> rifampin </e20> resulted in a 20% decrease in rifampin plasma levels and a significant increase in phenytoin plasma levels.
mechanism	Oral <e10> neomycin </e10> and <e20> valdecoxib </e20> inhibited the absorption of intravenously administered rifampicin by 23 and 35% respectively.
mechanism	Oral <e10> neomycin </e10> sulfate treatment significantly decreased the clearance of <e20> cefazolin </e20>, increased the clearance of digoxin and did not affect the clearance of carbamazepine.
mechanism	Oral <e10> neomycin </e10> can interfere with the absorption of other <e22> anticonvulsants </e22>.
mechanism	<e10> Clarithromycin </e10> may decrease <e20> carbamazepine </e20> clearance.
mechanism	Digoxin : Some <e12> antihistamines </e12> may increase serum levels of <e20> digoxin </e20>.
mechanism	A study in healthy volunteers, in whom both <e10> ketoconazole </e10> and <e20> estazolam </e20> were administered concomitantly, indicated that estazolam did not alter the metabolism of either ketoconazole or cimetidine.
mechanism	Coadministration of <e10> ketoconazole </e10> and <e20> fluconazole </e20> decreased the binding of rifabutin to Cizero_Titanium.
mechanism	Therefore, caution should be exercised when <e10> cholestyramine </e10> is administered concomitantly with drugs that induce hepatic metabolism of <e20> enoxacin </e20> (e,g,, fluconazole ), quinine, furosemide, sulfasalazine, or amiodarone.
mechanism	Uricosuric_drugs, such as <e10> indomethacin </e10>, sulfasalazine, and nizoral_acid, may inhibit the metabolism of <e20> leucovorin </e20>, resulting in increased serum levels of leucovorin.
mechanism	In patients given <e10> dexamethasone </e10> # mg per day for # days, the daily dose of <e20> cimetidine </e20> would increase by approximately 20% and would require approximately # hours of observation to achieve a desired serum cimetidine level.
mechanism	Elevated plasma levels of <e10> furosemide </e10> are associated with a decrease in the clearance of <e20> succinylcholine </e20>.
mechanism	Elevated serum levels of <e10> ketoconazole </e10> (4,828 ng/mL) were found in patients receiving <e20> lithium </e20> (400 mg three times a day for # days) and carbamazepine (4,828 ng/mL) concurrently.
mechanism	Some <e12> quinolones </e12> may be inhibitory when coadministered with <e22> quinolones </e22>.
mechanism	In addition, higher-than-expected levels of <e10> dantrolene </e10> were observed during studies in which <e20> theophylline </e20> was used as the source of methylation.
mechanism	There have been reports of patients with normal renal function on <e10> digoxin </e10> therapy who developed symptoms suggestive of renal disease after initiation of <e20> pentamidine </e20> therapy.
mechanism	There have been reports of interaction of <e10> diflunisal </e10> and other <e22> anticoagulants </e22> with warfarin and similar agents.
mechanism	Calcium_Antagonist s: After an intravenous dose of <e11> EQUETROTM </e11> # mg, the <e20> gentamicin </e20> dose required to achieve a decrease of serum creatinine was reduced by #% and the increase of serum creatinine by 22%.
mechanism	Pharmacokinetic data from in vitro studies indicate that <e10> phenytoin </e10> may increase the exposure of <e20> phenobarbital </e20>, which has a 50% efficacy reduction when given with the metabolite of phenytoin, phenytoin.
mechanism	Treatment with <e11> FLEXERIL </e11> (3 mg q # h) resulted in a significant increase in plasma <e20> carbamazepine </e20> concentrations of #% to # mg/L and decreased serum carbamazepine levels by approximately #% to # mg/L (P =.02 and P =.002, respectively).
mechanism	Probenecid : The dose of <e10> probenecid </e10> that increases plasma <e20> cyclosporine </e20> concentrations by 10% is 10 times higher than that of non-cytochrome P4503A4 substrates.
mechanism	Methotrexate : <e10> Cholestyramine </e10> in combination with <e20> methotrexate </e20> decreased the toxicity of methotrexate.
mechanism	Cimetidine : Co-administration of <e11> HUMORSOL </e11> with <e20> cimetidine </e20> increased the concentrations of cimetidine in urine by 15%.
mechanism	At higher than # micrograms/mL <e10> loperamide </e10>, <e20> clofibrate </e20> was # times more potent in causing a 50% decrease in V(max) at # micrograms/mL (theoretical # min increase).
mechanism	At # hours after initiation of <e10> astemizole </e10> therapy, <e20> zidovudine </e20> was withdrawn.
mechanism	Rifampin : Co-administration of <e10> ketoconazole </e10> with <e20> rifampin </e20> decreased the AUC of rifampin by 25% (P = #).
mechanism	Theophylline <e11> VIOXX </e11> reduced the hepatic metabolism of <e20> phenobarbital </e20>.
mechanism	Coadministration with compounds that are potent inhibitors of CYP3A4 (such as ketoconazole and itraconazole, nefazodone, troleandomycin, clarithromycin, erythromycin, ritonavir, <e10> saquinavir </e10>, saquinavir, indinavir, saquinavir, indinavir ) decreased <e20> alfentanil </e20> plasma concentrations.
mechanism	Coadministration with compounds that interfere with CYP3A4 activity, such as ketoconazole, itraconazole, ritonavir, erythromycin, indinavir, nefazodone, <e10> nelfinavir </e10>, saquinavir, and astemizole resulted in increases in plasma levels of <e20> vardenafil </e20> and astemizole.
mechanism	Coadministration with compounds that are not recognized as <e10> digoxin </e10> by the protease, cytochrome P450 3A4, has resulted in the coadministration of a potent CYP3A4 inhibitor, <e20> ketoconazole </e20>, and an ineffective fraction of the patient's daily dose of digoxin.
